Human metabolic models and methods

Information

  • Patent Grant
  • 8229673
  • Patent Number
    8,229,673
  • Date Filed
    Thursday, March 27, 2003
    21 years ago
  • Date Issued
    Tuesday, July 24, 2012
    12 years ago
Abstract
The invention provides in silico models for determining the physiological function of human cells, including human skeletal muscle cells. The models include a data structure relating a plurality of Homo sapiens reactants to a plurality of Homo sapiens reactions, a constraint set for the plurality of Homo sapiens reactions, and commands for determining a distribution of flux through the reactions that is predictive of a Homo sapiens physiological function. A model of the invention can further include a gene database containing information characterizing the associated gene or genes. A regulated Homo sapiens reaction can be represented in a model of the invention by including a variable constraint for the regulated reaction. The invention further provides methods for making an in silico Homo sapiens model and methods for determining a Homo sapiens physiological function using a model of the invention.
Description
BACKGROUND OF THE INVENTION

This invention relates generally to analysis of the activity of chemical reaction networks and, more specifically, to computational methods for simulating and predicting the activity of Homo sapiens reaction networks.


Therapeutic agents, including drugs and gene-based agents, are being rapidly developed by the pharmaceutical industry with the goal of preventing or treating human disease. Dietary supplements, including herbal products, vitamins and amino acids, are also being developed and marketed by the nutraceutical industry. Because of the complexity of the biochemical reaction networks in and between human cells, even relatively minor perturbations caused by a therapeutic agent or a dietary component in the abundance or activity of a particular target, such as a metabolite, gene or protein, can affect hundreds of biochemical reactions. These perturbations can lead to desirable therapeutic effects, such as cell stasis or cell death in the case of cancer cells or other pathologically hyperproliferative cells. However, these perturbations can also lead to undesirable side effects, such as production of toxic byproducts, if the systemic effects of the perturbations are not taken into account.


Current approaches to drug and nutraceutical development do not take into account the effect of a perturbation in a molecular target on systemic cellular behavior. In order to design effective methods of repairing, engineering or disabling cellular activities, it is essential to understand human cellular behavior from an integrated perspective.


Cellular metabolism, which is an example of a process involving a highly integrated network of biochemical reactions, is fundamental to all normal cellular or physiological processes, including homeostatis, proliferation, differentiation, programmed cell death (apoptosis) and motility. Alterations in cellular metabolism characterize a vast number of human diseases. For example, tissue injury is often characterized by increased catabolism of glucose, fatty acids and amino acids, which, if persistent, can lead to organ dysfunction. Conditions of low oxygen supply (hypoxia) and nutrient supply, such as occur in solid tumors, result in a myriad of adaptive metabolic changes including activation of glycolysis and neovascularization. Metabolic dysfunctions also contribute to neurodegenerative diseases, cardiovascular disease, neuromuscular diseases, obesity and diabetes. Currently, despite the importance of cellular metabolism to normal and pathological processes, a detailed systemic understanding of cellular metabolism in human cells is currently lacking.


Thus, there exists a need for models that describe Homo sapiens reaction networks, including core metabolic reaction networks and metabolic reaction networks in specialized cell types, which can be used to simulate different aspects of human cellular behavior under physiological, pathological and therapeutic conditions. The present invention satisfies this need, and provides related advantages as well.


SUMMARY OF THE INVENTION

The invention provides a computer readable medium or media, including: (a) a data structure relating a plurality of Homo sapiens reactants to a plurality of Homo sapiens reactions, wherein each of the Homo sapiens reactions includes a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product, (b) a constraint set for the plurality of Homo sapiens reactions, and (c) commands for determining at least one flux distribution that minimizes or maximizes an objective function when the constraint set is applied to the data representation, wherein the at least one flux distribution is predictive of a Homo sapiens physiological function. In one embodiment, at least one of the Homo sapiens reactions in the data structure is annotated to indicate an associated gene and the computer readable medium or media further includes a gene database including information characterizing the associated gene. In another embodiment, at least one of the Homo sapiens reactions is a regulated reaction and the computer readable medium or media further includes a constraint set for the plurality of Homo sapiens reactions, wherein the constraint set includes a variable constraint for the regulated reaction.


The invention provides a method for predicting a Homo sapiens physiological function, including: (a) providing a data structure relating a plurality of Homo sapiens reactants to a plurality of Homo sapiens reactions, wherein each of the Homo sapiens reactions includes a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product; (b) providing a constraint set for the plurality of Homo sapiens reactions; (c) providing an objective function, and (d) determining at least one flux distribution that minimizes or maximizes the objective function when the constraint set is applied to the data structure, thereby predicting a Homo sapiens physiological function. In one embodiment, at least one of the Homo sapiens reactions in the data structure is annotated to indicate an associated gene and the method predicts a Homo sapiens physiological function related to the gene.


The invention provides a method for predicting a Homo sapiens physiological function, including: (a) providing a data structure relating a plurality of Homo sapiens reactants to a plurality of Homo sapiens reactions, wherein each of the Homo sapiens reactions includes a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product, wherein at least one of the Homo sapiens reactions is a regulated reaction; (b) providing a constraint set for the plurality of Homo sapiens reactions, wherein the constraint set includes a variable constraint for the regulated reaction; (c) providing a condition-dependent value to the variable constraint; (d) providing an objective function, and (e) determining at least one flux distribution that minimizes or maximizes the objective function when the constraint set is applied to the data structure, thereby predicting a Homo sapiens physiological function.


Also provided by the invention is a method for making a data structure relating a plurality of Homo sapiens reactants to a plurality of Homo sapiens reactions in a computer readable medium or media, including: (a) identifying a plurality of Homo sapiens reactions and a plurality of Homo sapiens reactants that are substrates and products of the Homo sapiens reactions; (b) relating the plurality of Homo sapiens reactants to the plurality of Homo sapiens reactions in a data structure, wherein each of the Homo sapiens reactions includes a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product; (c) determining a constraint set for the plurality of Homo sapiens reactions; (d) providing an objective function; (e) determining at least one flux distribution that minimizes or maximizes the objective function when the constraint set is applied to the data structure, and (f) if the at least one flux distribution is not predictive of a Homo sapiens physiological function, then adding a reaction to or deleting a reaction from the data structure and repeating step (e), if the at least one flux distribution is predictive of a Homo sapiens physiological function, then storing the data structure in a computer readable medium or media. The invention further provides a data structure relating a plurality of Homo sapiens reactants to a plurality of Homo sapiens reactions, wherein the data structure is produced by the method.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 shows a schematic representation of a hypothetical metabolic network.



FIG. 2 shows mass balance constraints and flux constraints (reversibility constraints) that can be placed on the hypothetical metabolic network shown in FIG. 1.



FIG. 3 shows the stoichiometric matrix (S) for the hypothetical metabolic network shown in FIG. 1.



FIG. 4 shows, in Panel A, an exemplary biochemical reaction network and in Panel B, an exemplary regulatory control structure for the reaction network in panel A.





DETAILED DESCRIPTION OF THE INVENTION

The present invention provides in silico models that describe the interconnections between genes in the Homo sapiens genome and their associated reactions and reactants. The models can be used to simulate different aspects of the cellular behavior of human cells under different normal, pathological and therapeutic conditions, thereby providing valuable information for therapeutic, diagnostic and research applications. An advantage of the models of the invention is that they provide a holistic approach to simulating and predicting the activity of Homo sapiens cells. The models and methods can also be extended to simulate the activity of multiple interacting cells, including organs, physiological systems and whole body metabolism.


As an example, the Homo sapiens metabolic models of the invention can be used to determine the effects of changes from aerobic to anaerobic conditions, such as occurs in skeletal muscles during exercise or in tumors, or to determine the effect of various dietary changes. The Homo sapiens metabolic models can also be used to determine the consequences of genetic defects, such as deficiencies in metabolic enzymes such as phosphofructokinase, phosphoglycerate kinase, phosphoglycerate mutase, lactate dehydrogenase and adenosine deaminase.


The Homo sapiens metabolic models can also be used to choose appropriate targets for drug design. Such targets include genes, proteins or reactants, which when modulated positively or negatively in a simulation produce a desired therapeutic result. The models and methods of the invention can also be used to predict the effects of a therapeutic agent or dietary supplement on a cellular function of interest. Likewise, the models and methods can be used to predict both desirable and undesirable side effects of the therapeutic agent on an interrelated cellular function in the target cell, as well as the desirable and undesirable effects that may occur in other cell types. Thus, the models and methods of the invention can make the drug development process more rapid and cost effective than is currently possible.


The Homo sapiens metabolic models can also be used to predict or validate the assignment of particular biochemical reactions to the enzyme-encoding genes found in the genome, and to identify the presence of reactions or pathways not indicated by current genomic data. Thus, the models can be used to guide the research and discovery process, potentially leading to the identification of new enzymes, medicines or metabolites of clinical importance.


The models of the invention are based on a data structure relating a plurality of Homo sapiens reactants to a plurality of Homo sapiens reactions, wherein each of the Homo sapiens reactions includes a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product. The reactions included in the data structure can be those that are common to all or most Homo sapiens cells, such as core metabolic reactions, or reactions specific for one or more given cell type.


As used herein, the term “Homo sapiens reaction” is intended to mean a conversion that consumes a substrate or forms a product that occurs in or by a Homo sapiens cell. The term can include a conversion that occurs due to the activity of one or more enzymes that are genetically encoded by a Homo sapiens genome. The term can also include a conversion that occurs spontaneously in a Homo sapiens cell. Conversions included in the term include, for example, changes in chemical composition such as those due to nucleophilic or electrophilic addition, nucleophilic or electrophilic substitution, elimination, isomerization, deamination, phosphorylation, methylation, reduction, oxidation or changes in location such as those that occur due to a transport reaction that moves a reactant from one cellular compartment to another. In the case of a transport reaction, the substrate and product of the reaction can be chemically the same and the substrate and product can be differentiated according to location in a particular cellular compartment. Thus, a reaction that transports a chemically unchanged reactant from a first compartment to a second compartment has as its substrate the reactant in the first compartment and as its product the reactant in the second compartment. It will be understood that when used in reference to an in silico model or data structure, a reaction is intended to be a representation of a chemical conversion that consumes a substrate or produces a product.


As used herein, the term “Homo sapiens reactant” is intended to mean a chemical that is a substrate or a product of a reaction that occurs in or by a Homo sapiens cell. The term can include substrates or products of reactions performed by one or more enzymes encoded by a Homo sapiens genome, reactions occurring in Homo sapiens that are performed by one or more non-genetically encoded macromolecule, protein or enzyme, or reactions that occur spontaneously in a Homo sapiens cell. Metabolites are understood to be reactants within the meaning of the term. It will be understood that when used in reference to an in silico model or data structure, a reactant is intended to be a representation of a chemical that is a substrate or a product of a reaction that occurs in or by a Homo sapiens cell.


As used herein the term “substrate” is intended to mean a reactant that can be converted to one or more products by a reaction. The term can include, for example, a reactant that is to be chemically changed due to nucleophilic or electrophilic addition, nucleophilic or electrophilic substitution, elimination, isomerization, deamination, phosphorylation, methylation, reduction, oxidation or that is to change location such as by being transported across a membrane or to a different compartment.


As used herein, the term “product” is intended to mean a reactant that results from a reaction with one, or more substrates. The term can include, for example, a reactant that has been chemically changed due to nucleophilic or electrophilic addition, nucleophilic or electrophilic substitution, elimination, isomerization, deamination, phosphorylation, methylation, reduction or oxidation or that has changed location such as by being transported across a membrane or to a different compartment.


As used herein, the term “stoichiometric coefficient” is intended to mean a numerical constant correlating the number of one or more reactants and the number of one or more products in a chemical reaction. Typically, the numbers are integers as they denote the number of molecules of each reactant in an elementally balanced chemical equation that describes the corresponding conversion. However, in some cases the numbers can take on non-integer values, for example, when used in a lumped reaction or to reflect empirical data.


As used herein, the term “plurality,” when used in reference to Homo sapiens reactions or reactants, is intended to mean at least 2 reactions or reactants. The term can include any number of Homo sapiens reactions or reactants in the range from 2 to the number of naturally occurring reactants or reactions for a particular of Homo sapiens cell. Thus, the term can include, for example, at least 10, 20, 30, 50, 100, 150, 200, 300, 400, 500, 600 or more reactions or reactants. The number of reactions or reactants can be expressed as a portion of the total number of naturally occurring reactions for a particular Homo sapiens cell, such as at least 20%, 30%, 50%, 60%, 75%, 90%, 95% or 98% of the total number of naturally occurring reactions that occur in a particular Homo sapiens cell.


As used herein, the term “data structure” is intended to mean a physical or logical relationship among data elements, designed to support specific data manipulation functions. The term can include, for example, a list of data elements that can be added combined or otherwise manipulated such as a list of representations for reactions from which reactants can be related in a matrix or network. The term can also include a matrix that correlates data elements from two or more lists of information such as a matrix that correlates reactants to reactions. Information included in the term can represent, for example, a substrate or product of a chemical reaction, a chemical reaction relating one or more substrates to one or more products, a constraint placed on a reaction, or a stoichiometric coefficient.


As used herein, the term “constraint” is intended to mean an upper or lower boundary for a reaction. A boundary can specify a minimum or maximum flow of mass, electrons or energy through a reaction. A boundary can further specify directionality of a reaction. A boundary can be a constant value such as zero, infinity, or a numerical value such as an integer. Alternatively, a boundary can be a variable boundary value as set forth below.


As used herein, the term “variable,” when used in reference to a constraint is intended to mean capable of assuming any of a set of values in response to being acted upon by a constraint function. The term “function,” when used in the context of a constraint, is intended to be consistent with the meaning of the term as it is understood in the computer and mathematical arts. A function can be binary such that changes correspond to a reaction being off or on. Alternatively, continuous functions can be used such that changes in boundary values correspond to increases or decreases in activity. Such increases or decreases can also be binned or effectively digitized by a function capable of converting sets of values to discreet integer values. A function included in the term can correlate a boundary value with the presence, absence or amount of a biochemical reaction network participant such as a reactant, reaction, enzyme or gene. A function included in the term can correlate a boundary value with an outcome of at least one reaction in a reaction network that includes the reaction that is constrained by the boundary limit. A function included in the term can also correlate a boundary value with an environmental condition such as time, pH, temperature or redox potential.


As used herein, the term “activity,” when used in reference to a reaction, is intended to mean the amount of product produced by the reaction, the amount of substrate consumed by the reaction or the rate at which a product is produced or a substrate is consumed. The amount of product produced by the reaction, the amount of substrate consumed by the reaction or the rate at which a product is produced or a substrate is consumed can also be referred to as the flux for the reaction.


As used herein, the term “activity,” when used in reference to a Homo sapiens cell, is intended to mean the magnitude or rate of a change from an initial state to a final state. The term can include, for example, the amount of a chemical consumed or produced by a cell, the rate at which a chemical is consumed or produced by a cell, the amount or rate of growth of a cell or the amount of or rate at which energy, mass or electrons flow through a particular subset of reactions.


The invention provides a computer readable medium, having a data structure relating a plurality of Homo sapiens reactants to a plurality of Homo sapiens reactions, wherein each of the Homo sapiens reactions includes a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product.


Depending on the application, the plurality of Homo sapiens reactions can include reactions selected from core metabolic reactions or peripheral metabolic reactions. As used herein, the term “core,” when used in reference to a metabolic pathway, is intended to mean a metabolic pathway selected from glycolysis/gluconeogenesis, the pentose phosphate pathway (PPP), the tricarboxylic acid (TCA) cycle, glycogen storage, electron transfer system (ETS), the malate/aspartate shuttle, the glycerol phosphate shuttle, and plasma and mitochondrial membrane transporters. As used herein, the term “peripheral,” when used in reference to a metabolic pathway, is intended to mean a metabolic pathway that includes one or more reactions that are not a part of a core metabolic pathway.


A plurality of Homo sapiens reactants can be related to a plurality of Homo sapiens reactions in any data structure that represents, for each reactant, the reactions by which it is consumed or produced. Thus, the data structure, which is referred to herein as a “reaction network data structure,” serves as a representation of a biological reaction network or system. An example of a reaction network that can be represented in a reaction network data structure of the invention is the collection of reactions that constitute the core metabolic reactions of Homo sapiens, or the metabolic reactions of a skeletal muscle cell, as shown in the Examples.


The choice of reactions to include in a particular reaction network data structure, from among all the possible reactions that can occur in human cells, depends on the cell type or types and the physiological, pathological or therapeutic condition being modeled, and can be determined experimentally or from the literature, as described further below.


The reactions to be included in a particular network data structure of Homo sapiens can be determined experimentally using, for example, gene or protein expression profiles, where the molecular characteristics of the cell can be correlated to the expression levels. The expression or lack of expression of genes or proteins in a cell type can be used in determining whether a reaction is included in the model by association to the expressed gene(s) and or protein(s). Thus, it is possible to use experimental technologies to determine which genes and/or proteins are expressed in a specific cell type, and to further use this information to determine which reactions are present in the cell type of interest. In this way a subset of reactions from all of those reactions that can occur in human cells are selected to comprise the set of reactions that represent a specific cell type. cDNA expression profiles have been demonstrated to be useful, for example, for classification of breast cancer cells (Sorlie et al., Proc. Natl. Acad. Sci. U.S.A. 98(19):10869-10874 (2001)).


The methods and models of the invention can be applied to any Homo sapiens cell type at any stage of differentiation, including, for example, embryonic stem cells, hematopoietic stem cells, differentiated hematopoietic cells, skeletal muscle cells, cardiac muscle cells, smooth muscle cells, skin cells, nerve cells, kidney cells, pulmonary cells, liver cells, adipocytes and endocrine cells (e.g. beta islet cells of the pancreas, mammary gland cells, adrenal cells, and other specialized hormone secreting cells).


The methods and models of the invention can be applied to normal cells or pathological cells. Normal cells that exhibit a variety of physiological activities of interest, including homeostasis, proliferation, differentiation, apoptosis, contraction and motility, can be modeled. Pathological cells can also be modeled, including cells that reflect genetic or developmental abnormalities, nutritional deficiencies, environmental assaults, infection (such as by bacteria, viral, protozoan or fungal agents), neoplasia, aging, altered immune or endocrine function, tissue damage, or any combination of these factors. The pathological cells can be representative of any type of human pathology, including, for example, various metabolic disorders of carbohydrate, lipid or protein metabolism, obesity, diabetes, cardiovascular disease, fibrosis, various cancers, kidney failure, immune pathologies, neurodegenerative diseases, and various monogenetic metabolic diseases described in the Online Mendelian Inheritance in Man database (Center for Medical Genetics, Johns Hopkins University (Baltimore, Md.) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, Md.)).


The methods and models of the invention can also be applied to cells undergoing therapeutic perturbations, such as cells treated with drugs that target participants in a reaction network, cells treated with gene-based therapeutics that increase or decrease expression of an encoded protein, and cells treated with radiation. As used herein, the term “drug” refers to a compound of any molecular nature with a known or proposed therapeutic function, including, for example, small molecule compounds, peptides and other macromolecules, peptidomimetics and antibodies, any of which can optionally be tagged with cytostatic, targeting or detectable moieties. The term “gene-based therapeutic” refers to nucleic acid therapeutics, including, for example, expressible genes with normal or altered protein activity, antisense compounds, ribozymes, DNAzymes, RNA interference compounds (RNAi) and the like. The therapeutics can target any reaction network participant, in any cellular location, including participants in extracellular, cell surface, cytoplasmic, mitochondrial and nuclear locations. Experimental data that are gathered on the response of cells to therapeutic treatment, such as alterations in gene or protein expression profiles, can be used to tailor a network for a pathological state of a particular cell type.


The methods and models of the invention can be applied to Homo sapiens cells as they exist in any form, such as in primary cell isolates or in established cell lines, or in the whole body, in intact organs or in tissue explants. Accordingly, the methods and models can take into account intercellular communications and/or inter-organ communications, the effect of adhesion to a substrate or neighboring cells (such as a stem cell interacting with mesenchymal cells or a cancer cell interacting with its tissue microenvironment, or beta-islet cells without normal stroma), and other interactions relevant to multicellular systems.


The reactants to be used in a reaction network data structure of the invention can be obtained from or stored in a compound database. As used herein, the term “compound database” is intended to mean a computer readable medium or media containing a plurality of molecules that includes substrates and products of biological reactions. The plurality of molecules can include molecules found in multiple organisms, thereby constituting a universal compound database. Alternatively, the plurality of molecules can be limited to those that occur in a particular organism, thereby constituting an organism-specific compound database. Each reactant in a compound database can be identified according to the chemical species and the cellular compartment in which it is present. Thus, for example, a distinction can be made between glucose in the extracellular compartment versus glucose in the cytosol. Additionally each of the reactants can be specified as a metabolite of a primary or secondary metabolic pathway. Although identification of a reactant as a metabolite of a primary or secondary metabolic pathway does not indicate any chemical distinction between the reactants in a reaction, such a designation can assist in visual representations of large networks of reactions.


As used herein, the term “compartment” is intended to mean a subdivided region containing at least one reactant, such that the reactant is separated from at least one other reactant in a second region. A subdivided region included in the term can be correlated with a subdivided region of a cell. Thus, a subdivided region included in the term can be, for example, the intracellular space of a cell; the extracellular space around a cell; the periplasmic space, the interior space of an organelle such as a mitochondrium, endoplasmic reticulum, Golgi apparatus, vacuole or nucleus; or any subcellular space that is separated from another by a membrane or other physical barrier. Subdivided regions can also be made in order to create virtual boundaries in a reaction network that are not correlated with physical barriers. Virtual boundaries can be made for the purpose of segmenting the reactions in a network into different compartments or substructures.


As used herein, the term “substructure” is intended to mean a portion of the information in a data structure that is separated from other information in the data structure such that the portion of information can be separately manipulated or analyzed. The term can include portions subdivided according to a biological function including, for example, information relevant to a particular metabolic pathway such as an internal flux pathway, exchange flux pathway, central metabolic pathway, peripheral metabolic pathway, or secondary metabolic pathway. The term can include portions subdivided according to computational or mathematical principles that allow for a particular type of analysis or manipulation of the data structure.


The reactions included in a reaction network data structure can be obtained from a metabolic reaction database that includes the substrates, products, and stoichiometry of a plurality of metabolic reactions of Homo sapiens. The reactants in a reaction network data structure can be designated as either substrates or products of a particular reaction, each with a stoichiometric coefficient assigned to it to describe the chemical conversion taking place in the reaction. Each reaction is also described as occurring in either a reversible or irreversible direction. Reversible reactions can either be represented as one reaction that operates in both the forward and reverse direction or be decomposed into two irreversible reactions, one corresponding to the forward reaction and the other corresponding to the backward reaction.


Reactions included in a reaction network data structure can include intra-system or exchange reactions. Intra-system reactions are the chemically and electrically balanced interconversions of chemical species and transport processes, which serve to replenish or drain the relative amounts of certain metabolites. These intra-system reactions can be classified as either being transformations or translocations. A transformation is a reaction that contains distinct sets of compounds as substrates and products, while a translocation contains reactants located in different compartments. Thus a reaction that simply transports a metabolite from the extracellular environment to the cytosol, without changing its chemical composition is solely classified as a translocation, while a reaction that takes an extracellular substrate and converts it into a cytosolic product is both a translocation and a transformation.


Exchange reactions are those which constitute sources and sinks, allowing the passage of metabolites into and out of a compartment or across a hypothetical system boundary. These reactions are included in a model for simulation purposes and represent the metabolic demands placed on Homo sapiens. While they may be chemically balanced in certain cases, they are typically not balanced and can often have only a single substrate or product. As a matter of convention the exchange reactions are further classified into demand exchange and input/output exchange reactions.


The metabolic demands placed on the Homo sapiens metabolic reaction network can be readily determined from the dry weight composition of the cell which is available in the published literature or which can be determined experimentally. The uptake rates and maintenance requirements for Homo sapiens cells can also be obtained from the published literature or determined experimentally.


Input/output exchange reactions are used to allow extracellular reactants to enter or exit the reaction network represented by a model of the invention. For each of the extracellular metabolites a corresponding input/output exchange reaction can be created. These reactions are always reversible with the metabolite indicated as a substrate with a stoichiometric coefficient of one and no products produced by the reaction. This particular convention is adopted to allow the reaction to take on a positive flux value (activity level) when the metabolite is being produced or removed from the reaction network and a negative flux value when the metabolite is being consumed or introduced into the reaction network. These reactions will be further constrained during the course of a simulation to specify exactly which metabolites are available to the cell and which can be excreted by the cell.


A demand exchange reaction is always specified as an irreversible reaction containing at least one substrate. These reactions are typically formulated to represent the production of an intracellular metabolite by the metabolic network or the aggregate production of many reactants in balanced ratios such as in the representation of a reaction that leads to biomass formation, also referred to as growth.


A demand exchange reactions can be introduced for any metabolite in a model of the invention. Most commonly these reactions are introduced for metabolites that are required to be produced by the cell for the purposes of creating a new cell such as amino acids, nucleotides, phospholipids, and other biomass constituents, or metabolites that are to be produced for alternative purposes. Once these metabolites are identified, a demand exchange reaction that is irreversible and specifies the metabolite as a substrate with a stoichiometric coefficient of unity can be created. With these specifications, if the reaction is active it leads to the net production of the metabolite by the system meeting potential production demands. Examples of processes that can be represented as a demand exchange reaction in a reaction network data structure and analyzed by the methods of the invention include, for example, production or secretion of an individual protein; production or secretion of an individual metabolite such as an amino acid, vitamin, nucleoside, antibiotic or surfactant; production of ATP for extraneous energy requiring processes such as locomotion; or formation of biomass constituents.


In addition to these demand exchange reactions that are placed on individual metabolites, demand exchange reactions that utilize multiple metabolites in defined stoichiometric ratios can be introduced. These reactions are referred to as aggregate demand exchange reactions. An example of an aggregate demand reaction is a reaction used to simulate the concurrent growth demands or production requirements associated with cell growth that are placed on a cell, for example, by simulating the formation of multiple biomass constituents simultaneously at a particular cellular growth rate.


A hypothetical reaction network is provided in FIG. 1 to exemplify the above-described reactions and their interactions. The reactions can be represented in the exemplary data structure shown in FIG. 3 as set forth below. The reaction network, shown in FIG. 1, includes intrasystem reactions that occur entirely within the compartment indicated by the shaded oval such as reversible reaction R2 which acts on reactants B and G and reaction R3 which converts one equivalent of B to 2 equivalents of F. The reaction network shown in FIG. 1 also contains exchange reactions such as input/output exchange reactions Axt and Ext, and the demand exchange reaction, Vgrowth, which represents growth in response to the one equivalent of D and one equivalent of F. Other intrasystem reactions include R1 which is a translocation and transformation reaction that translocates reactant A into the compartment and transforms it to reactant G and reaction R6 which is a transport reaction that translocates reactant E out of the compartment.


A reaction network can be represented as a set of linear algebraic equations which can be presented as a stoichiometric matrix S, with S being an m x n matrix where m corresponds to the number of reactants or metabolites and n corresponds to the number of reactions taking place in the network. An example of a stoichiometric matrix representing the reaction network of FIG. 1 is shown in FIG. 3. As shown in FIG. 3, each column in the matrix corresponds to a particular reaction n, each row corresponds to a particular reactant m, and each Smn element corresponds to the stoichiometric coefficient of the reactant m in the reaction denoted n. The stoichiometric matrix includes intra-system reactions such as R2 and R3 which are related to reactants that participate in the respective reactions according to a stoichiometric coefficient having a sign indicative of whether the reactant is a substrate or product of the reaction and a value correlated with the number of equivalents of the reactant consumed or produced by the reaction. Exchange reactions such as −Ext and −Axt are similarly correlated with a stoichiometric coefficient. As exemplified by reactant E, the same compound can be treated separately as an internal reactant (E) and an external reactant (Eexternal) such that an exchange reaction (R6) exporting the compound is correlated by stoichiometric coefficients of −1 and 1, respectively. However, because the compound is treated as a separate reactant by virtue of its compartmental location, a reaction, such as R5, which produces the internal reactant (E) but does not act on the external reactant (Eexternal) is correlated by stoichiometric coefficients of 1 and 0, respectively. Demand reactions such as Vgrowth can also be included in the stoichiometric matrix being correlated with substrates by an appropriate stoichiometric coefficient.


As set forth in further detail below, a stoichiometric matrix provides a convenient format for representing and analyzing a reaction network because it can be readily manipulated and used to compute network properties, for example, by using linear programming or general convex analysis. A reaction network data structure can take on a variety of formats so long as it is capable of relating reactants and reactions in the manner exemplified above for a stoichiometric matrix and in a manner that can be manipulated to determine an activity of one or more reactions using methods such as those exemplified below. Other examples of reaction network data structures that are useful in the invention include a connected graph, list of chemical reactions or a table of reaction equations.


A reaction network data structure can be constructed to include all reactions that are involved in Homo sapiens metabolism or any portion thereof. A portion of Homo sapiens metabolic reactions that can be included in a reaction network data structure of the invention includes, for example, a central metabolic pathway such as glycolysis, the TCA cycle, the PPP or ETS; or a peripheral metabolic pathway such as amino acid biosynthesis, amino acid degradation, purine biosynthesis, pyrimidine biosynthesis, lipid biosynthesis, fatty acid metabolism, vitamin or cofactor biosynthesis, transport processes and alternative carbon source catabolism. Examples of individual pathways within the peripheral pathways are set forth in Table 1.


Depending upon a particular application, a reaction network data structure can include a plurality of Homo sapiens reactions including any or all of the reactions listed in Table 1.


For some applications, it can be advantageous to use a reaction network data structure that includes a minimal number of reactions to achieve a particular Homo sapiens activity under a particular set of environmental conditions. A reaction network data structure having a minimal number of reactions can be identified by performing the simulation methods described below in an iterative fashion where different reactions or sets of reactions are systematically removed and the effects observed. Accordingly, the invention provides a computer readable medium, containing a data structure relating a plurality of Homo sapiens reactants to a plurality of Homo sapiens reactions, wherein the plurality of Homo sapiens reactions contains at least 65 reactions. For example, the core metabolic reaction database shown in Tables 2 and 3 contains 65 reactions, and is sufficient to simulate aerobic and anaerobic metabolism on a number of carbon sources, including glucose.


Depending upon the particular cell type or types, the physiological, pathological or therapeutic conditions being tested and the desired activity, a reaction network data structure can contain smaller numbers of reactions such as at least 200, 150, 100 or 50 reactions. A reaction network data structure having relatively few reactions can provide the advantage of reducing computation time and resources required to perform a simulation. When desired, a reaction network data structure having a particular subset of reactions can be made or used in which reactions that are not relevant to the particular simulation are omitted. Alternatively, larger numbers of reactions can be included in order to increase the accuracy or molecular detail of the methods of the invention or to suit a particular application. Thus, a reaction network data structure can contain at least 300, 350, 400, 450, 500, 550, 600 or more reactions up to the number of reactions that occur in or by Homo sapiens or that are desired to simulate the activity of the full set of reactions occurring in Homo sapiens. A reaction network data structure that is substantially complete with respect to the metabolic reactions of Homo sapiens provides the advantage of being relevant to a wide range of conditions to be simulated, whereas those with smaller numbers of metabolic reactions are limited to a particular subset of conditions to be simulated.


A Homo sapiens reaction network data structure can include one or more reactions that occur in or by Homo sapiens and that do not occur, either naturally or following manipulation, in or by another organism, such as Saccharomiyces cerevisiae. It is understood that a Homo sapiens reaction network data structure of a particular cell type can also include one or more reactions that occur in another cell type. Addition of such heterologous reactions to a reaction network data structure of the invention can be used in methods to predict the consequences of heterologous gene transfer and protein expression, for example, when designing in vivo and ex vivo gene therapy approaches.


The reactions included in a reaction network data structure of the invention can be metabolic reactions. A reaction network data structure can also be constructed to include other types of reactions such as regulatory reactions, signal transduction reactions, cell cycle reactions, reactions controlling developmental processes, reactions involved in apoptosis, reactions involved in responses to hypoxia, reactions involved in responses to cell-cell or cell-substrate interactions, reactions involved in protein synthesis and regulation thereof, reactions involved in gene transcription and translation, and regulation thereof, and reactions involved in assembly of a cell and its subcellular components.


A reaction network data structure or index of reactions used in the data structure such as that available in a metabolic reaction database, as described above, can be annotated to include information about a particular reaction. A reaction can be annotated to indicate, for example, assignment of the reaction to a protein, macromolecule or enzyme that performs the reaction, assignment of a gene(s) that codes for the protein, macromolecule or enzyme, the Enzyme Commission (EC) number of the particular metabolic reaction, a subset of reactions to which the reaction belongs, citations to references from which information was obtained, or a level of confidence with which a reaction is believed to occur in Homo sapiens. A computer readable medium or media of the invention can include a gene database containing annotated reactions. Such information can be obtained during the course of building a metabolic reaction database or model of the invention as described below.


As used herein, the term “gene database” is intended to mean a computer readable medium or media that contains at least one reaction that is annotated to assign a reaction to one or more macromolecules that perform the reaction or to assign one or more nucleic acid that encodes the one or more macromolecules that perform the reaction. A gene database can contain a plurality of reactions, some or all of which are annotated. An annotation can include, for example, a name for a macromolecule; assignment of a function to a macromolecule; assignment of an organism that contains the macromolecule or produces the macromolecule; assignment of a subcellular location for the macromolecule; assignment of conditions under which a macromolecule is regulated with respect to performing a reaction, being expressed or being degraded; assignment of a cellular component that regulates a macromolecule; an amino acid or nucleotide sequence for the macromolecule; or any other annotation found for a macromolecule in a genome database such as those that can be found in Genbank, a site maintained by the NCBI (ncbi.nlm.gov), the Kyoto Encyclopedia of Genes and Genomes (KEGG) (www.genome.ad.jp/kegg/), the protein database SWISS-PROT (ca.expasy.org/sprot/), the LocusLink database maintained by the NCBI (www.ncbi.nlm.nih.gov/LocusLink/), the Enzyme Nomenclature database maintained by G. P. Moss of Queen Mary and Westfield College in the United Kingdom (www.chem.qmw.ac.uk/iubmb/enzyme/).


A gene database of the invention can include a substantially complete collection of genes or open reading frames in Homo sapiens or a substantially complete collection of the macromolecules encoded by the Homo sapiens genome. Alternatively, a gene database can include a portion of genes or open reading frames in Homo sapiens or a portion of the macromolecules encoded by the Homo sapiens genome, such as the portion that includes substantially all metabolic genes or macromolecules. The portion can be at least 10%, 15%, 20%, 25%, 50%, 75%, 90% or 95% of the genes or open reading frames encoded by the Homo sapiens genome, or the macromolecules encoded therein. A gene database can also include macromolecules encoded by at least a portion of the nucleotide sequence for the Homo sapiens genome such as at least 10%, 15%, 20%, 25%, 50%, 75%, 90% or 95% of the Homo sapiens genome. Accordingly, a computer readable medium or media of the invention can include at least one reaction for each macromolecule encoded by a portion of the Homo sapiens genome.


An in silico Homo sapiens model of the invention can be built by an iterative process which includes gathering information regarding particular reactions to be added to a model, representing the reactions in a reaction network data structure, and performing preliminary simulations wherein a set of constraints is placed on the reaction network and the output evaluated to identify errors in the network. Errors in the network such as gaps that lead to non-natural accumulation or consumption of a particular metabolite can be identified as described below and simulations repeated until a desired performance of the model is attained. An exemplary method for iterative model construction is provided in Example I.


Thus, the invention provides a method for making a data structure relating a plurality of Homo sapiens reactants to a plurality of Homo sapiens reactions in a computer readable medium or media. The method includes the steps of: (a) identifying a plurality of Homo sapiens reactions and a plurality of Homo sapiens reactants that are substrates and products of the Homo sapiens reactions; (by relating the plurality of Homo sapiens reactants to the plurality of Homo sapiens reactions in a data structure, wherein each of the Homo sapiens reactions includes a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product; (c) making a constraint set for the plurality of Homo sapiens reactions; (d) providing an objective function; (e) determining at least one flux distribution that minimizes or maximizes the objective function when the constraint set is applied to the data structure, and (f) if the at least one flux distribution is not predictive of Homo sapiens physiology, then adding a reaction to or deleting a reaction from the data structure and repeating step (e), if the at least one flux distribution is predictive of Homo sapiens physiology, then storing the data structure in a computer readable medium or media.


Information to be included in a data structure of the invention can be gathered from a variety of sources including, for example, annotated genome sequence information and biochemical literature.


Sources of annotated human genome sequence information include, for example, KEGG, SWISS-PROT, LocusLink, the Enzyme Nomenclature database, the International Human Genome Sequencing Consortium and commercial databases. KEGG contains a broad range of information, including a substantial amount of metabolic reconstruction. The genomes of 63 organisms can be accessed here, with gene products grouped by coordinated functions, often represented by a map (e.g., the enzymes involved in glycolysis would be grouped together). The maps are biochemical pathway templates which show enzymes connecting metabolites for various parts of metabolism. These general pathway templates are customized for a given organism by highlighting enzymes on a given template which have been identified in the genome of the organism. Enzymes and metabolites are active and yield useful information about stoichiometry, structure, alternative names and the like, when accessed.


SWISS-PROT contains detailed information about protein function. Accessible information includes alternate gene and gene product names, function, structure and sequence information, relevant literature references, and the like.


LocusLink contains general information about the locus where the gene is located and, of relevance, tissue specificity, cellular location, and implication of the gene product in various disease states.


The Enzyme Nomenclature database can be used to compare the gene products of two organisms. Often the gene names for genes with similar functions in two or more organisms are unrelated. When this is the case, the E. C. (Enzyme Commission) numbers can be used as unambiguous indicators of gene product function. The information in the Enzyme Nomenclature database is also published in Enzyme Nomenclature (Academic Press, San Diego, Calif., 1992) with 5 supplements to date, all found in the European Journal of Biochemistry (Blackwell Science, Malden, Mass.).


Sources of biochemical information include, for example, general resources relating to metabolism, resources relating specifically to human metabolism, and resources relating to the biochemistry, physiology and pathology of specific human cell types.


Sources of general information relating to metabolism, which were used to generate the human reaction databases and models described herein, were J. G. Salway, Metabolism at a Glance, 2nd ed., Blackwell Science, Malden, Mass. (1999) and T. M. Devlin, ed., Textbook of Biochemistry with Clinical Correlations, 4th ed., John Wiley and Sons, New York, NY (1997). Human metabolism-specific resources included J. R. Bronk, Human Metabolism: Functional Diversity and Integration, Addison Wesley Longman, Essex, England (1999).


The literature used in conjunction with the skeletal muscle metabolic models and simulations described herein included R. Maughan et al., Biochemistry of Exercise and Training, Oxford University Press, Oxford, England (1997), as well as references on muscle pathology such as S. Carpenter et al., Pathology of Skeletal Muscle, 2nd ed., Oxford University Press, Oxford, England (2001), and more specific articles on muscle metabolism as may be found in the Journal of Physiology (Cambridge University Press, Cambridge, England).


In the course of developing an in silico model of Homo sapiens metabolism, the types of data that can be considered include, for example, biochemical information which is information related to the experimental characterization of a chemical reaction, often directly indicating a protein(s) associated with a reaction and the stoichiometry of the reaction or indirectly demonstrating the existence of a reaction occurring within a cellular extract; genetic information, which is information related to the experimental identification and genetic characterization of a gene(s) shown to code for a particular protein(s) implicated in carrying out a biochemical event; genomic information, which is information related to the identification of an open reading frame and functional assignment, through computational sequence analysis, that is then linked to a protein performing a biochemical event; physiological information, which is information related to overall cellular physiology, fitness characteristics, substrate utilization, and phenotyping results, which provide evidence of the assimilation or dissimilation of a compound used to infer the presence of specific biochemical event (in particular translocations); and modeling information, which is information generated through the course of simulating activity of Homo sapiens cells using methods such as those described herein which lead to predictions regarding the status of a reaction such as whether or not the reaction is required to fulfill certain demands placed on a metabolic network. Additional information relevant to multicellular organisms that can be considered includes cell type-specific or condition-specific gene expression information, which can be determined experimentally, such as by gene array analysis or from expressed sequence tag (EST) analysis, or obtained from the biochemical and physiological literature.


The majority of the reactions occurring in Homo sapiens reaction networks are catalyzed by enzymes/proteins, which are created through the transcription and translation of the genes found within the chromosome in the cell. The remaining reactions occur either spontaneously or through non-enzymatic processes. Furthermore, a reaction network data structure can contain reactions that add or delete steps to or from a particular reaction pathway. For example, reactions can be added to optimize or improve performance of a Homo sapiens model in view of empirically observed activity. Alternatively, reactions can be deleted to remove intermediate steps in a pathway when the intermediate steps are not necessary to model flux through the pathway. For example, if a pathway contains 3 nonbranched steps, the reactions can be combined or added together to give a net reaction, thereby reducing memory required to store the reaction network data structure and the computational resources required for manipulation of the data structure.


The reactions that occur due to the activity of gene-encoded enzymes can be obtained from a genome database which lists genes identified from genome sequencing and subsequent genome annotation. Genome annotation consists of the locations of open reading frames and assignment of function from homology to other known genes or empirically determined activity. Such a genome database can be acquired through public or private databases containing annotated Homo sapiens nucleic acid or protein sequences. If desired, a model developer can perform a network reconstruction and establish the model content associations between the genes, proteins, and reactions as described, for example, in Covert et al. Trends in Biochemical Sciences 26:179-186 (2001) and Palsson, WO 00/46405.


As reactions are added to a reaction network data structure or metabolic reaction database, those having known or putative associations to the proteins/enzymes which enable/catalyze the reaction and the associated genes that code for these proteins can be identified by annotation. Accordingly, the appropriate associations for all of the reactions to their related proteins or genes or both can be assigned. These associations can be used to capture the non-linear relationship between the genes and proteins as well as between proteins and reactions. In some cases one gene codes for one protein which then perform one reaction. However, often there are multiple genes which are required to create an active enzyme complex and often there are multiple reactions that can be carried out by one protein or multiple proteins that can carry out the same reaction. These associations capture the logic (i.e. AND or OR relationships) within the associations. Annotating a metabolic reaction database with these associations can allow the methods to be used to determine the effects of adding or eliminating a particular reaction not only at the reaction level, but at the genetic or protein level in the context of running a simulation or predicting Homo sapiens activity.


A reaction network data structure of the invention can be used to determine the activity of one or more reactions in a plurality of Homo sapiens reactions independent of any knowledge or annotation of the identity of the protein that performs the reaction or the gene encoding the protein. A model that is annotated with gene or protein identities can include reactions for which a protein or encoding gene is not assigned. While a large portion of the reactions in a cellular metabolic network are associated with genes in the organism's genome, there are also a substantial number of reactions included in a model for which there are no known genetic associations. Such reactions can be added to a reaction database based upon other information that is not necessarily related to genetics such as biochemical or cell based measurements or theoretical considerations based on observed biochemical or cellular activity. For example, there are many reactions that can either occur spontaneously or are not protein-enabled reactions. Furthermore, the occurrence of a particular reaction in a cell for which no associated proteins or genetics have been currently identified can be indicated during the course of model building by the iterative model building methods of the invention.


The reactions in a reaction network data structure or reaction database can be assigned to subsystems by annotation, if desired. The reactions can be subdivided according to biological criteria, such as according to traditionally identified metabolic pathways (glycolysis, amino acid metabolism and the like) or according to mathematical or computational criteria that facilitate manipulation of a model that incorporates or manipulates the reactions. Methods and criteria for subdviding a reaction database are described in further detail in Schilling et al., J. Theor. Biol. 203:249-283 (2000), and in Schuster et al., Bioinformatics 18:351-361 (2002). The use of subsystems can be advantageous for a number of analysis methods, such as extreme pathway analysis, and can make the management of model content easier. Although assigning reactions to subsystems can be achieved without affecting the use of the entire model for simulation, assigning reactions to subsystems can allow a user to search for reactions in a particular subsystem which may be useful in performing various types of analyses. Therefore, a reaction network data structure can include any number of desired subsystems including, for example, 2 or more subsystems, 5 or more subsystems, 10 or more subsystems, 25 or more subsystems or 50 or more subsystems.


The reactions in a reaction network data structure or metabolic reaction database can be annotated with a value indicating the confidence with which the reaction is believed to occur in the Homo sapiens cell. The level of confidence can be, for example, a function of the amount and form of supporting data that is available. This data can come in various forms including published literature, documented experimental results, or results of computational analyses. Furthermore, the data can provide direct or indirect evidence for the existence of a chemical reaction in a cell based on genetic, biochemical, and/or physiological data.


The invention further provides a computer readable medium, containing (a) a data structure relating a plurality of Homo sapiens reactants to a plurality of Homo sapiens reactions, wherein each of the Homo sapiens reactions includes a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product, and (b) a constraint set for the plurality of Homo sapiens reactions.


Constraints can be placed on the value of any of the fluxes in the metabolic network using a constraint set. These constraints can be representative of a minimum or maximum allowable flux through a given reaction, possibly resulting from a limited amount of an enzyme present. Additionally, the constraints can determine the direction or reversibility of any of the reactions or transport fluxes in the reaction network data structure. Based on the in vivo environment where Homo sapiens lives the metabolic resources available to the cell for biosynthesis of essential molecules for can be determined. Allowing the corresponding transport fluxes to be active provides the in silico Homo sapiens with inputs and outputs for substrates and by-products produced by the metabolic network.


Returning to the hypothetical reaction network shown in FIG. 1, constraints can-be placed on each reaction in the exemplary format shown in FIG. 2, as follows. The constraints are provided in a format that can be used to constrain the reactions of the stoichiometric matrix shown in FIG. 3. The format for the constraints used for a matrix or in linear programming can be conveniently represented as a linear inequality such as

bj≦vj≦aj:j=1. . . n  (Eq. 1)

where vj is the metabolic flux vector, bj is the minimum flux value and aj is the maximum flux value. Thus, aj can take on a finite value representing a maximum allowable flux through a given reaction or bj can take on a finite value representing minimum allowable flux through a given reaction. Additionally, if one chooses to leave certain reversible reactions or transport fluxes to operate in a forward and reverse manner the flux may remain unconstrained by setting bj to negative infinity and aj to positive infinity as shown for reaction R2 in FIG. 2. If reactions proceed only in the forward reaction bj is set to zero while aj is set to positive infinity as shown for reactions R1, R3, R4, R5, and R6 in FIG. 2. As an example, to simulate the event of a genetic deletion or non-expression of a particular protein, the flux through all of the corresponding metabolic reactions related to the gene or protein in question are reduced to zero by setting aj and bj to be zero. Furthermore, if one wishes to simulate the absence of a particular growth substrate one can simply constrain the corresponding transport fluxes that allow the metabolite to enter the cell to be zero by setting aj and bj to be zero. On the other hand if a substrate is only allowed to enter or exit the cell via transport mechanisms, the corresponding fluxes can be properly constrained to reflect this scenario.


The ability of a reaction to be actively occurring is dependent on a large number of additional factors beyond just the availability of substrates. These factors, which can be represented as variable constraints in the models and methods of the invention include, for example, the presence of cofactors necessary to stabilize the protein/enzyme, the presence or absence of enzymatic inhibition and activation factors, the active formation of the protein/enzyme through translation of the corresponding mRNA transcript, the transcription of the associated gene(s) or the presence of chemical signals and/or proteins that assist in controlling these processes that ultimately determine whether a chemical reaction is capable of being carried out within an organism. Of particular importance in the regulation of human cell types is the implementation of paracrine and endocrine signaling pathways to control cellular activities. In these cases a cell secretes signaling molecules that may be carried far afield to act on distant targets (endocrine signaling), or act as local mediators (paracrine signaling). Examples of endocrine signaling molecules include hormones such as insulin, while examples of paracrine signaling molecules include neurotransmitters such as acetylcholine. These molecules induce cellular responses through signaling cascades that affect the activity of biochemical reactions in the cell.


Regulation can be represented in an in silico Homo sapiens model by providing a variable constraint as set forth below.


Thus, the invention provides a computer readable medium or media, including (a) a data structure relating a plurality of Homo sapiens reactants to a plurality of Homo sapiens reactions, wherein each of the reactions includes a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product, and wherein at least one of the reactions is a regulated reaction; and (b) a constraint set for the plurality of reactions, wherein the constraint set includes a variable constraint for the regulated reaction.


As used herein, the term “regulated,” when used in reference to a reaction in a data structure, is intended to mean a reaction that experiences an altered flux due to a change in the value of a constraint or a reaction that has a variable constraint.


As used herein, the term “regulatory reaction” is intended to mean a chemical conversion or interaction that alters the activity of a protein, macromolecule or enzyme. A chemical conversion or interaction can directly alter the activity of a protein, macromolecule or enzyme such as occurs when the protein, macromolecule or enzyme is post-translationally modified or can indirectly alter the activity of a protein, macromolecule or enzyme such as occurs when a chemical conversion or binding event leads to altered expression of the protein, macromolecule or enzyme. Thus, transcriptional or translational regulatory pathways can indirectly alter a protein, macromolecule or enzyme or an associated reaction. Similarly, indirect regulatory reactions can include reactions that occur due to downstream components or participants in a regulatory reaction network. When used in reference to a data structure or in silico Homo sapiens model, the term is intended to mean a first reaction that is related to a second reaction by a function that alters the flux through the second reaction by changing the value of a constraint on the second reaction.


As used herein, the term “regulatory data structure” is intended to mean a representation of an event, reaction or network of reactions that activate or inhibit a reaction, the representation being in a format that can be manipulated or analyzed. An event that activates a reaction can be an event that initiates the reaction or an event that increases the rate or level of activity for the reaction. An event that inhibits a reaction can be an event that stops the reaction or an event that decreases the rate or level of activity for the reaction. Reactions that can be represented in a regulatory data structure include, for example, reactions that control expression of a macromolecule that in turn, performs a reaction such as transcription and translation reactions, reactions that lead to post translational modification of a protein or enzyme such as phophorylation, dephosphorylation, prenylation, methylation, oxidation or covalent modification, reactions that process a protein or enzyme such as removal of a pre- or pro-sequence, reactions that degrade a protein or enzyme or reactions that lead to assembly of a protein or enzyme.


As used herein, the term “regulatory event” is intended to mean a modifier of the flux through a reaction that is independent of the amount of reactants available to the reaction. A modification included in the term can be a change in the presence, absence, or amount of an enzyme that performs a reaction. A modifier included in the term can be a regulatory reaction such as a signal transduction reaction or an environmental condition such as a change in pH, temperature, redox potential or time. It will be understood that when used in reference to an in silico Homo sapiens model or data structure a regulatory event is intended to be a representation of a modifier of the flux through a Homo sapiens reaction that is independent of the amount of reactants available to the reaction.


The effects of regulation on one or more reactions that occur in Homo sapiens can be predicted using an in silica Homo sapiens model of the invention. Regulation can be taken into consideration in the context of a particular condition being examined by providing a variable constraint for the reaction in an in silico Homo sapiens model. Such constraints constitute condition-dependent constraints. A data structure can represent regulatory reactions as Boolean logic statements (Reg-reaction). The variable takes on a value of 1 when the reaction is available for use in the reaction network and will take on a value of 0 if the reaction is restrained due to some regulatory feature. A series of Boolean statements can then be introduced to mathematically represent the regulatory network as described for example in Covert et al. J. Theor. Biol. 213:73-88 (2001). For example, in the case of a transport reaction (A_in) that imports metabolite A, where metabolite A inhibits reaction R2 as shown in FIG. 4, a Boolean rule can state that:

Reg−R2=IF NOT(A_in)  (Eq. 2)

This statement indicates that reaction R2 can occur if reaction A_in is not occurring (i.e. if metabolite A is not present). Similarly, it is possible to assign the regulation to a variable A which would indicate an amount of A above or below a threshold that leads to the inhibition of reaction R2. Any function that provides values for variables corresponding to each of the reactions in the biochemical reaction network can be used to represent a regulatory reaction or set of regulatory reactions in a regulatory data structure. Such functions can include, for example, fuzzy logic, heuristic rule-based descriptions, differential equations or kinetic equations detailing system dynamics.


A reaction constraint placed on a reaction can be incorporated into an in silico Homo sapiens model using the following general equation:

(Reg-Reaction) * bj≦vj≦aj* (Reg-Reaction)   (Eq. 3)

    • j=1 . . . n


      For the example of reaction R2 this equation is written as follows:

      (0)*Reg−R2≦R2≦(∞)·Reg−R2   (Eq. 4)

      Thus, during the course of a simulation, depending upon the presence or absence of metabolite A in the interior of the cell where reaction R2 occurs, the value for the upper boundary of flux for reaction R2 will change from 0 to infinity, respectively.


With the effects of a regulatory event or network taken into consideration by a constraint function and the condition-dependent constraints set to an initial relevant value, the behavior of the Homo sapiens reaction network can be simulated for the conditions considered as set forth below.


Although regulation has been exemplified above for the case where a variable constraint is dependent upon the outcome of a reaction in the data structure, a plurality of variable constraints can be included in an in silico Homo sapiens model to represent regulation of a plurality of reactions. Furthermore, in the exemplary case set forth above, the regulatory structure includes a general control stating that a reaction is inhibited by a particular environmental condition. Using a general control of this type, it is possible to incorporate molecular mechanisms and additional detail into the regulatory structure that is responsible for determining the active nature of a particular chemical reaction within an organism.


Regulation can also be simulated by a model of the invention and used to predict a Homo sapiens physiological function without knowledge of the precise molecular mechanisms involved in the reaction network being modeled. Thus, the model can be used to predict, in silico, overall regulatory events or causal relationships that are not apparent from in vivo observation of any one reaction in a network or whose in vivo effects on a particular reaction are not known. Such overall regulatory effects can include those that result from overall environmental conditions such as changes in pH, temperature, redox potential, or the passage of time.


The in silico Homo sapiens model and methods described herein can be implemented on any conventional host computer system, such as those based on Intel.RTM. microprocessors and running Microsoft Windows operating systems. Other systems, such as those using the UNIX or LINUX operating system and based on IBM.RTM., DEC.RTM. or Motorola.RTM. microprocessors are also contemplated. The systems and methods described herein can also be implemented to run on client-server systems and wide-area networks, such as the Internet.


Software to implement a method or model of the invention can be written in any well-known computer language, such as Java, C, C++, Visual Basic, FORTRAN or COBOL and compiled using any well-known compatible compiler. The software of the invention normally runs from instructions stored in a memory on a host computer system. A memory or computer readable medium can be a hard disk, floppy disc, compact disc, magneto-optical disc, Random Access Memory, Read Only Memory or Flash Memory. The memory or computer readable medium used in the invention can be contained within a single computer or distributed in a network. A network can be any of a number of conventional network systems known in the art such as a local area network (LAN) or a wide area network (WAN). Client-server environments, database servers and networks that can be used in the invention are well known in the art. For example, the database server can run on an operating system such as UNIX, running a relational database management system, a World Wide Web application and a World Wide Web server. Other types of memories and computer readable media are also contemplated to function within the scope of the invention.


A database or data structure of the invention can be represented in a markup language format including, for example, Standard Generalized Markup Language (SGML), Hypertext markup language (HTML) or Extensible Markup language (XML). Markup languages can be used to tag the information stored in a database or data structure of the invention, thereby providing convenient annotation and transfer of data between databases and data structures. In particular, an XML format can be useful for structuring the data representation of reactions, reactants and their annotations; for exchanging database contents, for example, over a network or internet; for updating individual elements using the document object model; or for providing differential access to multiple users for different information content of a data base or data structure of the invention. XML programming methods and editors for writing XML code are known in the art as described, for example, in Ray, “Learning XML” O'Reilly and Associates, Sebastopol, Calif. (2001).


A set of constraints can be applied to a reaction network data structure to simulate the flux of mass through the reaction network under a particular set of environmental conditions specified by a constraints set. Because the time constants characterizing metabolic transients and/or metabolic reactions are typically very rapid, on the order of milli-seconds to seconds, compared to the time constants of cell growth on the order of hours to days, the transient mass balances can be simplified to only consider the steady state behavior. Referring now to an example where the reaction network data structure is a stoichiometric matrix, the steady state mass balances can be applied using the following system of linear equations

S·v=0   (Eq. 5)

where S is the stoichiometric matrix as defined above and v is the flux vector. This equation defines the mass, energy, and redox potential constraints placed on the metabolic network as a result of stoichiometry. Together Equations 1 and 5 representing the reaction constraints and mass balances, respectively, effectively define the capabilities and constraints of the metabolic genotype and the organism's metabolic potential. All vectors, v, that satisfy Equation 5 are said to occur in the mathematical nullspace of S. Thus, the null space defines steady-state metabolic flux distributions that do not violate the mass, energy, or redox balance constraints. Typically, the number of fluxes is greater than the number of mass balance constraints, thus a plurality of flux distributions satisfy the mass balance constraints and occupy the null space. The null space, which defines the feasible set of metabolic flux distributions, is further reduced in size by applying the reaction constraints set forth in Equation 1 leading to a defined solution space. A point in this space represents a flux distribution and hence a metabolic phenotype for the network. An optimal solution within the set of all solutions can be determined using mathematical optimization methods when provided with a stated objective and a constraint set. The calculation of any solution constitutes a simulation of the model.


Objectives for activity of a human cell can be chosen. While the overall objective of a multi-cellular organism may be growth or reproduction, individual human cell types generally have much more complex objectives, even to the seemingly extreme objective of apoptosis (programmed cell death), which may benefit the organism but certainly not the individual cell. For example, certain cell types may have the objective of maximizing energy production, while others have the objective of maximizing the production of a particular hormone, extracellular matrix component, or a mechanical property such as contractile force. In cases where cell reproduction is slow, such as human skeletal muscle, growth and its effects need not be taken into account. In other cases, biomass composition and growth rate could be incorporated into a “maintenance” type of flux, where rather than optimizing for growth, production of precursors is set at a level consistent with experimental knowledge and a different objective is optimized.


Certain cell types, including cancer cells, can be viewed as having an objective of maximizing cell growth. Growth can be defined in terms of biosynthetic requirements based on literature values of biomass composition or experimentally determined values such as those obtained as described above. Thus, biomass generation can be defined as an exchange reaction that removes intermediate metabolites in the appropriate ratios and represented as an objective function. In addition to draining intermediate metabolites this reaction flux can be formed to utilize energy molecules such as ATP, NADH and NADPH so as to incorporate any maintenance requirement that must be met. This new reaction flux then becomes another constraint/balance equation that the system must satisfy as the objective function. Using the stoichiometric matrix of FIG. 3 as an example, adding such a constraint is analogous to adding the additional column Vgrowth to the stoichiometric matrix to represent fluxes to describe the production demands placed on the metabolic system. Setting this new flux as the objective function and asking the system to maximize the value of this flux for a given set of constraints on all the other fluxes is then a method to simulate the growth of the organism.


Continuing with the example of the stoichiometric matrix applying a constraint set to a reaction network data structure can be illustrated as follows. The solution to equation 5 can be formulated as an optimization problem, in which the flux distribution that minimizes a particular objective is found. Mathematically, this optimization problem can be stated as:

Minimize Z   (Eq. 6)
where z=Σci·vi  (Eq. 7)


where Z is the objective which is represented as a linear combination of metabolic fluxes vi using the weights ci in this linear combination. The optimization problem can also be stated as the equivalent maximization problem; i.e. by changing the sign on Z. Any commands for solving the optimazation problem can be used including, for example, linear programming commands.


A computer system of the invention can further include a user interface capable of receiving a representation of one or more reactions. A user interface of the invention can also be capable of sending at least one command for modifying the data structure, the constraint set or the commands for applying the constraint set to the data representation, or a combination thereof. The interface can be a graphic user interface having graphical means for making selections such as menus or dialog boxes. The interface can be arranged with layered screens accessible by making selections from a main screen. The user interface can provide access to other databases useful in the invention such as a metabolic reaction database or links to other databases having information relevant to the reactions or reactants in the reaction network data structure or to Homo sapiens physiology. Also, the user interface can display a graphical representation of a reaction network or the results of a simulation using a model of the invention.


Once an initial reaction network data structure and set of constraints has been created, this model can be tested by preliminary simulation. During preliminary simulation, gaps in the network or “dead-ends” in which a metabolite can be produced but not consumed or where a metabolite can be consumed but not produced can be identified. Based on the results of preliminary simulations areas of the metabolic reconstruction that require an additional reaction can be identified. The determination of these gaps can be readily calculated through appropriate queries of the reaction network data structure and need not require the use of simulation strategies, however, simulation would be an alternative approach to locating such gaps.


In the preliminary simulation testing and model content refinement stage the existing model is subjected to a series of functional tests to determine if it can perform basic requirements such as the ability to produce the required biomass constituents and generate predictions concerning the basic physiological characteristics of the particular cell type being modeled. The more preliminary testing that is conducted the higher the quality of the model that will be generated. Typically, the majority of the simulations used in this stage of development will be single optimizations. A single optimization can be used to calculate a single flux distribution demonstrating how metabolic resources are routed determined from the solution to one optimization problem. An optimization problem can be solved using linear programming as demonstrated in the Examples below. The result can be viewed as a display of a flux distribution on a reaction map. Temporary reactions can be added to the network to determine if they should be included into the model based on modeling/simulation requirements.


Once a model of the invention is sufficiently complete with respect to the content of the reaction network data structure according to the criteria set forth above, the model can be used to simulate activity of one or more reactions in a reaction network. The results of a simulation can be displayed in a variety of formats including, for example, a table, graph, reaction network, flux distribution map or a phenotypic phase plane graph.


Thus, the invention provides a method for predicting a Homo sapiens physiological function. The method includes the steps of (a) providing a data structure relating a plurality of Homo sapiens reactants to a plurality of Homo sapiens reactions, wherein each of the Homo sapiens reactions includes a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating said substrate and said product; (b) providing a constraint set for the plurality of Homo sapiens reactions; (c) providing an objective function, and (d) determining at least one flux distribution that minimizes or maximizes the objective function when the constraint set is applied to the data structure, thereby predicting a Homo sapiens physiological function.


A method for predicting a Homo sapiens physiological function can include the steps of (a) providing a data structure relating a plurality of Homo sapiens reactants to a plurality of Homo sapiens reactions, wherein each of the Homo sapiens reactions includes a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product, and wherein at least one of the reactions is a regulated reaction; (b) providing a constraint set for the plurality of reactions, wherein the constraint set includes a variable constraint for the regulated reaction; (c) providing a condition-dependent value to the variable constraint; (d) providing an objective function, and (e) determining at least one flux distribution that minimizes or maximizes the objective function when the constraint set is applied to the data structure, thereby predicting a Homo sapiens physiological function.


As used herein, the term “physiological function,” when used in reference to Homo sapiens, is intended to mean an activity of a Homo sapiens cell as a whole. An activity included in the term can be the magnitude or rate of a change from an initial state of a Homo sapiens cell to a final state of the Homo sapiens cell. An activity included in the term can be, for example, growth, energy production, redox equivalent production, biomass production, development, or consumption of carbon nitrogen, sulfur, phosphate, hydrogen or oxygen. An activity can also be an output of a particular reaction that is determined or predicted in the context of substantially all of the reactions that affect the particular reaction in a Homo sapiens cell or substantially all of the reactions that occur in a Homo sapiens cell (e.g. muscle contraction). Examples of a particular reaction included in the term are production of biomass precursors, production of a protein, production of an amino acid, production of a purine, production of a pyrimidine, production of a lipid, production of a fatty acid, production of a cofactor or transport of a metabolite. A physiological function can include an emergent property which emerges from the whole but not from the sum of parts where the parts are observed in isolation (see for example, Palsson, Nat. Biotech 18:1147-1150 (2000)).


A physiological function of Homo sapiens reactions can be determined using phase plane analysis of flux distributions. Phase planes are representations of the feasible set which can be presented in two or three dimensions. As an example, two parameters that describe the growth conditions such as substrate and oxygen uptake rates can be defined as two axes of a two-dimensional space. The optimal flux distribution can be calculated from a reaction network data structure and a set of constraints as set forth above for all points in this plane by repeatedly solving the linear programming problem while adjusting the exchange fluxes defining the two-dimensional space. A finite number of qualitatively different metabolic pathway utilization patterns can be identified in such a plane, and lines can be drawn to demarcate these regions. The demarcations defining the regions can be determined using shadow prices of linear optimization as described, for example in Chvatal, Linear Programming New York, W. H. Freeman and Co. (1983). The regions are referred to as regions of constant shadow price structure. The shadow prices define the intrinsic value of each reactant toward the objective function as a number that is either negative, zero, or positive and are graphed according to the uptake rates represented by the x and y axes. When the shadow prices become zero as the value of the uptake rates are changed there is a qualitative shift in the optimal reaction network.


One demarcation line in the phenotype phase plane is defined as the line of optimality (LO). This line represents the optimal relation between respective metabolic fluxes. The LO can be identified by varying the x-axis flux and calculating the optimal y-axis flux with the objective function defined as the growth flux From the phenotype phase plane analysis the conditions under which a desired activity is optimal can be determined. The maximal uptake rates lead to the definition of a finite area of the plot that is the predicted outcome of a reaction network within the environmental conditions represented by the constraint set. Similar analyses can be performed in multiple dimensions where each dimension on the plot corresponds to a different uptake rate. These and other methods for using phase plane analysis, such as those described in Edwards et al., Biotech Bioeng. 77:27-36(2002), can be used to analyze the results of a simulation using an in silico Homo sapiens model of the invention.


A physiological function of Homo sapiens can also be determined using a reaction map to display a flux distribution. A reaction map of Homo sapiens can be used to view reaction networks at a variety of levels. In the case of a cellular metabolic reaction network a reaction map can contain the entire reaction complement representing a global perspective. Alternatively, a reaction map can focus on a particular region of metabolism such as a region corresponding to a reaction subsystem described above or even on an individual pathway or reaction.


Thus, the invention provides an apparatus that produces a representation of a Homo sapiens physiological function, wherein the representation is produced by a process including the steps of: (a) providing a data structure relating a plurality of Homo sapiens reactants to a plurality of Homo sapiens reactions, wherein each of the Homo sapiens reactions includes a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating said substrate and said product; (b) providing a constraint set for the plurality of Homo sapiens reactions; (c) providing an objective function; (d) determining at least one flux distribution that minimizes or maximizes the objective function when the constraint set is applied to the data structure, thereby predicting a Homo sapiens physiological function, and (e) producing a representation of the activity of the one or more Homo sapiens reactions.


The methods of the invention can be used to determine the activity of a plurality of Homo sapiens reactions including, for example, biosynthesis of an amino acid, degradation of an amino acid, biosynthesis of a purine, biosynthesis of a pyrimidine, biosynthesis of a lipid, metabolism of a fatty acid, biosynthesis of a cofactor, transport of a metabolite and metabolism of an alternative carbon source. In addition, the methods can be used to determine the activity of one or more of the reactions described above or listed in Table 1.


The methods of the invention can be used to determine a phenotype of a Homo sapiens mutant. The activity of one or more Homo sapiens reactions can be determined using the methods described above, wherein the reaction network data structure lacks one or more gene-associated reactions that occur in Homo sapiens. Alternatively, the methods can be used to determine the activity of one or more Homo sapiens reactions when a reaction that does not naturally occur in Homo sapiens is added to the reaction network data structure. Deletion of a gene can also be represented in a model of the invention by constraining the flux through the reaction to zero, thereby allowing the reaction to remain within the data structure. Thus, simulations can be made to predict the effects of adding or removing genes to or from Homo sapiens. The methods can be particularly useful for determining the effects of adding or deleting a gene that encodes for a gene product that performs a reaction in a peripheral metabolic pathway.


A drug target or target for any other agent that affects Homo sapiens function can be predicted using the methods of the invention. Such predictions can be made by removing a reaction to simulate total inhibition or prevention by a drug or agent. Alternatively, partial inhibition or reduction in the activity a particular reaction can be predicted by performing the methods with altered constraints. For example, reduced activity can be introduced into a model of the invention by altering the aj or bj values for the metabolic flux vector of a target reaction to reflect a finite maximum or minimum flux value corresponding to the level of inhibition. Similarly, the effects of activating a reaction, by initiating or increasing the activity of the reaction, can be predicted by performing the methods with a reaction network data structure lacking a particular reaction or by altering the aj or bj values for the metabolic flux vector of a target reaction to reflect a maximum or minimum flux value corresponding to the level of activation. The methods can be particularly useful for identifying a target in a peripheral metabolic pathway.


Once a reaction has been identified for which activation or inhibition produces a desired effect on Homo sapiens function, an enzyme or macromolecule that performs the reaction in Homo sapiens or a gene that expresses the enzyme or macromolecule can be identified as a target for a drug or other agent. A candidate compound for a target identified by the methods of the invention can be isolated or synthesized using known methods. Such methods for isolating or synthesizing compounds can include, for example, rational design based on known properties of the target (see, for example, DeCamp et al., Protein Engineering Principles and Practice, Ed. Cleland and Craik, Wiley-Liss, New York, pp. 467-506 (1996)), screening the target against combinatorial libraries of compounds (see for example, Houghten et al., Nature, 354, 84-86 (1991); Dooley et al., Science, 266, 2019-2022 (1994), which describe an iterative approach, or R. Houghten et al. PCT/US91/08694 and U.S. Pat. No. 5,556,762 which describe the positional-scanning approach), or a combination of both to obtain focused libraries. Those skilled in the art will know or will be able to routinely determine assay conditions to be used in a screen based on properties of the target or activity assays known in the art.


A candidate drug or agent, whether identified by the methods described above or by other methods known in the art, can be validated using an in silico Homo sapiens model or method of the invention. The effect of a candidate drug or agent on Homo sapiens physiological function can be predicted based on the activity for a target in the presence of the candidate drug or agent measured in vitro or in vivo. This activity can be represented in an in silico Homo sapiens model by adding a reaction to the model, removing a reaction from the model or adjusting a constraint for a reaction in the model to reflect the measured effect of the candidate drug or agent on the activity of the reaction. By running a simulation under these conditions the holistic effect of the candidate drug or agent on Homo sapiens physiological function can be predicted.


The methods of the invention can be used to determine the effects of one or more environmental components or conditions on an activity of a Homo sapiens cell. As set forth above an exchange reaction can be added to a reaction network data structure corresponding to uptake of an environmental component, release of a component to the environment, or other environmental demand. The effect of the environmental component or condition can be further investigated by running simulations with adjusted aj or bj values for the metabolic flux vector of the exchange reaction target reaction to reflect a finite maximum or minimum flux value corresponding to the effect of the environmental component or condition. The environmental component can be, for example an alternative carbon source or a metabolite that when added to the environment of a Homo sapiens cell can be taken up and metabolized. The environmental component can also be a combination of components present for example in a minimal medium composition. Thus, the methods can be used to determine an optimal or minimal medium composition that is capable of supporting a particular activity of Homo sapiens.


The invention further provides a method for determining a set of environmental components to achieve a desired activity for Homo sapiens. The method includes the steps of (a) providing a data structure relating a plurality of Homo sapiens reactants to a plurality of Homo sapiens reactions, wherein each of the Homo sapiens reactions includes a reactant identified as a substrate of the reaction, a reactant identified as a product of the reaction and a stoichiometric coefficient relating the substrate and the product; (b)providing a constraint set for the plurality of Homo sapiens reactions; (c) applying the constraint set to the data representation, thereby determining the activity of one or more Homo sapiens reactions (d) determining the activity of one or more Homo sapiens reactions according to steps (a) through (c), wherein the constraint set includes an upper or lower bound on the amount of an environmental component and (e) repeating steps (a) through (c) with a changed constraint set, wherein the activity determined in step (e) is improved compared to the activity determined in step (d).


The following examples are intended to illustrate but not limit the present invention.


EXAMPLE I

This example shows the construction of a universal Homo sapiens metabolic reaction database, a Homo sapiens core metabolic reaction database and a Homo sapiens muscle cell metabolic reaction database. This example also shows the iterative model building process used to generate a Homo sapiens core metabolic model and a Homo sapiens muscle cell metabolic model.


A universal Homo sapiens reaction database was prepared from the genome databases and biochemical literature. The reaction database shown in Table 1 contains the following information:


Locus ID—the locus number of the gene found in the LocusLink website.


Gene Ab.—various abbreviations which are used for the gene.


Reaction Stoichiometry—includes all metabolites and direction of the reaction, as well as reversibility.


E.C.—The Enzyme Commission number.


Additional information included in the universal reaction database, although not shown in Table 1, included the chapter of Salway, supra (1999), where relevant reactions were found; the cellular location, if the reaction primarily occurs in a given compartment; the SWISS PROT identifier, which can be used to locate the gene record in SWISS PROT; the full name of the gene at the given locus; the chromosomal location of the gene; the Mendelian Inheritance in Man (MIM) data associated with the gene; and the tissue type, if the gene is primarily expressed in a certain tissue. Overall, 1130 metabolic enzyme- or transporter-encoding genes were included in the universal reaction database.


Fifty-nine reactions in the universal reaction database were identified and included based on biological data as found in Salway supra (1999), currently without genome annotation. Ten additional reactions, not described in the biochemical literature or genome annotation, were subsequently included in the reaction database following preliminary simulation testing and model content refinement. These 69 reactions are shown at the end of Table 1.


From the universal Homo sapiens reaction database shown in Table 1, a core metabolic reaction database was established, which included core metabolic reactions as well as some amino acid and fatty acid metabolic reactions, as described in Chapters 1, 3, 4, 7, 9, 10, 13, 17, 18 and 44 of J. G. Salway, Metabolism at a Glance, 2nd ed., Blackwell Science, Malden, Mass. (1999). The core metabolic reaction database included 211 unique reactions, accounting for 737 genes in the Homo sapiens genome. The core metabolic reaction database was used, although not in its entirety, to create the core metabolic model described in Example II.


To allow for the modeling of muscle cells, the core reaction database was expanded to include 446 unique reactions, accounting for 889 genes in the Homo sapiens genome. This skeletal muscle metabolic reaction database was used to create the skeletal muscle metabolic model described in Example II.


Once the core and muscle cell metabolic reaction databases were compiled, the reactions were represented as a metabolic network data structure, or “stoichiometric input file.” For example, the core metabolic network data structure shown in Table 2 contains 33 reversible reactions, 31 non-reversible reactions, 97 matrix columns and 52 unique enzymes. Each reaction in Table 2 is represented so as to indicate the substrate or substrates (a negative number) and the product or products (a positive number); the stoichiometry; the name of each reaction (the term following the zero); and whether the reaction is reversible (an R following the reaction name). A metabolite that appears in the mitochondria is indicated by an “m,” and a metabolite that appears in the extracellular space is indicated by an “ex.”


To perform a preliminary simulation or to simulate a physiological condition, a set of inputs and outputs has to be defined and the network objective function specified. To calculate the maximum ATP production of the Homo sapiens core metabolic network using glucose as a carbon source, a non-zero uptake value for glucose was assigned and ATP production was maximized as the objective function, using the representation shown in Table 2. The network's performance was examined by optimizing for the given objective function and the set of constraints defined in the input file, using flux balance analysis methods. The model was refined in an iterative manner by examining the results of the simulation and implementing the appropriate changes.


Using this iterative procedure, two metabolic reaction networks were generated, representing human core metabolism and human skeletal muscle cell metabolism.


EXAMPLE II

This example shows how human metabolism can be accurately simulated using a Homo sapiens core metabolic model.


The human core metabolic reaction database shown in Table 3 was used in simulations of human core metabolism. This reaction database contains a total of 65 reactions, covering the classic biochemical pathways of glycolysis, the pentose phosphate pathway, the tricitric acid cycle, oxidative phosphorylation, glycogen storage, the malate/aspartate shuttle, the glycerol phosphate shuttle, and plasma and mitochondrial membrane transporters. The reaction network was divided into three compartments: the cytosol, mitochondria, and the extracellular space. The total number of metabolites in the network is 50, of which 35 also appear in the mitochondria. This core metabolic network accounts for 250 human genes.


To perform simulations using the core metabolic network, network properties such as the P/O ratio were specified using Salway, supra (1999) as a reference. Oxidation of NADH through the Electron Transport System (ETS) was set to generate 2.5 ATP molecules (i.e. a P/O ratio of 2.5 for NADH), and that of FADH2 was set to 1.5 ATP molecules (i.e. a P/O ratio of 1.5 for FADH2).


Using the core metabolic network, aerobic and anaerobic metabolisms were simulated in silico. Secretion-of metabolic by-products was in agreement with the known physiological parameters. Maximum yield of all 12 precursor-metabolites (glucose-6-phosphate, fructose-6-phosphate, ribose-5-phosphate, erythrose-4-phosphate, triose phosphate, 3-phosphoglycerate, phosphoenolpyruvate, pyruvate, acetyl CoA, α-ketoglutarate, succinyl CoA, and oxaloacetate) was examined and none found to exceed the values of its theoretical yield.


Maximum ATP yield was also examined in the cytosol and mitochondria. Salway, supra (1999) reports that in the absence of membrane proton-coupled transport systems, the energy yield is 38 ATP molecules per molecule of glucose and otherwise 31 ATP molecules per molecule of glucose. The core metabolic model demonstrated the same values as described by Salway supra (1999). Energy yield in the mitochondria was determined to be 38 molecules of ATP per glucose molecule. This is equivalent to production of energy in the absence of proton-couple transporters across mitochondrial membrane since all the protons were utilized only in oxidative phosphorylation. In the cytosol, energy yield was calculated to be 30.5 molecules of ATP per glucose molecule. This value reflects the cost of metabolite exchange across the mitochondrial membrane as described by Salway, supra (1999).


EXAMPLE III

This example shows how human muscle cell metabolism can be accurately simulated under various physiological and pathological conditions using a Homo sapiens muscle cell metabolic model.


As described in Example I, the core metabolic model was extended to also include all the major reactions occurring in the skeletal muscle cell, adding new functions to the classical metabolic pathways found in the core model, such as fatty acid synthesis and β-oxidation, triacylglycerol and phospholipid formation, and amino acid metabolism. Simulations were performed using the muscle cell reaction database shown in Table 4. The biochemical reactions were again compartmentalized into cytosolic and mitochondrial compartments.


To simulate physiological behavior of human skeletal muscle cells, an objective function had to be defined. Growth of muscle cells occurs in time scales of several hours to days. The time scale of interest in the simulation, however, was in the order of several to tens of minutes, reflecting the time period of metabolic changes during exercise. Thus, contraction (defined as, and related to energy production) was chosen to be the objective function, and no additional constraints were imposed to represent growth demands in the cell.


To study and test the behavior of the network, twelve physiological cases (Table 5) and five disease cases (Table 6) were examined. The input and output of metabolites were specified as indicated in Table 5, and maximum energy production and metabolite secretions were calculated and taken into account.









TABLE 5







Metabolite



















Exchange
1
2
3
4
5
6
7
8
9
10
11
12





Glucose
I
I


I
I








O2
I

I

I

I

I

I



Palmitate
I
I






I
I




Glycogen
I
I
I
I










Phosphocrea-
I
I








I
I


tine


Triacylgly-
I
I




I
I






cerol


Isoleucine
I
I












Valine
I
I












Hydroxybuty-














rate


Pyruvate
O
O
O
O
O
O
O
O
O
O
O
O


Lactate
O
O
O
O
O
O
O
O
O
O
O
O


Albumin
O
O
O
O
O
O
O
O
O
O
O
O



















TABLE 6








Reaction



Disease
Enzyme Deficiency
Constrained








McArdle's disease
phosphorylase
GBE1



Tarui's disease
phosphofructokianse
PFKL



Phosphoglycerate
phosphoglycerate kinase
PGK1R



kinase deficiency





Phosphoglycerate
phosphoglycerate mutase
PGAM3R



mutase deficiency





Lactate dehydrogenase
Lactate dehyrogenase
LDHAR



deficiency









The skeletal muscle model was tested for utilization of various carbon sources available during various stages of exercise and food starvation (Table 5). The by-product secretion of the network in an aerobic to anaerobic shift was qualitatively compared to physiological outcome of exercise and found to exhibit the same general features such as secretion of fermentative by-products and lowered energy yield.


The network behavior was also examined for five disease cases (Table 6). The test cases were chosen based on their physiological relevance to the model's predictive capabilities. In brief, McArdle's disease is marked by the impairment of glycogen breakdown. Tarui's disease is characterized by a deficiency in phosphofructokinase. The remaining diseases examined are marked by a deficiency of metabolic enzymes phosphoglycerate kinase, phosphoglycerate mutase, and lactate dehydrogenase. In each case, the changes in flux and by-product secretion of metabolites were examined for an aerobic to anaerobic metabolic shift with glycogen and phosphocreatine as the sole carbon sources to the network and pyruvate, lactate, and albumin as the only metabolic by-products allowed to leave the system. To simulate the disease cases, the corresponding deficient enzyme was constrained to zero. In all cases, a severe reduction in energy production was demonstrated during exercise, representing the state of the disease as seen in clinical cases.


Throughout this application various publications have been referenced. The disclosures of these publications in their entireties are hereby incorporated by reference in this application in order to more fully describe the state of the art to which this invention pertains.


Although the invention has been described with reference to the examples provided above, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the claims.












TABLE 1





Locus





ID
Gene Ab.
Reaction Stoichiometry
E.C.















1. Carbohydrate Metabolism


1.1 Glycolysis/Gluconeogenesis [PATH: hsa00010]











3098

HK1
GLC + ATP -> G6P + ADP

2.7.1.1




3099

HK2
GLC + ATP -> G6P + ADP

2.7.1.1




3101

HK3
GLC + ATP -> G6P + ADP

2.7.1.1




2645

GCK, HK4, MODY2, NIDDM
GLC + ATP -> G6P + ADP

2.7.1.2




2538

G6PC, G6PT
G6P + H2O -> GLC + PI

3.1.3.9




2821

GPI
G6P <-> F6P

5.3.1.9




5211

PFKL
F6P + ATP -> FDP + ADP

2.7.1.11




5213

PFKM
F6P + ATP -> FDP + ADP

2.7.1.11




5214

PFKP, PFK-C
F6P + ATP -> FDP + ADP

2.7.1.11




5215

PFKX
F6P + ATP -> FDP + ADP

2.7.1.11




2203

FBP1, FBP
FDP + H2O -> F6P + PI

3.1.3.11




8789

FBP2
FDP + H2O -> F6P + PI

3.1.3.11




226

ALDOA
FDP <-> T3P2 + T3P1

4.1.2.13




229

ALDOB
FDP <-> T3P2 + T3P1

4.1.2.13




230

ALDOC
FDP <-> T3P2 + T3P1

4.1.2.13




7167

TPI1
T3P2 <-> T3P1

5.3.1.1




2597

GAPD, GAPDH
T3P1 + PI + NAD <-> NADH + 13PDG

1.2.1.12




26300

GAPDS, GAPDH-2
T3P1 + PI + NAD <-> NADH + 13PDG

1.2.1.12




5230

PGK1, PGKA
13PDG + ADP <-> 3PG + ATP

2.7.2.3




5233

PGK2
13PDG + ADP <-> 3PG + ATP

2.7.2.3




5223

PGAM1, PGAMA
13PDG -> 23PDG

5.4.2.4





23PDG + H2O -> 3PG + PI

3.1.3.13





3PG <-> 2PG

5.4.2.1




5224

PGAM2, PGAMM
13PDG <-> 23PDG

5.4.2.4





23PDG + H2O -> 3PG + PI

3.1.3.13





3PG <-> 2PG

5.4.2.1




669

BPGM
13PDG <-> 23PDG

5.4.2.4





23PDG + H2O <-> 3PG + PI

3.1.3.1.3





3PG <-> 2PG

5.4.2.1




2023

ENO1, PPH, ENO1L1
2PG <-> PEP + H2O

4.2.1.11




2026

ENO2
2PG <-> PEP + H2O

4.2.1.11




2027

ENO3
2PG <-> PEP + H2O

4.2.1.11




26237

ENO1B
2PG <-> PEP + H2O

4.2.1.11




5313

PKLR, PK1
PEP + ADP -> PYR + ATP

2.7.1.40




5315

PKM2, PK3, THBP1, OIP3
PEP + ADP -> PYR + ATP

2.7.1.40




5160

PDHA1, PHE1A, PDHA
PYRm + COAm + NADm -> + NADHm + CO2m + ACCOAm

1.2.4.1




5161

PDHA2, PDHAL
PYRm + COAm + NADm -> + NADHm + CO2m + ACCOAm

1.2.4.1




5162

PDHB
PYRm + COAm + NADm -> + NADHm + CO2m + ACCOAm

1.2.4.1




1737

DLAT, DLTA, PDC-E2
PYRm + COAm + NADm -> + NADHm + CO2m + ACCOAm

2.3.1.12




8050

PDX1, E3BP
PYRm + COAm + NADm -> + NADHm + CO2m + ACCOAm

2.3.1.12




3939

LDHA, LDH1
NAD + LAC <-> PYR + NADH

1.1.1.27




3945

LDHB
NAD + LAC <-> PYR + NADH

1.1.1.27




3948

LDHC, LDH3
NAD + LAC <-> PYR + NADH

1.1.1.27




5236

PGM1
G1P <-> G6P

5.4.2.2




5237

PGM2
G1P <-> G6P

5.4.2.2




5238

PGM3
G1P <-> G6P

5.4.2.2




1738

DLD, LAD, PHE3, DLDH, E3
DLIPOm + FADm <-> LIPOm + FADH2m

1.8.1.4




124

ADH1
ETH + NAD <-> ACAL + NADH

1.1.1.1




125

ADH2
ETH + NAD <-> ACAL + NADH

1.1.1.1




126

ADH3
ETH + NAD <-> ACAL + NADH

1.1.1.1




127

ADH4
ETH + NAD <-> ACAL + NADH

1.1.1.1




128

ADH5
FALD + RGT + NAD <-> FGT + NADH

1.2.1.1





ETH + NAD <-> ACAL + NADH

1.1.1.1




130

ADH6
ETH + NAD <-> ACAL + NADH

1.1.1.1




131

ADH7
ETH + NAD <-> ACAL + NADH

1.1.1.1




10327

AKR1A1, ALR, ALDR1


1.1.1.2




97

ACYP1


3.6.1.7




98

ACYP2


3.6.1.7








1.2 Citrate cycle (TCA cycle) PATH: hsa00020











1431

CS
ACCOAm + OAm + H2Om -> COAm + CITm

4.1.3.7




48

ACO1, IREB1, IRP1
CIT <-> ICIT

4.2.1.3




50

ACO2
CITm <-> ICITm

4.2.1.3




3417

IDH1
ICIT + NADP -> NADPH + CO2 + AKG

1.1.1.42




3418

IDH2
ICITm + NADPm -> NADPHm + CO2m + AKGm

1.1.1.42




3419

IDH3A
ICITm + NADm -> CO2m + NADHm + AKGm

1.1.1.41




3420

IDH3B
ICITm + NADm -> CO2m + NADHm + AKGm

1.1.1.41




3421

IDH3G
ICITm + NADm -> CO2m + NADHm + AKGm

1.1.1.41




4967

OGDH
AKGm + NADm + COAm -> CO2m + NADHm + SUCCOAm

1.2.4.2




1743

DLST, DLTS
AKGm + NADm + COAm -> CO2m + NADHm + SUCCOAm

2.3.1.61




8802

SUCLG1, SUCLA1
GTPm + SUCCm + COAm <-> GDPm + PIm + SUCCOAm

6.2.1.4




8803

SUCLA2
ATPm + SUCCm + COAm <-> ADPm + PIm + SUCCOAm

6.2.1.4




2271

FH
FUMm + H2Om <-> MALm

4.2.1.2




4190

MDH1
MAL + NAD <-> NADH + OA

1.1.1.37




4191

MDH2
MALm + NADm <-> NADHm + OAm

1.1.1.37




5091

PC, PCB
PYRm + ATPm + CO2m -> ADPm + OAm + PIm

6.4.1.1




47

ACLY, ATPCL, CLATP
ATP + CIT + COA + H2O -> ADP + PI + ACCOA + OA

4.1.3.8




3657







5105

PCK1
OA + GTP -> PEP + GDP + CO2

4.1.1.32




5106

PCK2, PEPCK
OAm + GTPm -> PEPm + GDPm + CO2m

4.1.1.32








1.3 Pentose phosphate cycle PATH: hsa00030











2539

G6PD, G6PD1
G6P + NADP <-> D6PGL + NADPH

1.1.1.49




9563

H6PD


1.1.1.47





D6PGL + H2O -> D6PGC

3.1.1.31




25796

PGLS, 6PGL
D6PGL + H2O -> D6PGC

3.1.1.31




5226

PGD
D6PGC + NADP -> NADPH + CO2 + RL5P

1.1.1.44




6120

RPE
RL5P <-> X5P

5.1.3.1




7086

TKT
R5P + X5P <-> T3P1 + S7P

2.2.1.1





X5P + E4P <-> F6P + T3P1




8277

TKTL1, TKR, TKT2
R5P + X5P <-> T3P1 + S7P

2.2.1.1





X5P + E4P <-> F6P + T3P1




6888

TALDO1
T3P1 + S7P <-> E4P + F6P

2.2.1.2




5631

PRPS1, PRS I, PRS, I
R5P + ATP <-> PRPP + AMP

2.7.6.1




5634

PRPS2, PRS II, PRS, II
R5P + ATP <-> PRPP + AMP

2.7.6.1




2663

GDH


1.1.1.47








1.4 Pentose and glucuronate interconversions PATH: hsa00040











231

AKR1B1, AR, ALDR1, ADR


1.1.1.21




7359

UGP1
G1P + UTP -> UDPG + PPI

2.7.7.9




7360

UGP2, UGPP2
G1P + UTP -> UDPG + PPI

2.7.7.9




7358

UGDH, UDPGDH


1.1.1.22




10720

UGT2B11


2.4.1.17




54658

UGT1A1, UGT1A, GNT1, UGT1


2.4.1.17




7361

UGT1A, UGT1, UGT1A


2.4.1.17




7362

UGT2B, UGT2, UGT2B


2.4.1.17




7363

UGT2B4, UGT2B11


2.4.1.17




7364

UGT2B7, UGT2B9


2.4.1.17




7365

UGT2B10


2.4.1.17




7366

UGT2B15, UGT2B8


2.4.1.17




7367

UGT2B17


2.4.1.17




13

AADAC, DAC


3.1.1.




3991

LIPE, LHS, HSL


3.1.1.








1.5 Fructose and mannose metabolism PATH: hsa00051











4351

MPI, PMI1
MAN6P <-> F6P

5.3.1.8




5372

PMM1
MAN6P <-> MAN1P

5.4.2.8




5373

PMM2, CDG1, CDGS
MAN6P <-> MAN1P

5.4.2.8




2762

GMDS


4.2.1.47




8790

FPGT, GFPP


2.7.7.30




5207

PFKFB1, PFRX
ATP + F6P -> ADP + F26P

2.7.1.105





F26P -> F6P + PI

3.1.3.46




5208

PFKFB2
ATP + F6P -> ADP + F26P

2.7.1.105





F26P -> F6P + PI

3.1.3.46




5209

PFKFB3
ATP + F6P -> ADP + F26P

2.7.1.105





F26P -> F6P + PI

3.1.3.46




5210

PFKFB4
ATP + F6P -> ADP + F26P

2.7.1.105





F26P -> F6P + PI

3.1.3.46




3795

KHK


2.7.1.3




6652

SORD
DSOT + NAD -> FRU + NADH

1.1.1.14




2526

FUT4, FCT3A, FUC-TIV


2.4.1.




2529

FUT7


2.4.1.




3036

HAS1, HAS


2.4.1.




3037

HAS2


2.4.1.




8473

OGT, O-GLCNAC


2.4.1.




51144

LOC51144


1.1.1.








1.6 Galactose metabolism PATH: hsa00052











2584

GALK1, GALK
GLAC + ATP -> GAL1P + ADP

2.7.1.6




2585

GALK2, GK2
GLAC + ATP -> GAL1P + ADP

2.7.1.6




2592

GALT
UTP + GAL1P <-> PPI + UDPGAL

2.7.7.10




2582

GALE
UDPGAL <-> UDPG

5.1.3.2




2720

GLB1


3.2.1.23




3938

LCT, LAC


3.2.1.62







3.2.1.108




2683

B4GALT1, GGTB2, BETA4GAL-T1,


2.4.1.90




GT1, GTB


2.4.1.38







2.4.1.22




3906

LALBA


2.4.1.22




2717

GLA, GALA
MELI -> GLC + GLAC

3.2.1.22




2548

GAA
MLT -> 2 GLC

3.2.1.20





6DGLC -> GLAC + GLC




2594

GANAB
MLT -> 2 GLC

3.2.1.20





6DGLC -> GLAC + GLC




2595

GANC
MLT -> 2 GLC

3.2.1.20





6DGLC -> GLAC + GLC




8972

MGAM, MG, MGA
MLT -> 2 GLC

3.2.1.20





6DGLC -> GLAC + GLC

3.2.1.3








1.7 Ascorbate and aldarate metabolism PATH: hsa00053











216

ALDH1, PUMB1
ACAL + NAD -> NADH + AC

1.2.1.3




217

ALDH2
ACALm + NADm -> NADHm + ACm

1.2.1.3




219

ALDH5, ALDHX


1.2.1.3




223

ALDH9, E3


1.2.1.3







1.2.1.19




224

ALDH10, FALDH, SLS


1.2.1.3




8854

RALDH2


1.2.1.3




1591

CYP24


1.14..




1592

CYP26A1, P450RAI


1.14..




1593

CYP27A1, CTX, CYP27


1.14..




1594

CYP27B1, PDDR, VDD1, VDR, CYP1,


1.14..




VDDR, I, P450C1









1.8 Pyruvate metabolism PATH: hsa00620











54988

FLJ20581
ATP + AC + COA -> AMP + PPI + ACCOA

6.2.1.1




31

ACACA, ACAC, ACC
ACCOA + ATP + CO2 <-> MALCOA + ADP + PI + H

6.4.1.2







6.3.4.14




32

ACACB, ACCB, HACC275, ACC2
ACCOA + ATP + CO2 <-> MALCOA + ADP + PI + H

6.4.1.2







6.3.4.14




2739

GLO1, GLYI
RGT + MTHGXL <-> LGT

4.4.1.5




3029

HAGH, GLO2
LGT -> RGT + LAC

3.1.2.6




2223

FDH
FALD + RGT + NAD <-> FGT + NADH

1.2.1.1




9380

GRHPR, GLXR


1.1.1.79




4200

ME2
MALm + NADm -> CO2m + NADHm + PYRm

1.1.1.38




10873

ME3
MALm + NADPm -> CO2m + NADPHm + PYRm

1.1.1.40




29897

HUMNDME
MAL + NADP -> CO2 + NADPH + PYR

1.1.1.40




4199

ME1
MAL + NADP -> CO2 + NADPH + PYR

1.1.1.40




38

ACAT1, ACAT, T2, THIL, MAT
2 ACCOAm <-> COAm + AACCOAm

2.3.1.9




39

ACAT2
2 ACCOAm <-> COAm + AACCOAm

2.3.1.9








1.9 Glyoxylate and dicarboxylate metabolism PATH: hsa00630











5240

PGP


3.1.3.18




2758

GLYD
3HPm + NADHm -> NADm + GLYAm

1.1.1.29




10797

MTHFD2, NMDMC
METHF <-> FTHF

3.5.4.9





METTHF + NAD -> METHF + NADH

1.5.1.15




4522

MTHFD1
METTHF + NADP <-> METHF + NADPH

1.5.1.15





METHF <-> FTHF

3.5.4.9





THF + FOR + ATP -> ADP + PI + FTHF

6.3.4.3








1.10 Propanoate metabolism PATH: hsa00640











34

ACADM, MCAD
MBCOAm + FADm -> MCCOAm + FADH2m

1.3.99.3





IBCOAm + FADm -> MACOAm + FADH2m





IVCOAm + FADm -> MCRCOAm + FADH2m




36

ACADSB
MBCOAm + FADm -> MCCOAm + FADH2m

1.3.99.3





IBCOAm + FADm -> MACOAm + FADH2m





IVCOAm + FADm -> MCRCOAm + FADH2m




1892

ECHS1, SCEH
MACOAm + H2Om -> HIBCOAm

4.2.1.17





MCCOAm + H2Om -> MHVCOAm




1962

EHHADH
MHVCOAm + NADm -> MAACOAm + NADHm

1.1.1.35





HIBm + NADm -> MMAm + NADHm





MACOAm + H2Om -> HIBCOAm

4.2.1.17





MCCOAm + H2Om -> MHVCOAm




3030

HADHA, MTPA, GBP
MHVCOAm + NADm -> MAACOAm + NADHm

1.1.1.35





HIBm + NADm -> MMAm + NADHm





MACOAm + H2Om -> HIBCOAm

4.2.1.17





MCCOAm + H2Om -> MHVCOAm





C16CARm + COAm + FADm + NADm -> FADH2m +

1.1.1.35





NADHm + C140COAm + ACCOAm

4.2.1.17




23417

MLYCD, MCD


4.1.1.19




18

ABAT, GABAT
GABA + AKG -> SUCCSAL + GLU

2.6.1.19




5095

PCCA
PROPCOAm + CO2m + ATPm -> ADPm + PIm + DMMCOAm

6.4.1.3




5096

PCCB
PROPCOAm + CO2m + ATPm -> ADPm + PIm + DMMCOAm

6.4.1.3




4594

MUT, MCM
LMMCOAm -> SUCCOAm

5.4.99.2




4329

MMSDH
MMAm + COAm + NADm -> NADHm + CO2m + PROPCOAm

1.2.1.27




8523

FACVL1, VLCS, VLACS


6.2.1.








1.11 Butanoate metabolism PATH: hsa00650











3028

HADH2, ERAB
C140COAm + 7 COAm + 7 FADm + 7 NADm -> 7 FADH2m + 7

1.1.1.35





NADHm + 7 ACCOAm




3033

HADHSC, SCHAD


1.1.1.35




35

ACADS, SCAD
MBCOAm + FADm -> MCCOAm + FADH2m

1.3.99.2





IBCOAm + FADm -> MACOAm + FADH2m




7915

ALDH5A1, SSADH, SSDH


1.2.1.24




2571

GAD1, GAD, GAD67, GAD25
GLU -> GABA + CO2

4.1.1.15




2572

GAD2
GLU -> GABA + CO2

4.1.1.15




2573

GAD3
GLU -> GABA + CO2

4.1.1.15




3157

HMGCS1, HMGCS
H3MCOA + COA <-> ACCOA + AACCOA

4.1.3.5




3158

HMGCS2
H3MCOA + COA <-> ACCOA + AACCOA

4.1.3.5




3155

HMGCL, HL
H3MCOAm -> ACCOAm + ACTACm

4.1.3.4




5019

OXCT


2.8.3.5




622

BDH
3HBm + NADm -> NADHm + Hm + ACTACm

1.1.1.30




1629

DBT, BCATE2
OMVALm + COAm + NADm -> MBCOAm + NADHm + CO2m

2.3.1.





OIVALm + COAm + NADm -> IBCOAm + NADHm + CO2m





OICAPm + COAm + NADHm -> IVCOAm + NADHm + CO2m








1.13 Inositol metabolism PATH: hsa00031


2. Energy Metabolism


2.1 Oxidative phosphorylation PATH: hsa00190











4535

MTND1
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3




4536

MTND2
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3




4537

MTND3
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3




4538

MTND4
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3




4539

MTND4L
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3




4540

MTND5
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3




4541

MTND6
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3




4694

NDUFA1, MWFE
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3




4695

NDUFA2, B8
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4696

NDUFA3, B9
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4697

NDUFA4, MLRQ
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4698

NDUFA5, UQOR13, B13
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4700

NDUFA6, B14
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4701

NDUFA7, B14.5a, B14.5A
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4702

NDUFA8, PGIV
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4704

NDUFA9, NDUFS2L
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4705

NDUFA10
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4706

NDUFAB1, SDAP
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4707

NDUFB1, MNLL, CI-SGDH
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4708

NDUFB2, AGGG
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4709

NDUFB3, B12
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4710

NDUFB4, B15
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4711

NDUFB5, SGDH
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4712

NDUFB6, B17
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4713

NDUFB7, B18
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4714

NDUFB8, ASHI
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4715

NDUFB9, UQOR22, B22
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4716

NDUFB10, PDSW
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4717

NDUFC1, KFYI
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4718

NDUFC2, B14.5b, B14.5B
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4724

NDUFS4, AQDQ
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4725

NDUFS5
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4726

NDUFS6
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4731

NDUFV3
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3




4727

NDUFS7, PSST
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4722

NDUFS3
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4720

NDUFS2
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3




4729

NDUFV2
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4723

NDUFV1, UQOR1
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




4719

NDUFS1, PRO1304
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3




4728

NDUFS8
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.5.3





NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H

1.6.99.3




6391

SDHC
SUCCm + FADm <-> FUMm + FADH2m

1.3.5.1





FADH2m + Qm <-> FADm + QH2m




6392

SDHD, CBT1, PGL, PGL1
SUCCm + FADm <-> FUMm + FADH2m

1.3.5.1





FADH2m + Qm <-> FADm + QH2m




6389

SDHA, SDH2, SDHF, FP
SUCCm + FADm <-> FUMm + FADH2m

1.3.5.1





FADH2m + Qm <-> FADm + QH2m




6390

SDHB, SDH1, IP, SDH
SUCCm + FADm <-> FUMm + FADH2m

1.3.5.1





FADH2m + Qm <-> FADm + QH2m




7386

UQCRFS1, RIS1
O2m + 4 FEROm + 4 Hm -> 4 FERIm + 2 H2Om + 4 H

1.10.2.2




4519

MTCYB
O2m + 4 FEROm + 4 Hm -> 4 FERIm + 2 H2Om + 4 H

1.10.2.2




1537

CYC1
O2m + 4 FEROm + 4 Hm -> 4 FERIm + 2 H2Om + 4 H

1.10.2.2




7384

UQCRC1, D3S3191
O2m + 4 FEROm + 4 Hm -> 4 FERIm + 2 H2Om + 4 H

1.10.2.2




7385

UQCRC2
O2m + 4 FEROm + 4 Hm -> 4 FERIm + 2 H2Om + 4 H

1.10.2.2




7388

UQCRH
O2m + 4 FEROm + 4 Hm -> 4 FERIm + 2 H2Om + 4 H

1.10.2.2




7381

UQCRB, QPC, UQBP, QP-C
O2m + 4 FEROm + 4 Hm -> 4 FERIm + 2 H2Om + 4 H

1.10.2.2




27089

QP-C
O2m + 4 FEROm + 4 Hm -> 4 FERIm + 2 H2Om + 4 H

1.10.2.2




10975

UQCR
O2m + 4 FEROm + 4 Hm -> 4 FERIm + 2 H2Om + 4 H

1.10.2.2




1333

COX5BL4
QH2m + 2 FERIm + 4 Hm -> Qm + 2 FEROm + 4 H

1.9.3.1




4514

MTCO3
QH2m + 2 FERIm + 4 Hm -> Qm + 2 FEROm + 4 H

1.9.3.1




4512

MTCO1
QH2m + 2 FERIm + 4 Hm -> Qm + 2 FEROm + 4 H

1.9.3.1




4513

MTCO2
QH2m + 2 FERIm + 4 Hm -> Qm + 2 FEROm + 4 H

1.9.3.1




1329

COX5B
QH2m + 2 FERIm + 4 Hm -> Qm + 2 FEROm + 4 H

1.9.3.1




1327

COX4
QH2m + 2 FERIm + 4 Hm -> Qm + 2 FEROm + 4 H

1.9.3.1




1337

COX6A1, COX6A
QH2m + 2 FERIm + 4 Hm -> Qm + 2 FEROm + 4 H

1.9.3.1




1339

COX6A2
QH2m + 2 FERIm + 4 Hm -> Qm + 2 FEROm + 4 H

1.9.3.1




1340

COX6B
QH2m + 2 FERIm + 4 Hm -> Qm + 2 FEROm + 4 H

1.9.3.1




1345

COX6C
QH2m + 2 FERIm + 4 Hm -> Qm + 2 FEROm + 4 H

1.9.3.1




9377

COX5A, COX, VA, COX-VA
QH2m + 2 FERIm + 4 Hm -> Qm + 2 FEROm + 4 H

1.9.3.1




1346

COX7A1, COX7AM, COX7A
QH2m + 2 FERIm + 4 Hm -> Qm + 2 FEROm + 4 H

1.9.3.1




1347

COX7A2, COX VIIa-L
QH2m + 2 FERIm + 4 Hm -> Qm + 2 FEROm + 4 H

1.9.3.1




1348

COX7A3
QH2m + 2 FERIm + 4 Hm -> Qm + 2 FEROm + 4 H

1.9.3.1




1349

COX7B
QH2m + 2 FERIm + 4 Hm -> Qm + 2 FEROm + 4 H

1.9.3.1




9167

COX7A2L, COX7RP, EB1
QH2m + 2 FERIm + 4 Hm -> Qm + 2 FEROm + 4 H

1.9.3.1




1350

COX7C
QH2m + 2 FERIm + 4 Hm -> Qm + 2 FEROm + 4 H

1.9.3.1




1351

COX8, COX VIII
QH2m + 2 FERIm + 4 Hm -> Qm + 2 FEROm + 4 H

1.9.3.1




4508

MTATP6
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




4509

MTATP8
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




499

ATP5A2
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




507

ATP5BL1, ATPSBL1
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




508

ATP5BL2, ATPSBL2
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




519

ATP5H
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




537

ATP6S1, ORF, VATPS1, XAP-3
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




514

ATP5E
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




513

ATP5D
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




506

ATP5B, ATPSB
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




509

ATP5C1, ATP5C
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




498

ATP5A1, ATP5A, ATPM, OMR, HATP1
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




539

ATP5O, ATPO, OSCP
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




516

ATP5G1, ATP5G
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




517

ATP5G2
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




518

ATP5G3
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




515

ATP5F1
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




521

ATP5I
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




522

ATP5J, ATP5A, ATPM, ATP5
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




9551

ATP5J2, ATP5JL, F1FO-ATPASE
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




10476

ATP5JD
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




10632

ATP5JG
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




9296

ATP6S14
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




528

ATP6D
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




523

ATP6A1, VPP2
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




524

ATP6A2, VPP2
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




525

ATP6B1, VPP3, VATB
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




526

ATP6B2, VPP3
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




529

ATP6E
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




527

ATP6C, ATPL
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




533

ATP6F
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




10312

TCIRG1, TIRC7, OC-116, OC-116kDa,
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




OC-116KDA, ATP6N1C





23545

TJ6
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




50617

ATP6N1B
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




535

ATP6N1
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




51382

VATD
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




8992

ATP6H
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




9550

ATP6J
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




51606

LOC51606
ADPm + Pim + 3 H -> ATPm + 3 Hm + H2Om

3.6.1.34




495

ATP4A, ATP6A
ATP + H + Kxt + H2O <-> ADP + PI + Hext + K

3.6.1.36




496

ATP4B, ATP6B
ATP + H + Kxt + H2O <-> ADP + PI + Hext + K

3.6.1.36




476

ATP1A1
ATP + 3 NA + 2 Kxt + H2O <-> ADP + 3 NAxt + 2 K + PI

3.6.1.37




477

ATP1A2
ATP + 3 NA + 2 Kxt + H2O <-> ADP + 3 NAxt + 2 K + PI

3.6.1.37




478

ATP1A3
ATP + 3 NA + 2 Kxt + H2O <-> ADP + 3 NAxt + 2 K + PI

3.6.1.37




479

ATP1AL1
ATP + 3 NA + 2 Kxt + H2O <-> ADP + 3 NAxt + 2 K + PI

3.6.1.37




23439

ATP1B4
ATP + 3 NA + 2 Kxt + H2O <-> ADP + 3 NAxt + 2 K + PI

3.6.1.37




481

ATP1B1, ATP1B
ATP + 3 NA + 2 Kxt + H2O <-> ADP + 3 NAxt + 2 K + PI

3.6.1.37




482

ATP1B2, AMOG
ATP + 3 NA + 2 Kxt + H2O <-> ADP + 3 NAxt + 2 K + PI

3.6.1.37




483

ATP1B3
ATP + 3 NA + 2 Kxt + H2O <-> ADP + 3 NAxt + 2 K + PI

3.6.1.37




27032

ATP2C1, ATP2C1A, PMR1
ATP + 2 CA + H2O <-> ADP + PI + 2 CAxt

3.6.1.38




487

ATP2A1, SERCA1, ATP2A
ATP + 2 CA + H2O <-> ADP + PI + 2 CAxt

3.6.1.38




488

ATP2A2, ATP2B, SERCA2, DAR, DD
ATP + 2 CA + H2O <-> ADP + PI + 2 CAxt

3.6.1.38




489

ATP2A3, SERCA3
ATP + 2 CA + H2O <-> ADP + PI + 2 CAxt

3.6.1.38




490

ATP2B1, PMCA1
ATP + 2 CA + H2O <-> ADP + PI + 2 CAxt

3.6.1.38




491

ATP2B2, PMCA2
ATP + 2 CA + H2O <-> ADP + PI + 2 CAxt

3.6.1.38




492

ATP2B3, PMCA3
ATP + 2 CA + H2O <-> ADP + PI + 2 CAxt

3.6.1.38




493

ATP2B4, ATP2B2, PMCA4
ATP + 2 CA + H2O <-> ADP + PI + 2 CAxt

3.6.1.38




538

ATP7A, MK, MNK, OHS
ATP + H2O + Cu2 -> ADP + PI + Cu2xt

3.6.3.4




540

ATP7B, WND
ATP + H20 + Cu2 -> ADP + PI + Cu2xt

3.6.3.4




5464

PP, SID6-8061
PPI -> 2 PI

3.6.1.1








2.2 Photosynthesis PATH: hsa00195


2.3 Carbon fixation PATH: hsa00710











2805

GOT1
OAm + GLUm <-> ASPm + AKGm

2.6.1.1




2806

GOT2
OA + GLU <-> ASP + AKG

2.6.1.1




2875

GPT
PYR + GLU <-> AKG + ALA

2.6.1.2








2.4 Reductive carboxylate cycle (CO2 fixation) PATH: hsa00720


2.5 Methane metabolism PATH: hsa00680











847

CAT
2H2O2 -> O2

1.11.1.6




4025

LPO, SPO


1.11.1.7




4353

MPO


1.11.1.7




8288

EPX, EPX-PEN, EPO, EPP


1.11.1.7




9588

KIAA0106, AOP2


1.11.1.7




6470

SHMT1, CSHMT
THF + SER <-> GLY + METTHF

2.1.2.1




6472

SHMT2, GLYA, SHMT
THFm + SERm <-> GLYm + METTHFm

2.1.2.1




51004

LOC51004
2OPMPm + O2m -> 2OPMBm

1.14.13.





2OPMMBm + O2m -> 2OMHMBm




9420

CYP7B1
2OPMPm + O2m -> 2OPMBm

1.14.13.





2OPMMBm + O2m -> 2OMHMBm








2.6 Nitrogen metabolism PATH: hsa00910











11238

CA5B


4.2.1.1




23632

CA14


4.2.1.1




759

CA1


4.2.1.1




760

CA2


4.2.1.1




761

CA3, CAIII


4.2.1.1




762

CA4, CAIV


4.2.1.1




763

CA5A, CA5, CAV, CAVA


4.2.1.1




765

CA6


4.2.1.1




766

CA7


4.2.1.1




767

CA8, CALS, CARP


4.2.1.1




768

CA9, MN


4.2.1.1




770

CA11, CARP2


4.2.1.1




771

CA12


4.2.1.1




1373

CPS1
GLUm + CO2m + 2 ATPm -> 2 ADPm + 2 PIm + CAPm

6.3.4.16




275

AMT
GLYm + THFm + NADm <-> METTHFm + NADHm + CO2m +

2.1.2.10





NH3m




3034

HAL, HSTD, HIS
HIS -> NH3 + URO

4.3.1.3




2746

GLUD1, GLUD
AKGm + NADHm + NH3m <-> NADm + H2Om + GLUm

1.4.1.3





AKGm + NADPHm + NH3m <-> NADPm + H2Om + GLUm




8307

GLUD2
AKGm + NADHm + NH3m <-> NADm + H2Om + GLUm

1.4.1.3





AKGm + NADPHm + NH3m <-> NADPm + H2Om + GLUm




2752

GLUL, GLNS
GLUm + NH3m + ATPm -> GLNm + ADPm + Pim

6.3.1.2




22842

KIAA0838
GLN -> GLU + NH3

3.5.1.2




27165

GA
GLN -> GLU + NH3

3.5.1.2




2744

GLS
GLNm -> GLUm + NH3m

3.5.1.2




440

ASNS
ASPm + ATPm + GLNm -> GLUm + ASNm + AMPm + PPIm

6.3.5.4




1491

CTH
LLCT + H2O -> CYS + HSER

4.4.1.1





OBUT + NH3 <-> HSER

4.4.1.1








2.7 Sulfur metabolism PATH: hsa00920











9060

PAPSS2, ATPSK2, SK2
APS + ATP -> ADP + PAPS

2.7.1.25





SLF + ATP -> PPI + APS

2.7.7.4




9061

PAPSS1, ATPSK1, SK1
APS + ATP -> ADP + PAPS

2.7.1.25





SLF + ATP -> PPI + APS

2.7.7.4




10380

BPNT1
PAP -> AMP + PI

3.1.3.7




6799

SULT1A2


2.8.2.1




6817

SULT1A1, STP1


2.8.2.1




6818

SULT1A3, STM


2.8.2.1.




6822

SULT2A1, STD


2.8.2.2




6783

STE, EST


2.8.2.4




6821

SUOX


1.8.3.1








3. Lipid Metabolism


3.1 Fatty acid biosynthesis (path 1) PATH: hsa00061











2194

FASN


2.3.1.85








3.2 Fatty acid biosynthesis (path 2) PATH: hsa00062











10449

ACAA2, DSAEC
MAACOAm -> ACCOAm + PROPCOAm

2.3.1.16




30

ACAA1, ACAA
MAACOA -> ACCOA + PROPCOA

2.3.1.16




3032

HADHB
MAACOA -> ACCOA + PROPCOA

2.3.1.16








3.3 Fatty acid metabolism PATH: hsa00071











51

ACOX1, ACOX


1.3.3.6




33

ACADL, LCAD


1.3.99.13




2639

GCDH


1.3.99.7




2179

FACL1, LACS
ATP + LCCA + COA <-> AMP + PPI + ACOA

6.2.1.3




2180

FACL2, FACL1, LACS2
ATP + LCCA + COA <-> AMP + PPI + ACOA

6.2.1.3




2182

FACL4, ACS4
ATP + LCCA + COA <-> AMP + PPI + ACOA

6.2.1.3




1374

CPT1A, CPT1, CPT1-L


2.3.1.21




1375

CPT1B, CPT1-M


2.3.1.21




1376

CPT2, CPT1, CPTASE


2.3.1.21




1632

DCI


5.3.3.8




11283

CYP4F8


1.14.14.1




1543

CYP1A1, CYP1


1.14.14.1




1544

CYP1A2


1.14.14.1




1545

CYP1B1, GLC3A


1.14.14.1




1548

CYP2A6, CYP2A3


1.14.14.1




1549

CYP2A7


1.14.14.1




1551

CYP3A7


1.14.14.1




1553

CYP2A13


1.14.14.1




1554

CYP2B


1.14.14.1




1555

CYP2B6


1.14.14.1




1557

CYP2C19, CYP2C, P450IIC19


1.14.14.1




1558

CYP2C8


1.14.14.1




1559

CYP2C9, P450IIC9, CYP2C10


1.14.14.1




1562

CYP2C18, P450IIC17, CYP2C17


1.14.14.1




1565

CYP2D6


1.14.14.1




1571

CYP2E, CYP2E1, P450C2E


1.14.14.1




1572

CYP2F1, CYP2F


1.14.14.1




1573

CYP2J2


1.14.14.1




1575

CYP3A3


1.14.14.1




1576

CYP3A4


1.14.14.1




1577

CYP3A5, PCN3


1.14.14.1




1580

CYP4B1


1.14.14.1




1588

CYP19, ARO


1.14.14.1




1595

CYP51


1.14.14.1




194

AHHR, AHH


1.14.14.1








3.4 Synthesis and degradation of ketone bodies PATH: hsa00072


3.5 Sterol biosynthesis PATH: hsa00100











3156

HMGCR
MVL + COA + 2 NADP <-> H3MCOA + 2 NADPH

1.1.1.34




4598

MVK, MVLK
ATP + MVL -> ADP + PMVL

2.7.1.36





CTP + MVL -> CDP + PMVL





GTP + MVL -> GDP + PMVL





UTP + MVL -> UDP + PMVL




10654

PMVK, PMKASE, PMK, HUMPMKI
ATP + PMVL -> ADP + PPMVL

2.7.4.2




4597

MVD, MPD
ATP + PPMVL -> ADP + PI + IPPP + CO2

4.1.1.33




3422

IDI1
IPPP <-> DMPP

5.3.3.2




2224

FDPS
GPP + IPPP -> FPP + PPI

2.5.1.10





DMPP + IPPP-> GPP + PPI

2.5.1.1




9453

GGPS1, GGPPS
DMPP + IPPP -> GPP + PPI

2.5.1.1





GPP + IPPP -> FPP + PPI

2.5.1.10







2.5.1.29




2222

FDFT1; DGPT
2 FPP + NADPH -> NADP + SQL

2.5.1.21




6713

SQLE
SQL + O2 + NADP -> S23E + NADPH

1.14.99.7




4047

LSS, OSC
S23E -> LNST

5.4.99.7




1728

DIA4, NMOR1, NQO1, NMORI


1.6.99.2




4835

NMOR2, NQO2


1.6.99.2




37

ACADVL, VLCAD, LCACD


1.3.99.








3.6 Bile acid biosynthesis PATH: hsa00120











1056

CEL, BSSL, BAL


3.1.1.3




3988

LIPA, LAL


3.1.1.13




6646

SOAT1, ACAT, STAT, SOAT, ACAT1,


3.1.1.13




ACACT


2.3.1.26




1581

CYP7A1, CYP7


1.14.13.17




6715

SRD5A1


1.3.99.5




6716

SRD5A2


1.3.99.5




6718

AKR1D1, SRD5B1, 3o5bred


1.3.99.6




570

BAAT, BAT


2.3.1.65








3.7 C21-Steroid hormone metabolism PATH: hsa00140











1583

CYP11A, P450SCC


1.14.15.6




3283

HSD3B1, HSD3B, HSDB3
IMZYMST -> IIMZYMST + CO2

5.3.3.1





IMZYMST -> IIZYMST + CO2

1.1.1.145




3284

HSD3B2
IMZYMST -> IIMZYMST + CO2

5.3.3.1





IMZYMST -> IIZYMST + CO2

1.1.1.145




1589

CYP21A2, CYP21, P450221B,


1.14.99.10





CA21H, CYP21B, P450c21B




1586

CYP17, P450C17


1.14.99.9




1584

CYP11B1, P450C11, CYP11B


1.14.15.4




1585

CYP11B2, CYP11B


1.14.15.4




3290

HSD11B1, HSD11, HSD11L, HSD11B


1.1.1.146




3291

HSD11B2, HSD11K


1.1.1.146








3.8 Androgen and estrogen metabolism PATH: hsa00150











3292

HSD17B1, EDH17B2, EDHB17,


1.1.1.62




HSD17





3293

HSD17B3, EDH17B3


1.1.1.62




3294

HSD17B2, EDH17B2


1.1.1.62




3295

HSD17B4


1.1.1.62




3296

HSD17BP1, EDH17B1, EDHB17,


1.1.1.62




HSD17





51478

HSD17B7, PRAP


1.1.1.62




412

STS, ARSC, ARSC1, SSDD


3.1.6.2




414

ARSD


3.1.6.1




415

ARSE, CDPX1, CDPXR, CDPX


3.1.6.1




11185

INMT


2.1.1.




24140

JM23


2.1.1.




29104

N6AMT1, PRED28


2.1.1.




29960

FJH1


2.1.1.




3276

HRMT1L2, HCP1, PRMT1


2.1.1.




51628

LOC51628


2.1.1.




54743

HASJ4442


2.1.1.




27292

HSA9761


2.1.1.








4. Nucleotide Metabolism


4.1 Purine metabolism PATH: hsa00230











11164

NUDT5, HYSAH1, YSA1H


3.6.1.13




5471

PPAT, GPAT
PRPP + GLN -> PPI + GLU + PRAM

2.4.2.14




2618

GART, PGFT, PRGS
PRAM + ATP + GLY <-> ADP + PI + GAR

6.3.4.13





FGAM + ATP -> ADP + PI + AIR

6.3.3.1





GAR + FTHF -> THF + FGAR

2.1.2.2




5198

PFAS, FGARAT, KIAA0361, PURL
FGAR + ATP + GLN -> GLU + ADP + PI + FGAM

6.3.5.3




10606

ADE2H1
CAIR + ATP + ASP <-> ADP + PI + SAICAR

6.3.2.6





CAIR <-> AIR + CO2

4.1.1.21




5059

PAICS, AIRC, PAIS
CAIR + ATP + ASP <-> ADP + PI + SAICAR

6.3.2.6




158

ADSL
ASUC <-> FUM + AMP

4.3.2.2




471

ATIC, PURH
AICAR + FTHF <-> THF + PRFICA

2.1.2.3





PRFICA <-> IMP

3.5.4.10




3251

HPRT1, HPRT, HGPRT
HYXAN + PRPP -> PPI + IMP

2.4.2.8





GN + PRPP -> PPI + GMP




3614

IMPDH1
IMP + NAD -> NADH + XMP

1.1.1.205




3615

IMPDH2
IMP + NAD -> NADH + XMP

1.1.1.205




8833

GMPS


6.3.5.2




114923







2987

GUK1
GMP + ATP <-> GDP + ADP

2.7.4.8





DGMP + ATP <-> DGDP + ADP





GMP + DATP <-> GDP + DADP




2988

GUK2
GMP + ATP <-> GDP + ADP

2.7.4.8





DGMP + ATP <-> DGDP + ADP





GMP + DATP <-> GDP + DADP




10621

RPC39


2.7.7.6




10622

RPC32


2.7.7.6




10623

RPC62


2.7.7.6




11128

RPC155


2.7.7.6




25885

DKFZP586M0122


2.7.7.6




30834

ZNRD1


2.7.7.6




51082

LOC51082


2.7.7.6




51728

LOC51728


2.7.7.6




5430

POLR2A, RPOL2, POLR2, POLRA


2.7.7.6




5431

POLR2B, POL2RB


2.7.7.6




5432

POLR2C


2.7.7.6




5433

POLR2D, HSRBP4, HSRPB4


2.7.7.6




5434

POLR2E, RPB5, XAP4


2.7.7.6




5435

POLR2F, RPB6, HRBP14.4


2.7.7.6




5436

POLR2G, RPB7


2.7.7.6




5437

POLR2H, RPB8, RPB17


2.7.7.6




5438

POLR2I


2.7.7.6




5439

POLR2J


2.7.7.6




5440

POLR2K, RPB7.0


2.7.7.6




5441

POLR2L, RPB7.6, RPB10


2.7.7.6




5442

POLRMT, APOLMT


2.7.7.6




54479

FLJ10816, Rpo1-2


2.7.7.6




55703

FLJ10388


2.7.7.6




661

BN51T


2.7.7.6




9533

RPA40, RPA39


2.7.7.6




10721

POLQ


2.7.7.7




11232

POLG2, MTPOLB, HP55, POLB


2.7.7.7




23649

POLA2


2.7.7.7




5422

POLA


2.7.7.7




5423

POLB


2.7.7.7




5424

POLD1, POLD


2.7.7.7




5425

POLD2


2.7.7.7




5426

POLE


2.7.7.7




5427

POLE2


2.7.7.7




5428

POLG


2.7.7.7




5980

REV3L, POLZ, REV3


2.7.7.7




7498

XDH


1.1.3.22




9615

GDA, KIAA1258, CYPIN, NEDASIN


1.1.1.204




2766

GMPR


3.5.4.3




51292

LOC51292


1.6.6.8




7377

UOX


1.6.6.8




6240

RRM1
ADP + RTHIO -> DADP + OTHIO

1.7.3.3





GDP + RTHIO -> DGDP + OTHIO

1.17.4.1





CDP + RTHIO -> DCDP + OTHIO





UDP + RTHIO -> DUDP + OTHIO




6241

RRM2
ADP + RTHIO -> DADP + OTHIO

1.17.4.1





GDP + RTHIO -> DGDP + OTHIO





CDP + RTHIO -> DCDP + OTHIO





UDP + RTHIO -> DUDP + OTHIO




4860

NP, PNP
AND + PI <-> AD + R1P

2.4.2.1





GSN + PI <-> GN + R1P





DA + PI <-> AD + R1P





DG + PI <-> GN + R1P





DIN + PI <-> HYXAN + R1P





INS + PI <-> HYXAN + R1P





XTSINE + PI <-> XAN + R1P




1890

ECGF1, hPD-ECGF
DU + PI <-> URA + DR1P

2.4.2.4





DT + PI <-> THY + DR1P




353

APRT
AD + PRPP -> PPI + AMP

2.4.2.7




132

ADK
ADN + ATP -> AMP + ADP

2.7.1.20




1633

DCK


2.7.1.74




1716

DGUOK


2.7.1.113




203

AK1
ATP + AMP <-> 2 ADP

2.7.4.3





GTP + AMP <-> ADP + GDP





ITP + AMP <-> ADP + IDP




204

AK2
ATP + AMP <-> 2 ADP

2.7.4.3





GTP + AMP <-> ADP + GDP





ITP + AMP <-> ADP + IDP




205

AK3
ATP + AMP <-> 2 ADP

2.7.4.3





GTP + AMP <-> ADP + GDP





ITP + AMP <-> ADP + IDP




26289

AK5
ATP + AMP <-> 2 ADP

2.7.4.3





GTP + AMP <-> ADP + GDP





ITP + AMP <-> ADP + IDP




4830

NME1, NM23, NM23-H1
UDP + ATP <-> UTP + ADP

2.7.4.6





CDP + ATP <-> CTP + ADP





GDP + ATP <-> GTP + ADP





IDP + ATP <-> ITP + IDP





DGDP + ATP <-> DGTP + ADP





DUDP + ATP <-> DUTP + ADP





DCDP + ATP <-> DCTP + ADP





DTDP + ATP <-> DTTP + ADP





DADP + ATP <-> DATP + ADP




4831

NME2, NM23-H2
UDP + ATP <-> UTP + ADP

2.7.4.6





CDP + ATP <-> CTP + ADP





GDP + ATP <-> GTP + ADP





IDP + ATP <-> ITP + IDP





DGDP + ATP <-> DGTP + ADP





DUDP + ATP <-> DUTP + ADP





DCDP + ATP <-> DCTP + ADP





DTDP + ATP <-> DTTP + ADP





DADP + ATP <-> DATP + ADP




4832

NME3, DR-nm23, DR-NM23
UDP + ATP <-> UTP + ADP

2.7.4.6





CDP + ATP <-> CTP + ADP





GDP + ATP <-> GTP + ADP





IDP + ATP <-> ITP + IDP





DGDP + ATP <-> DGTP + ADP





DUDP + ATP <-> DUTP + ADP





DCDP + ATP <-> DCTP + ADP





DTDP + ATP <-> DTTP + ADP





DADP + ATP <-> DATP + ADP




4833

NME4
UDPm + ATPm <-> UTPm + ADPm

2.7.4.6





CDPm + ATPm <-> CTPm + ADPm





GDPm + ATPm <-> GTPm + ADPm





IDPm + ATPm <-> ITPm + IDPm





DGDPm + ATPm <-> DGTPm + ADPm





DUDPm + ATPm <-> DUTPm + ADPm





DCDPm + ATPm <-> DCTPm + ADPm





DTDPm + ATPm <-> DTTPm + ADPm





DADPm + ATPm <-> DATPm + ADPm




22978

NT5B, PNT5, NT5B-PENDING
AMP + H2O -> PI + ADN

3.1.3.5





GMP -> PI + GSN





CMP -> CYTD + PI





UMP -> PI + URI





IMP -> PI + INS





DUMP -> DU + PI





DTMP -> DT + PI





DAMP -> DA + PI





DGMP -> DG + PI





DCMP -> DC + PI





XMP -> PI + XTSINE




4877

NT3
AMP -> PI + ADN

3.1.3.5





GMP -> PI + GSN





CMP -> CYTD + PI





UMP -> PI + URI





IMP -> PI + INS





DUMP -> DU + PI





DTMP -> DT + PI





DAMP -> DA + PI





DGMP -> DG + PI





DCMP -> DC + PI





XMP -> PI + XTSINE




4907

NT5, CD73
AMP -> PI + ADN

3.1.3.5





GMP -> PI + GSN





CMP -> CYTD + PI





UMP -> PI + URI





IMP -> PI + INS





DUMP -> DU + PI





DTMP -> DT + PI





DAMP -> DA + PI





DGMP -> DG + PI





DCMP -> DC + PI





XMP -> PI + XTSINE




7370

UMPH2
AMP -> PI + ADN

3.1.3.5





GMP -> PI + GSN





CMP -> CYTD + PI





UMP -> PI + URI





IMP -> PI + INS





DUMP -> DU + PI





DTMP -> DT + PI





DAMP -> DA + PI





DGMP -> DG + PI





DCMP -> DC + PI





XMP -> PI + XTSINE




10846

PDE10A
cAMP -> AMP

3.1.4.17





cAMP -> AMP





cdAMP -> dAMP





cIMP -> IMP





cGMP -> GMP





cCMP -> CMP




27115

PDE7B
cAMP -> AMP

3.1.4.17





cAMP -> AMP





cdAMP -> dAMP





cIMP -> IMP





cGMP -> GMP





cCMP -> CMP




5136

PDE1A
cAMP -> AMP

3.1.4.17





cAMP -> AMP





cdAMP -> dAMP





cIMP -> IMP





cGMP -> GMP





cCMP -> CMP




5137

PDE1C, HCAM3
cAMP -> AMP

3.1.4.17





cAMP -> AMP





cdAMP -> dAMP





cIMP -> IMP





cGMP -> GMP





cCMP -> CMP




5138

PDE2A
cAMP -> AMP

3.1.4.17





cAMP -> AMP





cdAMP -> dAMP





cIMP -> IMP





cGMP -> GMP





cCMP -> CMP




5139

PDE3A, CGI-PDE
cAMP -> AMP

3.1.4.17





cAMP -> AMP





cdAMP -> dAMP





cIMP -> IMP





cGMP -> GMP





cCMP -> CMP




5140

PDE3B
cAMP -> AMP

3.1.4.17





cAMP -> AMP





cdAMP -> dAMP





cIMP -> IMP





cGMP -> GMP





cCMP -> CMP




5141

PDE4A, DPDE2
cAMP -> AMP

3.1.4.17




5142

PDE4B, DPDE4, PDEIVB
cAMP -> AMP

3.1.4.17




5143

PDE4C, DPDE1
cAMP -> AMP

3.1.4.17




5144

PDE4D, DPDE3
cAMP -> AMP

3.1.4.17




5145

PDE6A, PDEA, CGPR-A
cGMP -> GMP

3.1.4.17




5146

PDE6C, PDEA2
cGMP -> GMP

3.1.4.17




5147

PDE6D
cGMP -> GMP

3.1.4.17




5148

PDE6G, PDEG
cGMP -> GMP

3.1.4.17




5149

PDE6H
cGMP -> GMP

3.1.4.17




5152

PDE9A
cAMP -> AMP

3.1.4.17





cAMP -> AMP





cdAMP -> dAMP





cIMP -> IMP





cGMP -> GMP





cCMP -> CMP




5153

PDES1B
cAMP -> AMP

3.1.4.17





cAMP -> AMP





cdAMP -> dAMP





cIMP -> IMP





cGMP -> GMP





cCMP -> CMP




5158

PDE6B, CSNB3, PDEB
cGMP -> GMP

3.1.4.17




8654

PDE5A
cGMP -> GMP

3.1.4.17




100

ADA
ADN -> INS + NH3

3.5.4.4





DA -> DIN + NH3




270

AMPD1, MADA
AMP -> IMP + NH3

3.5.4.6




271

AMPD2
AMP -> IMP + NH3

3.5.4.6




272

AMPD3
AMP -> IMP + NH3

3.5.4.6




953

ENTPD1, CD39


3.6.1.5




3704

ITPA


3.6.1.19




107

ADCY1
ATP -> cAMP + PPI

4.6.1.1




108

ADCY2, HBAC2
ATP -> cAMP + PPI

4.6.1.1




109

ADCY3, AC3, KIAA0511
ATP -> cAMP + PPI

4.6.1.1




110

ADCY4
ATP -> cAMP + PPI

4.6.1.1




111

ADCY5
ATP -> cAMP + PPI

4.6.1.1




112

ADCY6
ATP -> cAMP + PPI

4.6.1.1




113

ADCY7, KIAA0037
ATP -> cAMP + PPI

4.6.1.1




114

ADCY8, ADCY3, HBAC1
ATP -> cAMP + PPI

4.6.1.1




115

ADCY9
ATP -> cAMP + PPI

4.6.1.1




2977

GUCY1A2, GUC1A2, GC-SA2


4.6.1.2




2982

GUCY1A3, GUC1A3, GUCSA3, GC-


4.6.1.2





SA3




2983

GUCY1B3, GUC1B3, GUCSB3, GC-


4.6.1.2





SB3




2984

GUCY2C, GUC2C, STAR


4.6.1.2




2986

GUCY2F, GUC2F, GC-F, GUC2DL,


4.6.1.2





RETGC-2




3000

GUCY2D, CORD6, GUC2D, LCA1,


4.6.1.2





GUC1A4, LCA, retGC




4881

NPR1, ANPRA, GUC2A, NPRA


4.6.1.2




4882

NPR2, ANPRB, GUC2B, NPRB,


4.6.1.2





NPRBi




159

ADSS
IMP + GTP + ASP -> GDP + PI + ASUC

6.3.4.4




318

NUDT2, APAH1


3.6.1.17




5167

ENPP1, M6S1, NPPS, PCA1, PC-1,


3.6.1.9





PDNP1




5168

ENPP2, ATX, PD-IALPHA, PDNP2


3.6.1.9




5169

ENPP3, PD-IBETA, PDNP3


3.6.1.9







3.1.4.1




2272

FHIT


3.6.1.29








4.2 Pyrimidine metabolism PATH: hsa00240











790

CAD
GLN + 2 ATP + CO2 -> GLU + CAP + 2 ADP + PI

6.3.5.5





CAP + ASP -> CAASP + PI

2.1.3.2





CAASP <-> DOROA

3.5.2.3




1723

DHODH
DOROA + O2 <-> H2O2 + OROA

1.3.3.1




7372

UMPS, OPRT
OMP -> CO2 + UMP

4.1.1.23





OROA + PRPP <-> PPI + OMP

2.4.2.10




51727

LOC51727
ATP + UMP <-> ADP + UDP

2.7.4.14





CMP + ATP <-> ADP + CDP





DCMP + ATP <-> ADP + DCDP




50808

AKL3L


2.7.4.10




1503

CTPS
UTP + GLN + ATP -> GLU + CTP + ADP + PI

6.3.4.2





ATP + UTP + NH3 -> ADP + PI + CTP




7371

UMPK, TSA903
URI + ATP -> ADP + UMP

2.7.1.48





URI + GTP -> UMP + GDP





CYTD + GTP -> GDP + CMP




7378

UP
URI + PI <-> URA + R1P

2.4.2.3




1806

DPYD, DPD


1.3.1.2




1807

DPYS, DHPase, DHPASE, DHP


3.5.2.2




51733

LOC51733


3.5.1.6




7296

TXNRD1, TXNR
OTHIO + NADPH -> NADP + RTHIO

1.6.4.5




1854

DUT
DUTP -> PPI + DUMP

3.6.1.23




7298

TYMS, TMS, TS
DUMP + METTHF -> DHF + DTMP

2.1.1.45




978

CDA, CDD
CYTD -> URI + NH3

3.5.4.5





DC -> NH3 + DU




1635

DCTD
DCMP <-> DUMP + NH3

3.5.4.12




7083

TK1
DU + ATP -> DUMP + ADP

2.7.1.21





DT + ATP -> ADP + DTMP




7084

TK2
DUm + ATPm -> DUMPm + ADPm

2.7.1.21





DTm + ATPm -> ADPm + DTMPm




1841

DTYMK, TYMK, CDC8
DTMP + ATP <-> ADP + DTDP

2.7.4.9








4.3 Nucleotide sugars metabolism PATH: hsa00520











23483

TDPGD


4.2.1.46




1486

CTBS, CTB


3.2.1.








5. Amino Acid Metabolism


5.1 Glutamate metabolism PATH: hsa00251











8659

ALDH4, P5CDH
P5C + NAD + H2O -> NADH + GLU

1.5.1.12




2058

EPRS, QARS, QPRS
GLU + ATP -> GTRNA + AMP + PPI

6.1.1.17







6.1.1.15




2673

GFPT1, GFA, GFAT, GFPT
F6P + GLN -> GLU + GA6P

2.6.1.16




9945

GFPT2, GFAT2
F6P + GLN -> GLU + GA6P

2.6.1.16




5859

QARS


6.1.1.18




2729

GLCLC, GCS, GLCL
CYS + GLU + ATP -> GC + PI + ADP

6.3.2.2




2730

GLCLR
CYS + GLU + ATP -> GC + PI + ADP

6.3.2.2




2937

GSS, GSHS
GLY + GC + ATP -> RGT + PI + ADP

6.3.2.3




2936

GSR
NADPH + OGT -> NADP + RGT

1.6.4.2




5188

PET112L, PET112


6.3.5.








5.2 Alanine and aspartate metabolism PATH: hsa00252











4677

NARS, ASNRS
ATP + ASP + TRNA -> AMP + PPI + ASPTRNA

6.1.1.22




435

ASL
ARGSUCC -> FUM + ARG

4.3.2.1




189

AGXT, SPAT
SERm + PYRm <-> ALAm + 3HPm

2.6.1.51





ALA + GLX <-> PYR + GLY

2.6.1.44




16

AARS


6.1.1.7




1615

DARS


6.1.1.12




445

ASS, CTLN1, ASS1
CITR + ASP + ATP <-> AMP + PPI + ARGSUCC

6.3.4.5




443

ASPA, ASP, ACY2


3.5.1.15




1384

CRAT, CAT1


2.3.1.7





ACCOA + CAR -> COA + ACAR




8528

DDO


1.4.3.1








5.3 Glycine, serine and threonine metabolism PATH: hsa00260











5723

PSPH, PSP
3PSER + H2O -> PI + SER

3.1.3.3




29968

PSA
PHP + GLU <-> AKG + 3PSER

2.6.1.52





OHB + GLU <-> PHT + AKG




26227

PHGDH, SERA, PGDH, PGD, PGAD
3PG + NAD <-> NADH + PHP

1.1.1.95




23464

GCAT, KBL


2.3.1.29




211

ALAS1, ALAS
SUCCOA + GLY -> ALAV + COA + CO2

2.3.1.37




212

ALAS2, ANH1, ASB
SUCCOA + GLY -> ALAV + COA + CO2

2.3.1.37




4128

MAOA
AMA + H2O + FAD -> NH3 + FADH2 + MTHGXL

1.4.3.4




4129

MAOB
AMA + H2O + FAD -> NH3 + FADH2 + MTHGXL

1.4.3.4




26

ABP1, AOC1, DAO


1.4.3.6




314

AOC2, DAO2, RAO


1.4.3.6




8639

AOC3, VAP-1, VAP1, HPAO


1.4.3.6




2731

GLDC
GLY + LIPO <-> SAP + CO2

1.4.4.2




1610

DAO, DAMOX


1.4.3.3




2617

GARS


6.1.1.14




2628

GATM


2.1.4.1




2593

GAMT


2.1.1.2




PISD, PSSC, DKFZP566G2246,
PS -> PE + CO2




23761

DJ858B16


4.1.1.65




635

BHMT


2.1.1.5




29958

DMGDH


1.5.99.2




875

CBS
SER + HCYS -> LLCT + H2O

4.2.1.22




6301

SARS, SERS


6.1.1.11




10993

SDS, SDH
SER -> PYR + NH3 + H2O

4.2.1.13




6897

TARS


6.1.1.3








5.4 Methionine metabolism PATH: hsa00271











4143

MAT1A, MATA1, SAMS1, MAT, SAMS
MET + ATP + H2O -> PPI + PI + SAM

2.5.1.6




4144

MAT2A, MATA2, SAMS2, MATII
MET + ATP + H2O -> PPI + PI + SAM

2.5.1.6




1786

DNMT1, MCMT, DNMT
SAM + DNA-> SAH + DNA5MC

2.1.1.37




10768

AHCYL1, XPVKONA
SAH + H2O -> HCYS + ADN

3.3.1.1




191

AHCY, SAHH
SAH + H2O -> HCYS + ADN

3.3.1.1




4141

MARS, METRS, MTRNS


6.1.1.10




4548

MTR
HCYS + MTHF -> THF + MET

2.1.1.13








5.5 Cysteine metabolism PATH: hsa00272











833

CARS


6.1.1.16




1036

CDO1
CYS + O2 <-> CYSS

1.13.11.20




8509

NDST2, HSST2, NST2


2.8.2.








5.6 Valine, leucine and isoleucine degradation PATH: hsa00280











586

BCAT1, BCT1, ECA39, MECA39
AKG + ILE -> OMVAL + GLU

2.6.1.42





AKG + VAL -> OIVAL + GLU





AKG + LEU -> OICAP + GLU




587

BCAT2, BCT2
OICAPm + GLUm <-> AKGm + LEUm

2.6.1.42





OMVALm + GLUm <-> AKGm + ILEm




5014

OVD1A


1.2.4.4




593

BCKDHA, MSUD1
OMVALm + COAm + NADm -> MBCOAm + NADHm + CO2m

1.2.4.4





OIVALm + COAm + NADm -> IBCOAm + NADHm + CO2m





OICAPm + COAm + NADm -> IVOCAm + NADHm + CO2m




594

BCKDHB, E1B
OMVALm + COAm + NADm -> MBCOAm + NADHm + CO2m

1.2.4.4





OIVALm + COAm + NADm -> IBCOAm + NADHm + CO2m





OICAPm + COAm + NADH -> IVCOAm + NADHm + CO2m




3712

IVD
IVCOAm + FADm -> MCRCOAm + FADH2m

1.3.99.10




316

AOX1, AO


1.2.3.1




4164

MCCC1
MCRCOAm + ATPm + CO2m + H2Om -> MGCOAm + ADPm +

6.4.1.4





Pim




4165

MCCC2
MCRCOAm + ATPm + CO2m + H2Om -> MGCOAm + ADPm +

6.4.1.4





Pim








5.7 Valine, leucine and isoleucine biosynthesis PATH: hsa00290











23395

KIAA0028, LARS2


6.4.1.4




3926

LARS


6.4.1.4




3376

IARS, ILRS


6.1.1.5




7406

VARS1, VARS


6.1.1.9




7407

VARS2, G7A


6.1.1.9








5.8 Lysine biosynthesis PATH: hsa00300











3735

KARS, KIAA0070
ATP + LYS + LTRNA -> AMP + PPI + LLTRNA

6.1.1.6








5.9 Lysine degradation PATH: hsa00310











8424

BBOX, BBH, GAMMA-BBH, G-BBH


1.14.11.1




5351

PLOD, LLH


1.14.11.4




5352

PLOD2


1.14.11.4




8985

PLOD3, LH3


1.14.11.4




10157

LKR/SDH, AASS
LYS + NADPH + AKG -> NADP + H2O + SAC

1.5.1.9





SAC + H2O + NAD -> GLU + NADH + AASA








5.10 Arginine and proline metabolism PATH: hsa00330











5009

OTC
ORNm + CAPm -> CITRm + Pim + Hm

2.1.3.3




383

ARG1
ARG -> ORN + UREA

3.5.3.1




384

ARG2
ARG -> ORN + UREA

3.5.3.1




4842

NOS1, NOS


1.14.13.39




4843

NOS2A, NOS2


1.14.13.39




4846

NOS3, ECNOS


1.14.13.39




4942

OAT
ORN + AKG <-> GLUGSAL + GLU

2.6.1.13




5831

PYCR1, P5C, PYCR
P5C + NADPH -> PRO + NADP

1.5.1.2





P5C + NADH -> PRO + NAD





PHC + NADPH -> HPRO + NADP





PHC + NADH -> HPRO + NAD




5033

P4HA1, P4HA


1.14.11.2




5917

RARS
ATP + ARG + ATRNA -> AMP + PPI + ALTRNA

6.1.1.19




1152

CKB, CKBB
PCRE + ADP -> CRE + ATP

2.7.3.2




1156

CKBE


2.7.3.2




1158

CKM, CKMM


2.7.3.2




1159

CKMT1, CKMT, UMTCK


2.7.3.2




1160

CKMT2, SMTCK


2.7.3.2




6723

SRM, SPS1, SRML1
PTRSC + SAM -> SPRMD + 5MTA

2.5.1.16




262

AMD1, ADOMETDC
SAM <-> DSAM + CO2

4.1.1.50




263

AMDP1, AMD, AMD2
SAM <-> DSAM + CO2

4.1.1.50




1725

DHPS
SPRMD + Qm -> DAPRP + QH2m

1.5.99.6




6611

SMS
DSAM + SPRMD -> 5MTA + SPRM

2.5.1.22




4953

ODC1
ORN -> PTRSC + CO2

4.1.1.17




6303

SAT, SSAT


2.3.1.57








5.11 Histidine metabolism PATH: hsa00340











10841

FTCD
FIGLU + THF -> NFTHF + GLU

2.1.2.5







4.3.1.4




3067

HDC


4.1.1.22




1644

DDC, AADC


4.1.1.28




3176

HNMT


2.1.1.8




218

ALDH3
ACAL + NAD -> NADH + AC

1.2.1.5




220

ALDH6
ACAL + NAD -> NADH + AC

1.2.1.5




221

ALDH7, ALDH4
ACAL + NAD -> NADH + AC

1.2.1.5




222

ALDH8
ACAL + NAD -> NADH + AC

1.2.1.5




3035

HARS
ATP + HIS + HTRNA -> AMP + PPI + HHTRNA

6.1.1.21








5.12 Tyrosine metabolism PATH: hsa00350











6898

TAT
AKG + TYR -> HPHPYR + GLU

2.6.1.5




3242

HPD, PPD
HPHPYR + O2 -> HGTS + CO2

1.13.11.27




3081

HGD, AKU, HGO
HGTS + O2 -> MACA

1.13.11.5




2954

GSTZ1, MAAI
MACA -> FACA

5.2.1.2







2.5.1.18




2184

FAH
FACA + H2O -> FUM + ACA

3.7.1.2




7299

TYR, OCAIA


1.14.18.1




7054

TH, TYH


1.14.16.2




1621

DBH


1.14.17.1




5409

PNMT, PENT


2.1.1.28




1312

COMT


2.1.1.6




7173

TPO, TPX


1.11.1.8








5.13 Phenylalanine metabolism PATH: hsa00360











501

ATQ1


1.2.1.








5.14 Tryptophan metabolism PATH: hsa00380











6999

TDO2, TPH2, TRPO, TDO
TRP + O2 -> FKYN

1.13.11.11




8564

KMO
KYN + NADPH + O2 -> HKYN + NADP + H2O

1.14.13.9




8942

KYNU
KYN -> ALA + AN

3.7.1.3





HKYN + H2O -> HAN + ALA




23498

HAAO, HAO, 3-HAO
HAN + O2 -> CMUSA

1.13.11.6




7166

TPH, TPRH


1.14.16.4




438

ASMT, HIOMT, ASMTY


2.1.1.4




15

AANAT, SNAT


2.3.1.87




3620

INDO, IDO


1.13.11.42




10352

WARS2
ATPm + TRPm + TRNAm -> AMPm + PPIm + TRPTRNAm

6.1.1.2




7453

WARS, IFP53, IFI53, GAMMA-2
ATP + TRP + TRNA -> AMP + PPI + TRPTRNA

6.1.1.2




4734

NEDD4, KIAA0093


6.3.2.








5.15 Phenylalanine, tyrosine and tryptophan biosynthesis PATH: hsa00400











5053

PAH, PKU1
PHE + THBP + O2 -> TYR + DHBP + H2O

1.14.16.1




10667

FARS1


6.1.1.20




2193

FARSL, CML33


6.1.1.20




10056

PheHB


6.1.1.20




8565

YARS, TYRRS, YTS, YRS


6.1.1.1








5.16 Urea cycle and metabolism of amino groups PATH: hsa00220











5832

PYCS
GLUP + NADH -> NAD + PI + GLUGSAL

2.7.2.11





GLUP + NADPH -> NADP + PI + GLUGSAL

1.2.1.41




95

ACY1


3.5.1.14








6. Metabolism of Other Amino Acids


6.1 beta-Alanine metabolism PATH: hsa00410


6.2 Taurine and hypotaurine metabolism PATH: hsa00430











2678

GGT1, GTG, D22S672, D22S732,
RGT + ALA -> CGLY + ALAGLY

2.3.2.2




GGT





2679

GGT2, GGT
RGT + ALA -> CGLY + ALAGLY

2.3.2.2




2680

GGT3
RGT + ALA -> CGLY + ALAGLY

2.3.2.2




2687

GGTLA1, GGT-REL, DKFZP566O011
RGT + ALA -> CGLY + ALAGLY

2.3.2.2








6.3 Aminophosphonate metabolism PATH: hsa00440











5130

PCYT1A, CTPCT, CT, PCYT1
PCHO + CTP -> CDPCHO + PPI

2.7.7.15




9791

PTDSS1, KIAA0024, PSSA
CDPDG + SER <-> CMP + PS

2.7.8.








6.4 Selenoamino acid metabolism PATH: hsa00450











22928

SPS2


2.7.9.3




22929

SPS, SELD


2.7.9.3








6.5 Cyanoamino acid metabolism PATH: hsa00460


6.6 D-Glutamine and D-glutamate metabolism PATH: hsa00471


6.7 D-Arginine and D-ornithine metabolism PATH: hsa00472


6.9 Glutathione metabolism PATH: hsa00480











5182

PEPB


3.4.11.4




2655

GCTG


2.3.2.4




2876

GPX1, GSHPX1
2 RGT + H2O2 <-> OGT

1.11.1.9




2877

GPX2, GSHPX-GI
2 RGT + H2O2 <-> OGT

1.11.1.9




2878

GPX3
2 RGT + H2O2 <-> OGT

1.11.1.9




2879

GPX4
2 RGT + H2O2 <-> OGT

1.11.1.9




2880

GPX5
2 RGT + H2O2 <-> OGT

1.11.1.9




2881

GPX6
2 RGT + H2O2 <-> OGT

1.11.1.9




2938

GSTA1


2.5.1.18




2939

GSTA2, GST2


2.5.1.18




2940

GSTA3


2.5.1.18




2941

GSTA4


2.5.1.18




2944

GSTM1, GST1, MU


2.5.1.18




2946

GSTM2, GST4


2.5.1.18




2947

GSTM3, GST5


2.5.1.18




2948

GSTM4


2.5.1.18




2949

GSTM5


2.5.1.18




2950

GSTP1, FAEES3, DFN7, GST3, PI


2.5.1.18




2952

GSTT1


2.5.1.18




2953

GSTT2


2.5.1.18




4257

MGST1, GST12, MGST, MGST-I


2.5.1.18




4258

MGST2, GST2, MGST-II


2.5.1.18




4259

MGST3, GST-III


2.5.1.18








7. Metabolism of Complex Carbohydrates


7.1 Starch and sucrose metabolism PATH: hsa00500











6476

SI


3.2.1.10







3.2.1.48




11181

TREH, TRE, TREA
TRE -> 2 GLC

3.2.1.28




2990

GUSB


3.2.1.31




2632

GBE1
GLYCOGEN + PI -> G1P

2.4.1.18




5834

PYGB
GLYCOGEN + PI -> G1P

2.4.1.1




5836

PYGL
GLYCOGEN + PI -> G1P

2.4.1.1




5837

PYGM
GLYCOGEN + PI -> G1P

2.4.1.1




2997

GYS1, GYS
UDPG -> UDP + GLYCOGEN

2.4.1.11




2998

GYS2
UDPG -> UDP + GLYCOGEN

2.4.1.11




276

AMY1A, AMY1


3.2.1.1




277

AMY1B, AMY1


3.2.1.1




278

AMY1C, AMY1


3.2.1.1




279

AMY2A, AMY2


3.2.1.1




280

AMY2B, AMY2


3.2.1.1




178

AGL, GDE


2.4.1.25







3.2.1.33




10000

AKT3, PKBG, RAC-GAMMA, PRKBG


2.7.1.




1017

CDK2


2.7.1.




1018

CDK3


2.7.1.




1019

CDK4, PSK-J3


2.7.1.




1020

CDK5, PSSALRE


2.7.1.




1021

CDK6, PLSTIRE


2.7.1.




1022

CDK7, CAK1, STK1, CDKN7


2.7.1.




1024

CDK8, K35


2.7.1.




1025

CDK9, PITALRE, CDC2L4


2.7.1.




10298

PAK4


2.7.1.




10746

MAP3K2, MEKK2


2.7.1.




1111

CHEK1, CHK1


2.7.1.




11200

RAD53, CHK2, CDS1, HUCDS1


2.7.1.




1195

CLK1, CLK


2.7.1.




1326

MAP3K8, COT, EST, ESTF, TPL-2


2.7.1.




1432

MAPK14, CSBP2, CSPB1, PRKM14,


2.7.1.




PRKM15, CSBP1, P38, MXI2





1452

CSNK1A1


2.7.1.




1453

CSNK1D, HCKID


2.7.1.




1454

CSNK1E, HCKIE


2.7.1.




1455

CSNK1G2


2.7.1.




1456

CSNK1G3


2.7.1.




1612

DAPK1, DAPK


2.7.1.




1760

DMPK, DM, DMK, DM1


2.7.1.




1859

DYRK1A, DYRK1, DYRK,


2.7.1.




MNB, MNBH





208

AKT2, RAG-BETA, PRKBB, PKBBETA


2.7.1.




269

AMHR2, AMHR


2.7.1.




27330

RPS6KA6, RSK4


2.7.1.




2868

GPRK2L, GPRK4


2.7.1.




2869

GPRK5, GRK5


2.7.1.




2870

GPRK6, GRK6


2.7.1.




29904

HSU93850


2.7.1.




30811

HUNK


2.7.1.




3611

ILK, P59


2.7.1.




3654

IRAK1, IRAK


2.7.1.




369

ARAF1, PKS2, RAFA1


2.7.1.




370

ARAF2P, PKS1, ARAF2


2.7.1.




3984

LIMK1, LIMK


2.7.1.




3985

LIMK2


2.7.1.




4117

MAK


2.7.1.




4140

MARK3, KP78


2.7.1.




4215

MAP3K3, MAPKKK3, MEKK3


2.7.1.




4216

MAP3K4, MAPKKK4, MTK1, MEKK4,


2.7.1.




KIAA0213





4217

MAP3K5, ASK1, MAPKKK5, MEKK5


2.7.1.




4293

MAP3K9, PRKE1, MLK1


2.7.1.




4294

MAP3K10, MLK2, MST


2.7.1.




4342

MOS


2.7.1.




4751

NEK2, NLK1


2.7.1.




4752

NEK3


2.7.1.




5058

PAK1, PAKalpha


2.7.1.




5062

PAK2, PAK65, PAKgamma


2.7.1.




5063

PAK3, MRX30, PAK3beta


2.7.1.




5127

PCTK1, PCTGAIRE


2.7.1.




5128

PCTK2


2.7.1.




5129

PCTK3, PCTAIRE


2.7.1.




5292

PIM1, PIM


2.7.1.




5347

PLK, PLK1


2.7.1.




5562

PRKAA1


2.7.1.




5563

PRKAA2, AMPK, PRKAA


2.7.1.




5578

PRKCA, PKCA


2.7.1.




5579

PRKCB1, PKCB, PRKCB, PRKCB2


2.7.1.




5580

PRKCD


2.7.1.




5581

PRKCE


2.7.1.




5582

PRKCG, PKCC, PKCG


2.7.1.




5583

PRKCH, PKC-L, PRKCL


2.7.1.




5584

PRKCI, DXS1179E, PKCI


2.7.1.




5585

PRKCL1, PAK1, PRK1, DBK, PKN


2.7.1.




5586

PRKCL2, PRK2


2.7.1.




5588

PRKCQ


2.7.1.




5590

PRKCZ


2.7.1.




MAPK1, PRKM1, P41MAPK,





5594

P42MAPK, ERK2, ERK, MAPK2,


2.7.1.




PRKM2





5595

MAPK3, ERK1, PRKM3, P44ERK1,


2.7.1.




P44MAPK





5597

MAPK6, PRKM6, P97MAPK, ERK3


2.7.1.




5598

MAPK7, BMK1, ERK5, PRKM7


2.7.1.




5599

MAPK8, JNK, JNK1, SAPK1, PRKM8,


2.7.1.




JNK1A2





5601

MAPK9, JNK2, PRKM9, P54ASAPK,


2.7.1.




JUNKINASE





5602

MAPK10, JNK3, PRKM10, P493F12,


2.7.1.




P54BSAPK





5603

MAPK13, SAPK4, PRKM13,


2.7.1.




P38DELTA





5604

MAP2K1, MAPKK1, MEK1, MKK1,


2.7.1.




PRKMK1





5605

MAP2K2, MEK2, PRKMK2


2.7.1.




5606

MAP2K3, MEK3, MKK3, PRKMK3


2.7.1.




5607

MAP2K5, MEK5, PRKMK5


2.7.1.




5608

MAP2K6, MEK6, MKK6, SAPKK3,


2.7.1.




PRKMK6





5609

MAP2K7, MAPKK7, MKK7, PRKMK7,


2.7.1.




JNKK2





5610

PRKR, EIF2AK1, PKR


2.7.1.




5613

PRKX, PKX1


2.7.1.




5894

RAF1


2.7.1.




613

BCR, CML, PHL, BCR1, D22S11,


2.7.1.




D22S662





6195

RPS6KA1, HU-1, RSK, RSK1,


2.7.1.




MAPKAPK1A





6196

RPS6KA2, HU-2, MAPKAPK1C, RSK,


2.7.1.




RSK3





6197

RPS6KA3, RSK2, HU-2, HU-3, RSK,


2.7.1.




MAPKAPK1B, ISPK-1





6198

RPS6KB1, STK14A


2.7.1.




6199

RPS6KB2, P70-BETA, P70S6KB


2.7.1.




6300

MAPK12, ERK6, PRKM12, SAPK3,


2.7.1.




P38GAMMA, SAPK-3





6416

MAP2K4, JNKK1, MEK4, PRKMK4,


2.7.1.




SERK1, MKK4





6446

SGK


2.7.1.




658

BMPR1B, ALK-6, ALK6


2.7.1.




659

BMPR2, BMPR-II, BMPR3, BRK-3


2.7.1.




673

BRAF


2.7.1.




6792

STK9


2.7.1.




6794

STK11, LKB1, PJS


2.7.1.




6885

MAP3K7, TAK1


2.7.1.




699

BUB1


2.7.1.




701

BUB1B, BUBR1, MAD3L


2.7.1.




7016

TESK1


2.7.1.




7272

TTK, MPS1L1


2.7.1.




7867

MAPKAPK3, 3PK, MAPKAP3


2.7.1.




8408

ULK1


2.7.1.




8558

CDK10, PISSLRE


2.7.1.




8621

CDC2L5, CDC2L, CHED


2.7.1.




8737

RIPK1, RIP


2.7.1.




8814

CDKL1, KKIALRE


2.7.1.




8899

PRP4, PR4H


2.7.1.




9064

MAP3K6, MAPKKK6


2.7.1.




9149

DYRK1B


2.7.1.




92

ACVR2, ACTRII


2.7.1.




9201

DCAMKL1, KIAA0369


2.7.1.




93

ACVR2B


2.7.1.




983

CDC2


2.7.1.




984

CDC2L1


2.7.1.




5205

FIC1, BRIC, PFIC1, PFIC, ATP8B1


3.6.1.





DHPP -> DHP + PI





GTP -> GSN + 3 PI





DGTP -> DG + 3 PI








7.2 Glycoprotein biosynthesis PATH: hsa00510











1798

DPAGT1, DPAGT, UGAT, UAGT,


2.7.8.15




D11S366, DGPT, DPAGT2, GPT





29880

ALG5


2.4.1.117




8813

DPM1
GDPMAN + DOLP -> GDP + DOLMANP

2.4.1.83




1650

DDOST, OST, OST48, KIAA0115


2.4.1.119




6184

RPN1


2.4.1.119




6185

RPN2


2.4.1.119




10130

P5


5.3.4.1




10954

PDIR


5.3.4.1




11008

PDI


5.3.4.1




2923

GRP58, ERp57, ERp60, ERp61,


5.3.4.1




GRP57, P58, PI-PLC, ERP57, ERP60,





ERP61





5034

P4HB, PROHB, PO4DB, ERBA2L


5.3.4.1




7841

GCS1


3.2.1.106




4121

MAN1A1, MAN9, HUMM9


3.2.1.113




4245

MGAT1, GLYT1, GLCNAC-TI, GNT-I,


2.4.1.101




MGAT





4122

MAN2A2, MANA2X


3.2.1.114




4124

MAN2A1, MANA2


3.2.1.114




4247

MGAT2, CDGS2, GNT-II, GLCNACTII,


2.4.1.143




GNT2





4248

MGAT3, GNT-III


2.4.1.144




6487

SIAT6, ST3GALII


2.4.99.6




6480

SIAT1


2.4.99.1




2339

FNTA, FPTA, PGGT1A


2.5.1.




2342

FNTB, FPTB


2.5.1.




5229

PGGT1B, BGGI, GGTI


2.5.1.




5875

RABGGTA


2.5.1.




5876

RABGGTB


2.5.1.




1352

COX10


2.5.1.








7.3 Glycoprotein degradation PATH: hsa00511











4758

NEU1, NEU


3.2.1.18




3073

HEXA, TSD


3.2.1.52




3074

HEXB


3.2.1.52




4123

MAN2C1, MANA, MANA1, MAN6A8


3.2.1.24




4125

MAN2B1, MANB, LAMAN


3.2.1.24




4126

MANBA, MANB1


3.2.1.25




2517

FUCA1


3.2.1.51




2519

FUCA2


3.2.1.51




175

AGA, AGU


3.5.1.26








7.4 Aminosugars metabolism PATH: hsa00530











6675

UAP1, SPAG2, AGX1
UTP + NAGA1P <-> UDPNAG + PPI

2.7.7.23




10020

GNE, GLCNE


5.1.3.14




22951

CMAS


2.7.7.43




1727

DIA1


1.6.2.2




4669

NAGLU, NAG


3.2.1.50








7.5 Lipopolysaccharide biosynthesis PATH: hsa00540











6485

SIAT5, SAT3, STZ


2.4.99.




7903

SIAT8D, PST, PST1, ST8SIA-IV


2.4.99.




8128

SIAT8B, STX, ST8SIA-II


2.4.99.








7.7 Glycosaminoglycan degradation PATH: hsa00531











3423

IDS, MPS2, SIDS


3.1.6.13




3425

IDUA, IDA


3.2.1.76




411

ARSB


3.1.6.12




2799

GNS, G6S


3.1.6.14




2588

GALNS, MPS4A, GALNAC6S, GAS


3.1.6.4








8. Metabolism of Complex Lipids


8.1 Glycerolipid metabolism PATH: hsa00561











10554

AGPAT1, LPAAT-ALPHA, G15
AGL3P + 0.017 C100ACP + 0.062 C120ACP + 0.100 C140ACP + 0.270

2.3.1.51





C160ACP + 0.169 C161ACP + 0.055 C180ACP + 0.235





C181ACP + 0.093 C182ACP -> PA + ACP




10555

AGPAT2, LPAAT-BETA
AGL3P + 0.017 C100ACP + 0.062 C120ACP + 0.100 C140ACP + 0.270

2.3.1.51





C160ACP + 0.169 C161ACP + 0.055 C180ACP + 0.235





C181ACP + 0.093 C182ACP -> PA + ACP




1606

DGKA, DAGK, DAGK1


2.7.1.107




1608

DGKG, DAGK3


2.7.1.107




1609

DGKQ, DAGK4


2.7.1.107




8525

DGKZ, DAGK5, HDGKZETA


2.7.1.107




8526

DGKE, DAGK6, DGK


2.7.1.107




8527

DGKD, DGKDELTA, KIAA0145


2.7.1.107




1120

CHKL
ATP + CHO -> ADP + PCHO

2.7.1.32




EKI1
ATP + ETHM -> ADP + PETHM

2.7.1.82




1119

CHK, CKI
ATP + CHO -> ADP + PCHO

2.7.1.32




43

ACHE, YT


3.1.1.7




1103

CHAT


2.3.1.6




5337

PLD1


3.1.4.4




26279

PLA2G2D, SPLA2S


3.1.1.4




30814

PLA2G2E


3.1.1.4




5319

PLA2G1B, PLA2, PLA2A, PPLA2


3.1.1.4




5320

PLA2G2A, MOM1, PLA2B, PLA2L


3.1.1.4




5322

PLA2G5


3.1.1.4




8398

PLA2G6, IPLA2


3.1.1.4




8399

PLA2G10, SPLA2


3.1.1.4




1040

CDS1
PA + CTP <-> CDPDG + PPI

2.7.7.41




10423

PIS
CDPDG + MYOI -> CMP + PINS

2.7.8.11




2710

GK
GL + ATP -> GL3P + ADP

2.7.1.30




2820

GPD2
GL3Pm + FADm -> T3P2m + FADH2m

1.1.99.5




2819

GPD1
T3P2 + NADH <-> GL3P + NAD

1.1.1.8




248

ALPI
AHTD -> DHP + 3 PI

3.1.3.1




249

ALPL, HOPS, TNSALP
AHTD -> DHP + 3 PI

3.1.3.1




250

ALPP
AHTD -> DHP + 3 PI

3.1.3.1




251

ALPPL2
AHTD -> DHP + 3 PI

3.1.3.1




439

ASNA1, ARSA-I


3.6.1.16




8694

DGAT, ARGP1
DAGLY + 0.017 C100ACP + 0.062 C120ACP + 0.100 C140ACP + 0.270

2.3.1.20





C160ACP + 0.169 C161ACP + 0.055 C180ACP + 0.235





C181ACP + 0.093 C182ACP -> TAGLY + ACP




3989

LIPB


3.1.1.3




3990

LIPC, HL


3.1.1.3




5406

PNLIP


3.1.1.3




5407

PNLIPRP1, PLRP1


3.1.1.3




5408

PNLIPRP2, PLRP2


3.1.1.3




8513

LIPF, HGL, HLAL


3.1.1.3




4023

LPL, LIPD


3.1.1.34




8443

GNPAT, DHAPAT, DAP-AT


2.3.1.42




8540

AGPS, ADAP-S, ADAS, ADHAPS,


2.5.1.26




ADPS, ALDHPSY





4186

MDCR, MDS, LIS1


3.1.1.47




5048

PAFAH1B1, LIS1, MDCR, PAFAH


3.1.1.47




5049

PAFAH1B2


3.1.1.47




5050

PAFAH1B3


3.1.1.47




5051

PAFAH2, HSD-PLA2


3.1.1.47




7941

PLA2G7, PAFAH, LDL-PLA2


3.1.1.47








8.2 Inositol phosphate metabolism PATH: hsa00562











5290

PIK3CA
ATP + PINS -> ADP + PINSP

2.7.1.137




5291

PIK3CB, PIK3C1
ATP + PINS -> ADP + PINSP

2.7.1.137




5293

PIK3CD
ATP + PINS -> ADP + PINSP

2.7.1.137




5294

PIK3CG
ATP + PINS -> ADP + PINSP

2.7.1.137




5297

PIK4CA, PI4K-ALPHA
ATP + PINS -> ADP + PINS4P

2.7.1.67




5305

PIP5K2A
PINS4P + ATP -> D45PI + ADP

2.7.1.68




5330

PLCB2
D45PI -> TPI + DAGLY

3.1.4.11




5331

PLCB3
D45PI -> TPI + DAGLY

3.1.4.11




5333

PLCD1
D45PI -> TPI + DAGLY

3.1.4.11




5335

PLCG1, PLC1
D45PI -> TPI + DAGLY

3.1.4.11




5336

PLCG2
D45PI -> TPI + DAGLY

3.1.4.11




3612

IMPA1, IMPA
MI1P -> MYOI + PI

3.1.3.25




3613

IMPA2
MI1P -> MYOI + PI

3.1.3.25




3628

INPP1


3.1.3.57




3632

INPP5A





3633

INPP5B


3.1.3.56




3636

INPPL1, SHIP2


3.1.3.56




4952

OCRL, LOCR, OCRL1, INPP5F


3.1.3.56




8867

SYNJ1, INPP5G


3.1.3.56




3706

ITPKA


2.7.1.127




51477

ISYNA1
G6P -> MI1P

5.5.1.4




3631

INPP4A, INPP4


3.1.3.66




8821

INPP4B


3.1.3.66








8.3 Sphingophospholipid biosynthesis PATH: hsa00570











6609

SMPD1, NPD


3.1.4.12








8.4 Phospholipid degradation PATH: hsa00580











1178

CLC


3.1.1.5




5321

PLA2G4A, CPLA2-ALPHA, PLA2G4


3.1.1.5








8.5 Sphingoglycolipid metabolism PATH: hsa00600











10558

SPTLC1, LCB1, SPTI
PALCOA + SER -> COA + DHSPH + CO2

2.3.1.50




9517

SPTLC2, KIAA0526, LCB2
PALCOA + SER -> COA + DHSPH + CO2

2.3.1.50




427

ASAH, AC, PHP32


3.5.1.23




7357

UGCG, GCS


2.4.1.80




2629

GDA G UC


3.2.1.45




2583

GALGT, GALNACT


2.4.1.92




6489

SIAT8A, SIAT8, ST8SIA-I


2.4.99.8




6481

SIAT2


2.4.99.2




4668

NAGA, D22S674, GALB


3.2.1.49




9514

CST


2.8.2.11




410

ARSA, MLD


3.1.6.8








8.6 Blood group glycolipid biosynthesis —lact series PATH: hsa00601











28

ABO


2.4.1.40







2.4.1.37




2525

FUT3, LE


2.4.1.65




2527

FUT5, FUC-TV


2.4.1.65




2528

FUT6


2.4.1.65




2523

FUT1, H, HH


2.4.1.69




2524

FUT2, SE


2.4.1.69








8.7 Blood group glycolipid biosynthesis —neolact series PATH: hsa00602











2651

GCNT2, IGNT, NACGT1, NAGCT1


2.4.1.150








8.8 Prostaglandin and leukotriene metabolism PATH: hsa00590











239

ALOX12, LOG12


1.13.11.31




246

ALOX15


1.13.11.33




240

ALOX5


1.13.11.34




4056

LTC4S


2.5.1.37




4048

LTA4H


3.3.2.6




4051

CYP4F3, CYP4F, LTB4H


1.14.13.30




8529

CYP4F2


1.14.13.30




5742

PTGS1, PGHS-1


1.14.99.1




5743

PTGS2, COX-2, COX2


1.14.99.1




27306

PGDS


5.3.99.2




5730

PTGDS


5.3.99.2




5740

PTGIS, CYP8, PGIS


5.3.99.4




6916

TBXAS1, CYP5


5.3.99.5




873

CBR1, CBR


1.1.1.184







1.1.1.189







1.1.1.197




874

CBR3


1.1.1.184








9. Metabolism of Cofactors and Vitamins


9.2 Riboflavin metabolism PATH: hsa00740











52

ACP1


3.1.3.48





FMN -> RIBOFLAV + PI

3.1.3.2




53

ACP2
FMN -> RIBOFLAV + PI

3.1.3.2




54

ACP5, TRAP
FMN -> RIBOFLAV + PI

3.1.3.2




55

ACPP, PAP
FMN -> RIBOFLAV + PI

3.1.3.2








9.3 Vitamin B6 metabolism PATH: hsa00750











8566

PDXK, PKH, PNK
PYRDX + ATP -> P5P + ADP

2.7.1.35





PDLA + ATP -> PDLA5P + ADP





PL + ATP -> PL5P + ADP








9.4 Nicotinate and nicotinamide metabolism PATH: hsa00760











23475

QPRT
QA + PRPP -> NAMN + CO2 + PPI

2.4.2.19




4837

NNMT


2.1.1.1




683

BST1, CD157
NAD -> NAM + ADPRIB

3.2.2.5




952

CD38
NAD -> NAM + ADPRIB

3.2.2.5




23530

NNT


1.6.1.2








9.5 Pantothenate and CoA biosynthesis PATH: hsa00770


9.6 Biotin metabolism PATH: hsa00780











3141

HLCS, HCS


6.3.4.







6.3.4.9







6.3.4.10







6.3.4.11







6.3.4.15




686

BTD


3.5.1.12








9.7 Folate biosynthesis PATH: hsa00790











2643

GCH1, DYT5, GCH, GTPCH1
GTP -> FOR + AHTD

3.5.4.16




1719

DHFR
DHF + NADPH -> NADP + THF

1.5.1.3




2356

FPGS
THF + ATP + GLU <-> ADP + PI + THFG

6.3.2.17




8836

GGH, GH


3.4.19.9




5805

PTS


4.6.1.10




6697

SPR


1.1.1.153




5860

QDPR, DHPR, PKU2
NADPH + DHBP -> NADP + THBP

1.6.99.7








9.8 One carbon pool by folate PATH: hsa00670











10840

FTHFD


1.5.1.6




10588

MTHFS
ATP + FTHF -> ADP + PI + MTHF

6.3.3.2








9.10 Porphyrin and chlorophyll metabolism PATH: hsa00860











210

ALAD
2 ALAV -> PBG

4.2.1.24




3145

HMBS, PBGD, UPS
4 PBG -> HMB + 4 NH3

4.3.1.8




7390

UROS
HMB -> UPRG

4.2.1.75




7389

UROD
UPRG -> 4 CO2 + CPP

4.1.1.37




1371

CPO, CPX
O2 + CPP -> 2 CO2 + PPHG

1.3.3.3




5498

PPOX, PPO
O2 + PPHGm -> PPIXm

1.3.3.4




2235

FECH, FCE
PPIXm -> PTHm

4.99.1.1




3162

HMOX1, HO-1


1.14.99.3




3163

HMOX2, HO-2


1.14.99.3




644

BLVRA, BLVR


1.3.1.24




645

BLVRB, FLR


1.3.1.24







1.6.99.1




2232

FDXR, ADXR


1.18.1.2




3052

HCCS, CCHL


4.4.1.17




1356

CP


1.16.3.1








9.11 Ubiquinone biosynthesis PATH: hsa00130











4938

OAS1, IFI-4, OIAS


2.7.7.




4939

OAS2, P69


2.7.7.




5557

PRIM1


2.7.7.




5558

PRIM2A, PRIM2


2.7.7.




5559

PRIM2B, PRIM2


2.7.7.




7015

TERT, EST2, TCS1, TP2, TRT


2.7.7.




8638

OASL, TRIP14


2.7.7.








10. Metabolism of Other Substances


10.1 Terpenoid biosynthesis PATH: hsa00900


10.2 Flavonoids, stilbene and lignin biosynthesis PATH: hsa00940


10.3 Alkaloid biosynthesis I PATH: hsa00950


10.4 Alkaloid biosynthesis II PATH: hsa00960


10.6 Streptomycin biosynthesis PATH: hsa00521


10.7 Erythromycin biosynthesis PATH: hsa00522


10.8 Tetracycline biosynthesis PATH: hsa00253


10.14 gamma-Hexachlorocyclohexane degradation PATH: hsa00361











5444

PON1, ESA, PON


3.1.8.1







3.1.1.2




5445

PON2


3.1.1.2







3.1.8.1








10.18 1,2-Dichloroethane degradation PATH: hsa00631


10.20 Tetrachloroethene degradation PATH: hsa00625











2052

EPHX1, EPHX, MEH


3.3.2.3




2053

EPHX2


3.3.2.3








10.21 Styrene degradation PATH: hsa00643


11. Transcription (condensed)


11.1 RNA polymerase PATH: hsa03020


11.2 Transcription factors PATH: hsa03022


12. Translation (condensed)


12.1 Ribosome PATH: hsa03010


12.2 Translation factors PATH: hsa03012











1915

EEF1A1, EF1A, ALPHA, EEF-1,


3.6.1.48




EEF1A





1917

EEF1A2, EF1A


3.6.1.48




1938

EEF2, EF2, EEF-2


3.6.1.48








12.3 Aminoacyl-tRNA biosynthesis PATH: hsa00970


13. Sorting and Degradation (condensed)


13.1 Protein export PATH: hsa03060











23478

SPC18


3.4.21.89








13.4 Proteasome PATH: hsa03050











5687

PSMA6, IOTA, PROS27


3.4.99.46




5683

PSMA2, HC3, MU, PMSA2, PSC2


3.4.99.46




5685

PSMA4, HC9


3.4.99.46




5688

PSMA7, XAPC7


3.4.99.46




5686

PSMA5, ZETA, PSC5


3.4.99.46




5682

PSMA1, HC2, NU, PROS30


3.4.99.46




5684

PSMA3, HC8


3.4.99.46




5698

PSMB9, LMP2, RING12


3.4.99.46




5695

PSMB7, Z


3.4.99.46




5691

PSMB3, HC10-II


3.4.99.46




5690

PSMB2, HC7-I


3.4.99.46




5693

PSMB5, LMPX, MB1


3.4.99.46




5689

PSMB1, HC5, PMSB1


3.4.99.46




5692

PSMB4, HN3, PROS26


3.4.99.46








14. Replication and Repair


14.1 DNA polymerase PATH: hsa03030


14.2 Replication Complex PATH: hsa03032











23626

SPO11


5.99.1.3




7153

TOP2A, TOP2


5.99.1.3




7155

TOP2B


5.99.1.3




7156

TOP3A, TOP3


5.99.1.2




8940

TOP3B


5.99.1.2








22. Enzyme Complex


22.1 Electron Transport System, Complex I PATH: hsa03100


22.2 Electron Transport System, Complex II PATH: hsa03150


22.3 Electron Transport System, Complex III PATH: hsa03140


22.4 Electron Transport System, Complex IV PATH: hsa03130


22.5 ATP Synthase PATH: hsa03110


22.8 ATPases PATH: hsa03230


23. Unassigned


23.1 Enzymes










5538
PPT1, CLN1, PPT, INCL
C160ACP + H2O -> C160 + ACP
3.1.2.22







23.2 Non-enzymes











22934

RPIA, RPI
RL5P <-> R5P

5.3.1.6




5250

SLC25A3, PHC
PI + H <-> Hm + PIm




6576


CIT + MALm <-> CITm + MAL




51166

LOC51166
AADP + AKG -> GLU + KADP

2.6.1.39




5625

PRODH
PRO + FAD -> P5C + FADH2

1.5.3.



6517
SLC2A4, GLUT4
GLCxt -> GLC



6513
SLC2A1, GLUT1, GLUT
GLCxt -> GLC



26275
HIBCH, HIBYL-COA-H
HIBCOAm + H2Om -> HIBm + COAm
3.1.2.4


23305
KIAA0837, ACS2, LACS5, LACS2
C160 + COA + ATP -> AMP + PPI + C160COA



8611
PPAP2A, PAP-2A
PA + H2O -> DAGLY + PI



8612
PPAP2C, PAP-2C
PA + H2O -> DAGLY + PI



8613
PPAP2B, PAP-2B
PA + H2O -> DAGLY + PI



56994
LOC56994
CDPCHO + DAGLY -> PC + CMP



10400
PEMT, PEMT2
SAM + PE -> SAH + PMME



5833
PCYT2, ET
PETHM + CTP -> CDPETN + PPI



10390
CEPT1
CDPETN + DAGLY <-> CMP + PE



8394
PIP5K1A
PINS4P + ATP -> D45PI + ADP



8395
PIP5K1B, STM7, MSS4
PINS4P + ATP -> D45PI + ADP



8396
PIP5K2B
PINS4P + ATP -> D45PI + ADP



23396
PIP5K1C, KIAA0589, PIP5K-GAMMA
PINS4P + ATP -> D45PI + ADP








24. Our own reactions which need to be found in KEGG










GL3P <-> GL3Pm




T3P2 <-> T3P2m




PYR <-> PYRm + Hm




ADP + ATPm + PI + H -> Hm + ADPm + ATP + PIm




AKG + MALm <-> AKGm + MAL




ASPm + GLU + H -> Hm + GLUm + ASP




GDP + GTPm + PI + H -> Hm + GDPm + GTP + PIm




C160Axt + FABP -> C160FP + ALBxt




C160FP -> C160 + FABP




C180Axt + FABP -> C180FP + ALBxt




C180FP -> C180 + FABP




C161Axt + FABP -> C161FP + ALBxt




C161FP -> C161 + FABP




C181Axt + FABP -> C181FP + ALBxt




C181FP -> C181 + FABP




C182Axt + FABP -> C182FP + ALBxt




C182FP -> C182 + FABP




C204Axt + FABP -> C204FP + ALBxt




C204FP -> C204 + FABP




O2xt -> O2




O2 <-> O2m




ACTACm + SUCCOAm -> SUCCm + AACCOAm




3HB -> 3HBm




MGCOAm + H2Om -> H3MCOAm
4.2.1.18



OMVAL -> OMVALm




OIVAL -> OIVALm




OICAP -> OICAPm




C160CAR <-> C160CARm




CAR <-> CARm




DMMCOAm -> LMMCOAm
5.1.99.1







amino acid metabolism










THR -> NH3 + H2O + OBUT

4.2.1.16




THR + NAD -> CO2 + NADH + AMA

1.1.1.103




THR + NAD + COA -> NADH + ACCOA + GLY




AASA + NAD -> NADH + AADP

1.2.1.31




FKYN + H2O -> FOR + KYN

3.5.1.9




CMUSA -> CO2 + AM6SA

4.1.1.45




AM6SA + NAD -> AMUCO + NADH

1.2.1.32




AMUCO + NADPH -> KADP + NADP + NH4

1.5.1.




CYSS + AKG <-> GLU + SPYR




URO + H2O -> 4I5P

4.2.1.49




4I5P + H2O -> FIGLU

3.5.2.7




GLU <-> GLUm + Hm




ORN + Hm -> ORNm




ORN + Hm + CITRm <-> CITR + ORNm




GLU + ATP + NADPH -> NADP + ADP + PI + GLUGSAL




GLYAm + ATPm -> ADPm + 2PGm




AM6SA -> PIC




SPYR + H2O -> H2SO3 + PYR




P5C <-> GLUGSAL








fatty acid synthesis










MALCOA + ACP <-> MALACP + COA
2.3.1.39



ACCOA + ACP <-> ACACP + COA




ACACP + 4 MALACP + 8 NADPH -> 8 NADP + C100ACP + 4




CO2 + 4 ACP




ACACP + 5 MALACP + 10 NADPH -> 10 NADP + C120ACP + 5




CO2 + 5 ACP




ACACP + 6 MALACP + 12 NADPH -> 12 NADP + C140ACP + 6




CO2 + 6 ACP




ACACP + 6 MALACP + 11 NADPH -> 11 NADP + C141ACP + 6




CO2 + 6 ACP




ACACP + 7 MALACP + 14 NADPH -> 14 NADP + C160ACP + 7




CO2 + 7 ACP




ACACP + 7 MALACP + 13 NADPH -> 13 NADP + C161ACP + 7




CO2 + 7 ACP




ACACP + 8 MALACP + 16 NADPH -> 16 NADP + C180ACP + 8




CO2 + 8 ACP




ACACP + 8 MALACP + 15 NADPH -> 15 NADP + C181ACP + 8




CO2 + 8 ACP




ACACP + 8 MALACP + 14 NADPH -> 14 NADP + C182ACP + 8




CO2 + 8 ACP




C160COA + CAR -> C160CAR + COA




C160CARm + COAm -> C160COAm + CARm








fatty acid degredation










GL3P + 0.017 C100ACP + 0.062 C120ACP + 0.1 C140ACP + 0.27




C160ACP + 0.169 C161ACP + 0.055 C180ACP + 0.235




C181ACP + 0.093 C182ACP -> AGL3P + ACP




TAGLYm + 3 H2Om -> GLm + 3 C160m








Phospholipid metabolism










SAM + PMME -> SAH + PDME




PDME + SAM -> PC + SAH




PE + SER <-> PS + ETHM








Muscle contraction










MYOACT + ATP -> MYOATP + ACTIN




MYOATP + ACTIN -> MYOADPAC




MYOADPAC -> ADP + PI + MYOACT + CONTRACT
















TABLE 2







// Homo Sapiens Core Metabolic Network //


// Glycolysis //


−1 GLC −1 ATP +1 G6P +1 ADP 0 HK1


−1 G6P −1 H2O +1 GLC +1 P1 0 G6PC


−1 G6P +1 F6P 0 GPIR


−1 F6P −1 ATP +1 FDP +1 ADP 0 PFKL


−1 FDP −1 H2O +1 F6P +1 PI 0 FBP1


−1 FDP +1 T3P2 +1 T3P1 0 ALDOAR


−1 T3P2 +1 T3P1 0 TPI1R


−1 T3P1 −1 PI −1 AND +1 NADH +1 13PDG 0 GAPDR


−1 13PDG −1 ADP +1 3PG +1 ATP 0 PGK1R


−1 13PDG +1 23PDG 0 PGAM1


−1 23PDG −1 H2O +1 3PG +1 PI 0 PGAM2


−1 3PG +1 2PG 0 PGAM3R


−1 2PG +1 PEP +1 H2O 0 ENO1R


−1 PEP −1 ADP +1 PYR +1 ATP 0 PKLR


−1 PYRm −1 COAm −1 NADm +1 NADHm +1


CO2m +1 ACCOAm 0 PDHA1


−1 AND −1 LAC +1 PYR +1 NADH 0 LDHAR


−1 G1P +1 G6P 0 PGM1R


// TCA //


−1 ACCOAm −1 OAm −1 H2Om +1 COAm +1 CITm 0 CS


−1 CIT +1 ICIT 0 ACO1R


−1 CITm +1 ICITm 0 ACO2R


−1 ICIT −1 NADP +1 NADPH +1 CO2 +1 AKG 0 IDH1


−1 ICITm −1 NADPm +1 NADPHm +1 CO2m +1 AKGm 0 IDH2


−1 ICITm −1 NADm +1 CO2m +1 NADHm +1 AKOm 0 IDH3A


−1 AKGm −1 NADm −1 COAm +1 CO2m +1


NADHm +1 SUCCOAm 0 OGDH


−1 GTPm −1 SUCCm −1 COAm +1


GDPm +1 PIm +1 SUCCAm 0 SUCLG1R


−1 ATPm −1 SUCCm −1 COAm +1


ADPm +1 PIm +1 SUCCOAm 0 SUCLA2R


−1 FUMm −1 H2Om +1 MALm 0 FHR


−1 MAL −1 AND +1 NADH +1 OA 0 MDH1R


−1 MALm −1 NADm +1 NADHm +1 OAm 0 MDH2R


−1 PYRm −1 ATPm −1 CO2m +1 ADPm +1 OAm +1 PIm 0 PC


−1 OA −1 GTP +1 PEP +1 GDP +1 CO2 0 PCK1


−1 OAm −1 GTPm +1 PEPm +1 GDPm +1 CO2m 0 PCK2


−1 ATP −1 CIT −1 COA −1 H2O +1


ADP +1 PT +1 ACCOA +1 OA 0 ACLY


// PPP //


−1 G6P −1 NADP +1 D6PGL +1 NADPH 0 G6PDR


−1 D6PGL −1 H2O +1 D6PGC 0 PGLS


−1 D6PGC −1 NADP +1 NADPH +1 CO2 +1 RL5P 0 PGD


−1 RL5P +1 X5P 0 RPER


−1 R5P −1 X5P +1 T3P1 +1 S7P 0 TKT1R


−1 X5P −1 E4P +1 F6P +1 T3P1 0 TKT2R


1 T3Pl −1 S7P +1 E4P +1 F6P 0 TALDO1R


−1 RL5P +1 R5P 0 RPIAR


// Glycogen //


−1 G1P −1 UTP +1 UDPG +1 PPI 0 UGP1


−1 UDPG +1 UDP +1 GLYCOGEN 0 GYS1


−1 GLYCOGEN −1 PI +1 G1P 0 GBE1


// ETS //


−1 MALm −1 NADPm +1 CO2m +1 NADPHm +1 PYRm 0 ME3


−1 MALm −1 NADm +1 CO2m +1 NADHm +1 PYRm 0 ME2


−1 MAL −1 NADP +1 CO2 +1 NADPH +1 PYR 0 ME1


−1 NADHm −1 Qm −4 Hm +1 QH2m +1 NADm +4 H 0 MTND1


−1 SUCCm −1 FADm +1 FUMm +1 FADH2m 0 SDHC1R


−1 FADH2m −1 Qm +1 FADm +1 QH2m 0 SDHC2R


−1 O2m −4 FEROm −4 Hm +4 FERIm +2 H2Om +4 H 0 UQCRFS1


−1 QH2m −2 FERIm −4 Hm +1 Qm +2 FEROm +4 H 0 COX5BL4


−1 ADPm −1 PIm −3 H +1 ATPm +3 Hm +1 H2Om 0 MTAT


−1 ADP −1 ATPm −1 PI −1 H +1


Hm +1 ADPm +1 ATP +1 PIm 0 ATPMC


−1 GDP −1 GTPm −1 PI −1 H +1


Hm +1 GDPm +1 GTP +1 PIm 0 GTPMC


−1 PPI +2 PI 0 PP


−1 ACCOA −l ATP −l C02 +1 MALCOA +1 ADP +1 PT 0 ACACAR


−1 GDP −1 ATP +1 GTP +1 ADP 0 GOT3R


// Transporters //


−1 CIT −1 MALm +1 CITm +1 MAL 0 CITMCR


−1 PYR −1 H +1 PYRm +1 Hm 0 PYRMCR


// Glycerol Phosphate Shuttle //


−1 GL3Pm −1 FADm +1 T3P2m +1 FADH2m 0 GPD2


−1 T3P2 −1 NADH +1 GL3P +1 AND 0 GPD1


−1 GL3P +1 GL3Pm 0 GL3PMCR


−1 T3P2 +1 T3P2m 0 T3P2MCR


// Malate/Aspartate Shuttle //


−1 OAm −1 GLUm +1 ASPm +1 AKGm 0 GOT1R


−1 ASP −1 AKG +1 OA +1 GLU 0 GOT2R


−1 AKG −1 MALm +1 AKGm +1 MAL 0 MALMCR


−1 ASPm −1 GLU −1 H +1 Hm +1 GLUm +1 ASP 0 ASPMC


// Exchange Fluxes //


+1 GLC 0 GLCexR


+1 PYR 0 PYRexR


+1 CO2 0 CO2exR


+1 O2 0 O2exR


+1 PI 0 PIexR


+1 H2O 0 H2OexR


+1 LAC 0 LACexR


+1 CO2m 0 CO2min


−1 CO2m 0 CO2mout


+1 O2m 0 O2min


−1 O2m 0 O2mout


+1 H2Om 0 H2Omin


−1 H2Om 0 H2Omout


+1 PIm 0 PImin


−1 PIm 0 PImout


// Output //


−1 ATP +1 ADP +1 P1 0 Output


0.0 end


end E 0


max


1 Output


0 end


0 GLCexR 1


−1000 PYRexR 0


−1000 LACexR 0


0 end 0


rev. rxn 33


nonrev. rxn 31


total rxn 64


matrix columns 97


unique enzymes 52


















TABLE 3





Abbrev.
Reaction
Rxn Name







Glycolysis




HK1
GLC + ATP -> G6P + ADP
HK1


G6PC, G6PT
G6P + H20 -> GLC + P1
G6PC


GPI
G6P <-> F6P
GPI


PFKL
F6P + ATP -> FDP + ADP
PFKL


FBP1, FBP
FDP + H2O -> F6P + PI
FBP1


ALDOA
FDP <-> T3P2 + T3P1
ALDOA


TPI1
T3P2 <-> T3P1
TPI1


GAPD, GAPDH
T3P1 + PI + NAD <-> NADH + 13PDG
GAPD


PGK1, PGKA
13PDG + ADP <-> 3PG + ATP
PGK1


PGAM1, PGAMA
13PDG <-> 23PDG
PGAM1



23PDG + H2O -> 3PG + P1
PGAM2



3PG <-> 2PG
PGAM3


ENO1, PPH, ENO1L1
2PG <-> PEP + H2O
ENO1


PKLR, PK1
PEP + ADP -> PYR + ATP
PKLR


PDHA1, PHE1A, PDHA
PYRm + COAm + NADm -> + NADHm + CO2m + ACCOAm
PDHA1


LDHA, LDH1
NAD + LAC <-> PYR + NADH
LDHA


PGM1
G1P <-> G6P
PGM1


TCA


CS
ACCOAm + OAm + H2Om -> COAm + CITm
CS


ACO1, IREB1, IRP1
CIT <-> ICIT
ACO1


ACO2
CITm <-> ICITm
ACO2


IDH1
ICIT + NADP -> NADPH + CO2 + AKG
IDH1


IDH2
ICITm + NADPm -> NADPHm + CO2m + AKGm
IDH2


IDH3A
ICITm + NADm -> CO2m + NADHm + AKGm
IDH3A


OGDH
AKGm + NADm + COAm -> CO2m + NADHm + SUCCOAm
OGDH


SUCLG1, SUCLA1
GTPm + SUCCm + COAm <-> GDPm + PIm + SUCCOAm
SUCLG1


SUCLA2
ATPm + SUCCm + COAm <-> ADPm + PIm + SUCCOAm
SUCLA2


FH
FUMm + H2Om <-> MALm
FH


MDH1
MAL + NAD <-> NADH + OA
MDH1


MDH2
MALm + NADm <-> NADHm + OAm
MDH2


PC, PCB
PYRm + ATPm + CO2m -> ADPm + OAm + PIm
PC


ACLY, ATPCL, CLATP
ATP + CIT + COA + H2O -> ADP + PI + ACCOA + OA
ACLY


PCK1
OA + GTP -> PEP + GDP + CO2
PCK1


PPP


G6PD, G6PD1
G6P + NADP <-> D6PGL + NADPH
G6PD


PGLS, 6PGL
D6PGL + H2O -> D6PGC
PGLS


PGD
D6PGC + NADP -> NADPH + CO2 + RL5P
PGD


RPE
RL5P <-> X5P
RPE


TKT
R5P + X5P <-> T3P1 + S7P
TKT1



X5P + E4P <-> F6P + T3P1
TKT2


TALDO1
T3P1 + S7P <-> E4P + F6P
TALDO1


UGP1
G1P + UTP -> UDPG + PPI
UGP1


ACACA, ACAC, ACC
ACCOA + ATP + CO2 <-> MALCOA + ADP + PI + H
ACACA


ETS


ME3
MALm + NADPm -> CO2m + NADPHm + PYRm
ME3


MTND1
NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H
MTND1


SDHC
SUCCm + FADm <-> FUMm + FADH2m
SDHC1



FADH2m + Qm <-> FADm + QH2m
SDHC2


UQCRFS1, RIS1
O2m + 4 FEROm + 4 Hm -> 4 FERIm + 2 H2Om + 4 H
UQCRFS1


COX5BL4
QH2m + 2 FERIm + 4 Hm -> Qm + 2 FEROm + 4 H
COX5BL4


MTATP6
ADPm + PIm + 3 H -> ATPm + 3 Hm + H2Om
MTAT


PP, SID6-8061
PPI -> 2 PI
PP


Malate Aspartate shunttle


GOT1
OAm + GLUm <-> ASPm + AKGm
GOT1


GOT2
OA + GLU <-> ASP + AKG
GOT2



GDP + ATP <-> GTP + ADP
GOT3


Glycogen


GBE1
GLYCOGEN + PI -> G1P
GBE1


GYS1, GYS
UDPG -> UDP + GLYCOGEN
GYS1


Glycerol Phosphate Shunttle


GPD2
GL3Pm + FADm -> T3P2m + FADH2m
GPD2


GPD1
T3P2 + NADH -> GL3P + NAD
GPD1


RPIA, RPI
RL5P <-> R5P
RPIA


Mitochondria Transport



CIT + MALm <-> CITm + MAL
CITMC



GL3P <-> GL3Pm
GL3PMC



T3P2 <-> T3P2m
T3P2MC



PYR <-> PYRm + Hm
PYRMC



ADP + ATPm + PI + H -> Hm + ADPm + ATP + PIm
ATPMC



AKG + MALm <-> AKGm + MAL
MALMC



ASPm + GLU + H -> Hm + GLUm + ASP
ASPMC



GDP + GTPm + PI + H -> Hm + GDPm + GTP + PIm
GTPMC
















TABLE 4







Metabolic Reaction for Muscle Cells








Reaction
Rxt Name





GLC + ATP -> G6P + ADP
0 HK1


G6P <-> F6P
0 GPI


F6P + ATP -> FDP + ADP
0 PFKL1


FDP + H2O -> F6P + PI
0 FBP1


FDP <-> T3P2 + T3P1
0 ALDOA


T3P2 <-> T3P1
0 TPI1


T3P1 + PI + NAD <-> NADH + 13PDG
0 GAPD


13PDG + ADP <-> 3PG + ATP
0 PGK1


3PG <-> 2PG
0 PGAM3


2PG <-> PEP + H2O
0 ENO1


PEP + ADP -> PYR + ATP
0 PK1


PYRm + COAm + NADm -> + NADHm + CO2m + ACCOAm
0 PDHA1


NAD + LAC <-> PYR + NADH
0 LDHA


G1P <-> G6P
0 PGM1


ACCOAm + OAm + H2Om -> COAm + CITm
0 CS


CIT <-> ICIT
0 ACO1


CITm <-> ICITm
0 ACO2


ICIT + NADP -> NADPH + CO2 + AKG
0 IDH1


ICITm + NADPm -> NADPHm + CO2m + AKGm
0 IDH2


ICITm + NADm -> CO2m + NADHm + AKGm
0 IDH3A


AKGm + NADm + COAm -> CO2m + NADHm + SUCCOAm
0 OGDH


GTPm + SUCCm + COAm <-> GDPm + PIm + SUCCOAm
0 SUCLG1


ATPm + SUCCm + COAm <-> ADPm + PIm + SUCCOAm
0 SUCLA2


FUMm + H2Om <-> MALm
0 FH


MAL + NAD <-> NADH + OA
0 MDH1


MALm + NADm <-> NADHm + OAm
0 MDH2


PYRm + ATPm + CO2m -> ADPm + OAm + PIm
0 PC


ATP + CIT + COA + H2O -> ADP + PI + ACCOA + OA
0 ACLY


OA + GTP -> PEP + GDP + CO2
0 PCK1


OAm + GTPm -> PEPm + GDPm + CO2m
0 PCK2


G6P + NADP <-> D6PGL + NADPH
0 G6PD


D6PGL + H2O -> D6PGC
0 H6PD


D6PGC + NADP -> NADPH + CO2 + RL5P
0 PGD


RL5P <-> X5P
0 RPE


R5P + X5P <-> T3P1 + S7P
0 TKT1


X5P + E4P <-> F6P + T3P1
0 TKT2


T3P1 + S7P <-> E4P + F6P
0 TALDO1


RL5P <-> R5P
0 RPIA


G1P + UTP -> UDPG + PPI
0 UGP1


GLYCOGEN + PI -> G1P
0 GBE1


UDPG -> UDP + GLYCOGEN
0 GYS1


MALm + NADm -> CO2m + NADHm + PYRm
0 ME2


MALm + NADPm -> CO2m + NADPHm + PYRm
0 ME3


MAL + NADP -> CO2 + NADPH + PYR
0 HUMNDME


NADHm + Qm + 4 Hm -> QH2m + NADm + 4 H
0 MTND1


SUCCm + FADm <-> FUMm + FADH2m
0 SDHC1


FADH2m + Qm <-> FADm + QH2m
0 SDHC2


O2m + 4 FEROm + 4 Hm -> 4 FERIm + 2 H2Om + 4 H
0 UQCRFS1


QH2m + 2 FERIm + 4 Hm -> Qm + 2 FEROm + 4 H
0 COX5BL4


ADPm + PIm + 3 H -> ATPm + 3 Hm + H2Om
0 MTAT1


ADP + ATPm + PI + H -> Hm + ADPm + ATP + PIm
0 ATPMC


GDP + GTPm + PI + H -> Hm + GDPm + GTP + PIm
0 GTPMC


PPI -> 2 PI
0 PP


GDP + ATP <-> GTP + ADP
0 NME1


ACCOA + ATP + CO2 <-> MALCOA + ADP + PI + H
0 ACACA


MALCOA + ACP <-> MALACP + COA
0 FAS1_1


ACCOA + ACP <-> ACACP + COA
0 FAS1_2


ACACP + 4 MALACP + 8 NADPH -> 8 NADP + C100ACP + 4 CO2 + 4 ACP
0 C100SY


ACACP + 5 MALACP + 10 NADPH -> 10 NADP + C120ACP + 5 CO2 + 5
0 C120SY


ACP


ACACP + 6 MALACP + 12 NADPH -> 12 NADP + C120ACP + 6 CO2 + 6
0 C140SY


ACP


ACACP + 6 MALACP + 11 NADPH -> 11 NADP + C141ACP + 6 CO2 + 6
0 C141SY


ACP


ACACP + 7 MALACP + 14 NADPH -> 14 NADP + C160ACP + 7 CO2 + 7
0 C160SY


ACP


ACACP + 7 MALACP + 13 NADPH -> 13 NADP + C161ACP + 7 CO2 + 7
0 C161SY


ACP


ACACP + 8 MALACP + 16 NADPH -> 16 NADP + C180ACP + 8 CO2 + 8
0 C180SY


ACP


ACACP + 8 MALACP + 15 NADPH -> 15 NADP + C181ACP + 8 CO2 + 8
0 C181SY


ACP


ACACP + 8 MALACP + 14 NADPH -> 14 NADP + C182ACP + 8 CO2 + 8
0 C182SY


ACP


C160ACP + H2O -> C160 + ACP
0 PPT1


C160 + COA + ATP -> AMP + PPI + C160COA
0 KIAA


C160COA + CAR -> C160CAR + COA
0 C160CA


C160CARm + COAm -> C160COAm + CARm
0 C160CB


C160CARm + COAm + FADm + NADm -> FADH2m + NADHm +
0 HADHA


C140COAm + ACCOAm


C140COAm + 7 COAm + 7 FADm + 7 NADm -> 7 FADH2m + 7 NADHm + 7
0 HADH2


ACCOAm


TAGLYm + 3 H2Om -> GLm + 3 C160m
0 TAGRXN


GL3P + 0.017 C100ACP + 0.062 C120ACP + 0.1 C140ACP + 0.27
0 GAT1


C160ACP + 0.169 C161ACP + 0.055 C180ACP + 0.235 C181ACP + 0.093


C182CP -> AGL3P + ACP


AGL3P + 0.017 C100ACP + 0.062 C120ACP + 0.100 C140ACP + 0.270
0 AGPAT1


C160ACP + 0.169 C161ACP + 0.055 C180ACP + C181ACP + 0.093


C182ACP -> PA + ACP


ATP + CHO -> ADP + PCHO
0 CHKL1


PCHO + CTP -> CDPCHO + PPI
0 PCYT1A


CDPCHO + DAGLY -> PC + CMP
0 LOC


SAM + PE -> SAH + PMME
0 PEMT


SAM + PMME -> SAH + PDME
0 MFPS


PDME + SAM -> PC + SAH
0 PNMNM


G6P -> MI1P
0 ISYNA1


MI1P -> MYOI + PI
0 IMPA1


PA + CTP <-> CDPDG + PPI
0 CDS1


CDPDG + MYOI -> CMP + PINS
0 PIS


ATP + PINS -> ADP + PINSP
0 PIK3CA


ATP + PINS -> ADP + PINS4P
0 PIK4CA


PINS4P + ATP -> D45PI + ADP
0 PIP5K1


D45PI -> TPI + DAGLY
0 PLCB2


PA + H2O -> DAGLY + PI
0 PPAP2A


DAGLY + 0.017 C100ACP + 0.062 C120ACP + 0.100 C140ACP +
0 DGAT


0.270 C160ACP + 0.169 C161ACP + 0.055 C180ACP + 0.235 C181ACP +


0.093 C182ACP -> TAGLY + ACP


CDPDG + SER <-> CMP + PS
0 PTDS


CDPETN + DAGLY <-> CMP + PE
0 CEPT1


PE + SER <-> PS + ETHM
0 PESER


ATP + ETHM -> ADP + PETHM
0 EKI1


PETHM + CTP -> CDPETN + PPI
0 PCYT2


PS -> PE + CO2
0 PISD


3HBm + NADm -> NADHm + Hm + ACTACm
0 BDH


ACTACm + SUCCOAm -> SUCCm + AACOAm
0 3OCT


THF + SER <-> GLY + METTHF
0 SHMT1


THFm + SERm <-> GLYm + METTHFm
0 SHMT2


SERm + PYRm <-> ALAm + 3HPm
0 AGXT


3PG + NAD <-> NADH + PHP
0 PHGDH


PHP + GLU <-> AKG + 3PSER
0 PSA


3PSER + H2O -> PI + SER
0 PSPH


3HPm + NADHm -> NADm + GLYAm
0 GLYD


SER -> PYR + NH3 + H2O
0 SDS


GLYAm + ATPm -> ADPm + 2PGm
0 GLTK


PYR + GLU <-> AKG + ALA
0 GPT


GLUm + CO2m + 2 ATPm -> 2 ADPm + 2 PIm + CAPm
0 CPS1


AKGm + NADHm + NH3m <-> NADm + H2Om + GLUm
0 GLUD1


AKGm + NADPHm + NH3m <-> NADPm + H2Om + GLUm
0 GLUD2


GLUm + NH3m + ATPm -> GLNm + ADPm + PIm
0 GLUL


ASPm + ATPm + GLNm -> GLUm + ASNm + AMPm + PPIm
0 ASNS


ORN + AKG <-> GLUGSAL + GLU
0 OAT


GLU <-> GLUm + Hm
0 GLUMT


GLU + ATP + NADPH -> NADP + ADP + PI + GLUGSAL
0 P5CS


GLUP + NADH -> NAD + PI + GLUGSAL
0 PYCS


P5C <-> GLUGSAL
0 SPTC


HIS -> NH3 + URO
0 HAL


URO + H2O -> 4I5P
0 UROH


4I5P + H2O -> FIGLU
0 IMPR


FIGLU + THF -> NFTHF + GLU
0 FTCD


MET + ATP + H2O -> PPI + PI + SAM
0 MAT1A


SAM + DNA -> SAH + DNA5MC
0 DNMT1


SAH + H2O -> HCYS + ADN
0 AHCYL1


HCYS + MTHF -> THF + MET
0 MTR


SER + HCYS -> LLCT + H2O
0 CBS


LLCT + H2O -> CYS + HSER
0 CTH1


OBUT + NH3 <-> HSER
0 CTH2


CYS + O2 <-> CYSS
0 CDO1


CYSS + AKG <-> GLU + SPYR
0 CYSAT


SPYR + H2O -> H2SO3 + PYR
0 SPTB


LYS + NADPH + AKG -> NADP + H2O + SAC
0 LKR1


SAC + H2O + NAD -> GLU + NADH + AASA
0 LKR2


AASA + NAD -> NADH + AADP
0 2ASD


AADP + AKG -> GLU + KADP
0 LOC5


TRP + O2 -> FKYN
0 TDO2


FKYN + H2O -> FOR + KYN
0 KYNF


KYN + NADPH + O2 -> HKYN + NADP + H2O
0 KMO


HKYN + H2O -> HAN + ALA
0 KYNU2


HAN + O2 -> CMUSA
0 HAAO


CMUSA -> CO2 + AM6SA
0 ACSD


AM6SA -> PIC
0 SPTA


AM6SA + NAD -> AMUCO + NADH
0 AMSD


AMUCO + NADPH -> KADP + NADP + NH4
0 2AMR


ARG -> ORN + UREA
0 ARG2


ORN + Hm -> ORNm
0 ORNMT


ORN + Hm + CITRm <-> CITR + ORNm
0 ORNCITT


ORNm + CAPm -> CITRm + Pim + Hm
0 OTC


CITR + ASP + ATP <-> AMP <-> AMP + PPI + ARGSUCC
0 ASS


ARGSUCC -> FUM + ARG
0 ASL


PRO + FAD -> P5C + FADH2
0 PRODH


P5C + NADPH -> PRO + NADP
0 PYCR1


THR -> NH3 + H2O + OBUT
0 WTDH


THR + NAD -> CO2 + NADH + AMA
0 TDH


AMA + H2O + FAD -> NH3 + FADH2 + MTHGXL
0 MAOA


GLYm + THFm + NADm <-> METTHFm + NADHm + CO2m + NH3m
0 AMT


PHE + THBP + O2 -> TYR + DHBP + H2O
0 PAH


NADPH + DHBP -> NADP + THBP
0 QDPR


AKG + TYR -> HPHPYR + GLU
0 TAT


HPHPYR + O2 -> HGTS + CO2
0 HPD


HGTS + O2 -> MACA
0 HGD


MACA -> FACA
0 GSTZ1


FACA + H2O -> FUM + ACA
0 FAH


AKG + ILE -> OMVAL + GLU
0 BCAT1A


OMVALm + COAm + NADm -> MBCOAm + NADHm + CO2m
0 BCKDHAA


MBCOAm + FADm -> MCCOAm + FADH2m
0 ACADMA


MCCOAm + H2Om -> MHVCOAm
0 ECHS1B


MHVCOAm + NADm -> MAACOAm + NADHm
0 EHHADHA


MAACOAm -> ACCOAm + PROPCOAm
0 ACAA2


2 ACCOAm <-> COAm + AACCOAm
0 ACATm1


AKG + VAL -> OIVAL + GLU
0 BCAT1B


OIVALm + COAm + NADm -> IBCOAm + NADHm + CO2m
0 BCKDHAB


IBCOAm + FADm -> MACOAm + FADH2m
0 ACADSB


MACOAm + H2Om -> HIBCOAm
0 EHHADHC


HIBCOAm + H2Om -> HIBm + COAm
0 HIBCHA


HIBm + NADm -> MMAm + NADHm
0 EHHADHB


MMAm + COAm + NADm -> NADHm + CO2m + PROPCOAm
0 MMSDH


PROPCOAm + CO2m + ATPm -> ADPm + PIm + DMMCOAm
0 PCCA


DMMCOAm -> LMMCOAm
0 HIBCHF


LMMCOAm -> SUCCOAm
0 MUT


AKG + LEU -> OICAP + GLU
0 BCAT1C


OICAPm + COAm + NADm -> IVCOAm + NADHm + CO2m
0 BCKDHAC


OICAPm + COAm + NADH -> IVCOAm + NADHm + CO2m
0 BCKDHBC


OICAPm + COAm + NADHm -> IVCOAm + NADHm + CO2m
0 DBTC


IVCOAm + FADm -> MCRCOAm + FADH2m
0 IVD


MCRCOAm + ATPm + CO2m + H2Om -> MGCOAm + ADPm + Pim
0 MCCC1


MGCOAm + H2Om -> H3MCOAm
0 HIBCHB


H3MCOAm -> ACCOAm + ACTACm
0 HMGCL


MYOACT + ATP -> MYOATP + ACTIN
0 MYOSA


MYOATP + ACTIN -> MYOADPAC
0 MYOSB


MYOADPAC -> ADP + PI + MYOACT + CONTRACT
0 MYOSC


PCRE + ADP -> CRE + ATP
0 CREATA


AMP + H2O -> PI + ADN
0 CREATB


ATP + AMP <-> 2 ADP
0 CREATC


O2 <-> O2m
0 O2MT


3HB -> 3HBm
0 HBMT


CIT + MALm <-> CITm + MAL
0 CITMC


PYR <-> PYRm + Hm
0 PYRMC


C160CAR + COAm -> C160COAm + CAR
0 C160CM


OMVAL -> OMVALm
0 HIBCHC


OIVAL -> OIVALm
0 HIBCHD


OICAP -> OICAPm
0 HIBCHE


GL <-> GLm
0 GLMT


GL3Pm + FADm -> T3P2m + FADH2m
0 GPD2


T3P2 + NADH <-> GL3P + NAD
0 GPD1


GL3P <-> GL3Pm
0 GL3PMC


T3P2 <-> T3P2m
0 T3P2MC


OAm + GLUm <-> ASPm + AKGm
0 GOT1


OA + GLU <-> ASP + AKG
0 GOT2


AKG + MALm <-> AKGm + MAL
0 MALMC


ASPm + GLU + H -> Hm + GLUm + ASP
0 ASPMC


GLCxt -> GLC
0 GLUT4


O2xt -> O2
0 O2UP


C160Axt + FABP -> C160FP + ALBxt
0 FAT1


C160FP -> C160 + FABP
0 FAT2


C180Axt + FABP -> C180FP + ALBxt
0 FAT3


C180FP -> C180 + FABP
0 FAT4


C161Axt + FABP -> C161FP + ALBxt
0 FAT5


C161FP -> C161 + FABP
0 FAT6


C181Axt + FABP -> C181FP + ALBxt
0 FAT7


C181FP -> C181 + FABP
0 FAT8


C182Axt + FABP -> C182FP + ALBxt
0 FAT9


C182FP -> C182 + FABP
0 FAT10


C204Axt + FABP -> C204FP + ALBxt
0 FAT11


C204FP -> C204 + FABP
0 FAT12


PYRxt + HEXT <-> PYR + H
0 PYRUP


LACxt + HEXT <-> LAC + HEXT
0 LACUP


H <-> HEXT
0 HextUP


CO2 <-> CO2m
0 CO2MT


H2O <-> H2Om
0 H2OMT


ATP + AC + COA -> AMP + PPI + ACCOA
0 FLJ2


C160CAR <-> C160CARm
0 C160MT


CARm <-> CAR
0 CARMT


CO2xt <-> CO2
0 CO2UP


H2Oxt <-> H2O
0 H2OUP


Pixt + HEXT <-> HEXT + PI
0 PIUP


<-> GLCxt
0 GLCexR


<-> PYRxt
0 PYRexR


<-> CO2xt
0 CO2exR


<-> O2xt
0 O2exR


<-> PIxt
0 PIexR


<-> H2Oxt
0 H2OexR


<-> LACxt
0 LACexR


<-> C160Axt
0 C160AexR


<-> C161Axt
0 C161AexR


<-> C180Axt
0 C180AexR


<-> C181Axt
0 C181AexR


<-> C182Axt
0 C182AexR


<-> C20Axt
0 C204AexR


<-> ALBxt
0 ALBexR


<-> 3HB
0 HBexR


<-> GLYCOGEN
0 GLYex


<-> PCRE
0 PCREex


<-> TAGLYm
0 TAGmex


<-> ILE
0 ILEex


<-> VAL
0 VALex


<-> CRE
0 CREex


<-> ADN
0 ADNex


<-> PI
0 PIex








Claims
  • 1. A computer readable medium or media having stored thereon computer-implemented instructions suitably programmed to cause a processor to perform the computer executable steps of: (a) providing a stoichiometric matrix having rows and columns of elements that correspond to stoichiometric coefficients of a plurality of Homo sapiens reactions between a plurality of Homo sapiens reactants, wherein each of said Homo sapiens reactions comprises a reactant identified as a substrate of the reaction and a reactant identified as a product of the reaction, the stoichiometric coefficient relating said substrate and said product,wherein at least one of said Homo sapiens reactions is annotated to indicate an associated gene encoding a macromolecule that performs said reaction and wherein a plurality of chemically and electrochemically balanced Homo sapiens reactions are assigned to a plurality of different membranous compartments;(b) providing a gene database comprising information characterizing said associated gene;(c) providing a constraint set for said plurality of Homo sapiens reactions, the constraint set representing an upper or lower boundary condition of flux through each of the Homo sapiens reactions described in the stoichiometric matrix;(d) defining an objective function to be a linear combination of fluxes through the Homo sapiens reactions described in the stoichiometric matrix that optimizes cell growth, reproduction, apoptosis, energy production, production of a particular compound, or a mechanical property;(e) determining at least one steady state flux distribution for said plurality of chemically and electrochemically balanced Homo sapiens reactions across said plurality of different membranous compartments by (i) identifying a plurality of flux vectors that each satisfy a steady state condition for the stoichiometric matrix and satisfy the constraint set and (ii) identifying at least one linear combination of the flux vectors that minimizes or maximizes the objective function, wherein said at least one steady state flux distribution is predictive of a Homo sapiens physiological function at steady state; and(f) providing output to a user of said at least one steady state flux distribution determined in step (e).
  • 2. The computer readable medium or media of claim 1, wherein said plurality of Homo sapiens reactions comprises at least one reaction from a peripheral metabolic pathway.
  • 3. The computer readable medium or media of claim 2, wherein said peripheral metabolic pathway is selected from the group consisting of amino acid biosynthesis, amino acid degradation, purine biosynthesis, pyrimidine biosynthesis, lipid biosynthesis, fatty acid metabolism, cofactor biosynthesis and transport processes.
  • 4. The computer readable medium or media of claim 1, wherein said Homo sapiens physiological function is selected from the group consisting of growth, energy production, redox equivalent production, biomass production, production of biomass precursors, production of a protein, production of an amino acid, production of a purine, production of a pyrimidine, production of a lipid, production of a fatty acid, production of a cofactor, transport of a metabolite, and consumption of carbon, nitrogen, sulfur, phosphate, hydrogen or oxygen.
  • 5. The computer readable medium or media of claim 1, wherein said Homo sapiens physiological function is selected from the group consisting of degradation of a protein, degradation of an amino acid, degradation of a purine, degradation of a pyrimidine, degradation of a lipid, degradation of a fatty acid and degradation of a cofactor.
  • 6. The computer readable medium or media of claim 1, wherein a first substrate or product in said plurality of Homo sapiens reactions is assigned to a first compartment and a second substrate or product in said plurality of Homo sapiens reactions is assigned to a second compartment.
  • 7. The computer readable medium or media of claim 1, wherein a plurality of said Homo sapiens reactions is annotated to indicate a plurality of associated genes and wherein said gene database comprises information characterizing said plurality of associated genes.
  • 8. The computer readable medium or media of claim 1, wherein at least one of said Homo sapiens reactions is a regulated reaction and wherein said constraint set includes a variable boundary condition for said regulated reaction.
  • 9. The computer readable medium or media of claim 8, wherein said variable boundary condition is dependent upon an outcome of at least one reaction in said stoichiometric matrix.
  • 10. The computer readable medium or media of claim 8, wherein said variable boundary condition is dependent upon an outcome of a regulatory event.
  • 11. The computer readable medium or media of claim 8, wherein said variable boundary condition is dependent upon time.
  • 12. The computer readable medium or media of claim 8, wherein said variable boundary condition is dependent upon the presence of a biochemical reaction network participant.
  • 13. The computer readable medium or media of claim 12, wherein said participant is selected from the group consisting of a substrate, product, reaction, protein, macromolecule, enzyme and gene.
  • 14. The computer readable medium or media of claim 8, wherein a plurality of said reactions are regulated reactions and said constraint set comprises variable boundary conditions for said regulated reactions.
  • 15. The computer readable medium or media of claim 1, wherein the stoichiometric matrix includes rows and columns of elements that correspond to stoichiometric coefficients of a plurality of Homo sapiens reactions between a plurality of Homo sapiens skeletal muscle cell reactants, and wherein said at least one flux distribution is predictive of Homo sapiens skeletal muscle cell energy production.
  • 16. A method for predicting a Homo sapiens physiological function, the method comprising: (a) providing a stoichiometric matrix having rows and columns of elements that correspond to stoichiometric coefficients of a plurality of Homo sapiens reactions between a plurality of Homo sapiens reactants, wherein each of said Homo sapiens reactions comprises a reactant identified as a substrate of the reaction and a reactant identified as a product of the reaction, the stoichiometric coefficient relating said substrate and said product,wherein at least one of said Homo sapiens reactions is annotated to indicate an associated gene encoding a macromolecule that performs said reaction and wherein a plurality of chemically and electrochemically balanced Homo sapiens reactions are assigned to a plurality of different membranous compartments;(b) providing a gene database comprising information characterizing said associated gene;(c) providing a constraint set for said plurality of Homo sapiens reactions, the constraint set representing an upper or lower boundary condition of flux through each of the Homo sapiens reactions described in the stoichiometric matrix;(d) defining an objective function to be a linear combination of fluxes through the Homo sapiens reactions described in the stoichiometric matrix that optimizes cell growth, reproduction, apoptosis, energy production, production of a particular compound, or a mechanical property;(e) determining at least one steady state flux distribution for said plurality of chemically and electrochemically balanced Homo sapiens reactions across said plurality of different membranous compartments by (i) identifying a plurality of flux vectors that each satisfy a steady state condition for the stoichiometric matrix and satisfy the constrain set and (ii) identifying at least one linear combination of the flux vectors that minimizes or maximizes said objective function, wherein said at least one steady state flux distribution is predictive of a Homo sapiens physiological function; and(f) providing output to a user of said at least one steady state flux distribution determined ins step (e).
  • 17. The method of claim 16, wherein said plurality of Homo sapiens reactions comprises at least one reaction from a peripheral metabolic pathway.
  • 18. The method of claim 17, wherein said peripheral metabolic pathway is selected from the group consisting of amino acid biosynthesis, amino acid degradation, purine biosynthesis, pyrimidine biosynthesis, lipid biosynthesis, fatty acid metabolism, cofactor biosynthesis and transport processes.
  • 19. The method of claim 16, wherein said Homo sapiens physiological function is selected from the group consisting of growth, energy production, redox equivalent production, biomass production, production of biomass precursors, production of a protein, production of an amino acid, production of a purine, production of a pyrimidine, production of a lipid, production of a fatty acid, production of a cofactor, transport of a metabolite, and consumption of carbon, nitrogen, sulfur, phosphate, hydrogen or oxygen.
  • 20. The method of claim 16, wherein said Homo sapiens physiological function is selected from the group consisting of glycolysis, the TCA cycle, pentose phosphate pathway, respiration, biosynthesis of an amino acid, degradation of an amino acid, biosynthesis of a purine, biosynthesis of a pyrimidine, biosynthesis of a lipid, metabolism of a fatty acid, biosynthesis of a cofactor, transport of a metabolite and metabolism of a carbon source, nitrogen source, oxygen source, phosphate source, hydrogen source or sulfur source.
  • 21. The method of claim 16, further comprising: (g) providing a modified stoichiometric matrix, wherein said modified stoichiometric matrix comprises at least one row of elements corresponding to stoichiometric coefficients of at least one added reaction, compared to the stoichiometric matrix of step (a), and(h) determining at least one modified steady state flux distribution by (i) identifying a modified plurality of flux vectors that satisfy the steady state condition for the modified stoichiometric matrix and (ii) identifying at least one linear combination of the modified flux vectors that minimizes or maximizes said objective function, thereby predicting a modified Homo sapiens physiological function.
  • 22. The method of claim 21, further comprising identifying at least one participant in said at least one added reaction.
  • 23. The method of claim 22, wherein said identifying at least one participant comprises associating a Homo sapiens protein with said at least one reaction.
  • 24. The method of claim 23, further comprising identifying at least one gene that encodes said protein.
  • 25. The method of claim 22, further comprising identifying at least one compound that alters the activity or amount of said at least one participant, thereby identifying a candidate drug or agent that alters a Homo sapiens physiological function.
  • 26. The method of claim 16, further comprising: (e) providing a modified data structure, wherein said modified data structure lacks at least one reaction compared to the data structure of part (a), and(f) determining at least one flux distribution that minimizes or maximizes said objective function when said constraint set is applied to said modified data structure, thereby predicting a Homo sapiens physiological function.
  • 27. The method of claim 26, further comprising identifying at least one participant in said at least one reaction.
  • 28. The method of claim 27, wherein said identifying at least one participant comprises associating a Homo sapiens protein with said at least one reaction.
  • 29. The method of claim 28, further comprising identifying at least one gene that encodes said protein that performs said at least one reaction.
  • 30. The method of claim 27, further comprising identifying at least one compound that alters the activity or amount of said at least one participant, thereby identifying a candidate drug or agent that alters a Homo sapiens physiological function.
  • 31. The method of claim 16, further comprising: (g) providing a modified constraint set, wherein said modified constraint set comprises a changed upper or lower boundary condition of flux through at least one reaction compared to the upper or lower boundary condition of flux through that reaction in step (c), and(h) determining at least one modified steady state flux distribution by (i) identifying a modified plurality of flux vectors that satisfy the steady state condition for the stoichiometric matrix and satisfy the modified constraint set and (ii) identifying at least one linear combination of the modified flux vectors that minimizes or maximizes said objective function, thereby predicting a modified Homo sapiens physiological function.
  • 32. The method of claim 31, further comprising identifying at least one participant in said at least one reaction.
  • 33. The method of claim 32, wherein said identifying at least one participant comprises associating a Homo sapiens protein with said at least one reaction.
  • 34. The method of claim 33, further comprising identifying at least one gene that encodes said protein.
  • 35. The method of claim 32, further comprising identifying at least one compound that alters the activity or amount of said at least one participant, thereby identifying a candidate drug or agent that alters a Homo sapiens physiological function.
  • 36. The method of claim 16, wherein the gene database relates one or more reactions in said data structure with one or more genes or proteins in Homo sapiens.
  • 37. The method of claim 16, wherein at least one of said Homo sapiens reactions is a regulated reaction and wherein said constraint set includes a variable boundary condition for said regulated reaction.
  • 38. The method of claim 37, wherein said variable boundary condition changes in response to an outcome of at least one reaction in said stoichiometric matrix.
  • 39. The method of claim 37, wherein said variable boundary condition changes in response to an outcome of a regulatory event.
  • 40. The method of claim 37, wherein said variable boundary condition changes in response to time.
  • 41. The method of claim 37, wherein said variable boundary condition changes in response to the presence of a biochemical reaction network participant.
  • 42. The method of claim 41, wherein said participant is selected from the group consisting of a substrate, product, reaction, enzyme, protein, macromolecule and gene.
  • 43. The method of claim 37, wherein a plurality of said reactions are regulated reactions and said constraint set comprises variable boundary conditions for said regulated reactions.
  • 44. The method of claim 16, wherein the stoichiometric matrix includes rows and columns of elements that correspond to stoichiometric coefficients of a plurality of Homo sapiens reactions between a plurality of Homo sapiens skeletal muscle cell reactants wherein said at least one steady state flux distribution is predictive of Homo sapiens skeletal muscle cell energy production.
Parent Case Info

This application claims benefit of the filing date of U.S. Provisional Application No. 60/368,588, filed Mar. 29, 2002, and which is incorporated herein by reference.

US Referenced Citations (28)
Number Name Date Kind
5273038 Beavin et al. Dec 1993 A
5556762 Pinilla et al. Sep 1996 A
5639949 Ligon et al. Jun 1997 A
5689633 Cotner et al. Nov 1997 A
5914891 Arkin et al. Jun 1999 A
5930154 Thalhammer-Reyero Jul 1999 A
5947899 Scollan et al. Sep 1999 A
5980096 Thalhammer-Reyero Nov 1999 A
6132969 Stoughton et al. Oct 2000 A
6165709 Friend et al. Dec 2000 A
6200803 Roberts Mar 2001 B1
6221597 Roberts Apr 2001 B1
6302302 Albisetti Oct 2001 B1
6329139 Nova et al. Dec 2001 B1
6351712 Stoughton et al. Feb 2002 B1
6370478 Stoughton et al. Apr 2002 B1
6379964 del Cardayre et al. Apr 2002 B1
6983227 Thalhammer-Reyero Jan 2006 B1
7127379 Palsson et al. Oct 2006 B2
20020012939 Palsson Jan 2002 A1
20020051998 Schmidt et al. May 2002 A1
20020168654 Maranas et al. Nov 2002 A1
20030059792 Palsson et al. Mar 2003 A1
20030113761 Tan et al. Jun 2003 A1
20030224363 Park et al. Dec 2003 A1
20030233218 Schilling Dec 2003 A1
20040009466 Maranas et al. Jan 2004 A1
20040029149 Palsson et al. Feb 2004 A1
Foreign Referenced Citations (6)
Number Date Country
WO 9209300 Jun 1992 WO
WO 0046405 Aug 2000 WO
WO 0136658 May 2001 WO
WO 0157775 Sep 2001 WO
WO 02055995 Jul 2002 WO
WO 02061115 Aug 2002 WO
Related Publications (1)
Number Date Country
20040029149 A1 Feb 2004 US
Provisional Applications (1)
Number Date Country
60368588 Mar 2002 US